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Abstract
Predictable levels of transgene expression will be essential for full
exploitation of human ES cells (hES) in basic research and medicine. In practice
however, transgene expression in mammalian cells is often found to be silenced, low
or variegated presenting a serious drawback in this area of research. Unpredictability
of transgene expression arises mostly as a consequence of variable transgene copy
number and/or inhibitory effects of surrounding chromatin structures in which the
transgene has randomly integrated.
We have addressed this issue in hES cells, by combining gene targeting and
site-specific recombination at the (3-casein and the hypoxanthine
phosphoribosyltransferase {hprt) genes. A neomycin expression cassette flanked by
heterospecific lox sites is first introduced by homologous recombination (HR). In a
subsequent step, recombinase-mediated cassette exchange (RMCE), permits the
exchange of the neomycin gene with a transgene containing a blasticidin-oct-4-GFP
expression cassette flanked by the same set of heterospecific lox sites. Using a
promoter trap strategy, site-specific integrants can be directly selected with
blasticidin.
While we failed to target the p-casein gene in hES cells, we obtained
homologous-recombinants with targeting frequencies of up to 0.4 % at the hprt gene
in the male hES cell line (HI). F/prMargeted HI cells were shown to maintain a
normal karyotype; to exhibit common hES cell surface markers; and to differentiate
down the osteogenic lineage pathway. Additionally, subsequent targeted correction
of hprt-targeted HI mutant cells was achieved, restoring structure and function of the
hprt gene.
Following RMCE, site-specific integrant were recovered with 100 %
efficiency using a promoter trap strategy at the hprt locus. However, site-specific
integrants were characterised by a progressive down-regulation of GFP, possibly as a
result of transcriptional interference from the BSD cassette or inhibitory elements
present at the site of integration. Further work will be required to investigate the
nature of this silencing.
Targeting transgenes with reliable transgene expression at specific loci in
human ES cells will be important for modifying specific ES cell-derived tissues for
therapeutic applications in regenerative medicine. Engineering the hprt locus should
prove very useful for addressing issues such as directed differentiation,
immunotolerance as well as protection against tumorigenesis.
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1.2. Transgene Expression in Mammalian Cells
1.3. Gene Targeting and the CrelLoxP System




The success of many transgenic applications relies on the stability of
integration, expression and inheritance of the transgene or endogenous gene
modification. Predictable levels of transgene expression in mammalian cells will be
critical for many applications, including the correction of genetic defects in human
somatic cells by gene therapy (Kren and Steer, 2002) and the genetic modification of
large animals such as pigs for xenotransplantation and sheep for bioreactors
(Niemann et al., 2005). In addition, with the recent isolation of human embryonic
stem cells (Thomson et al., 1998), reliable transgene expression will provide an
important asset to a broader range of transgenic and medical applications.
Very often however, the desired level of transgene expression in mammalian
cells is not realised in practice, presenting a serious drawback for transgenic research
and medicine. Transgene expression may be silenced or low, and frequently,
expression is not seen in all cells-so-called variegated expression (Clark et al., 1994).
Unpredictability of transgene expression arises from the use of incomplete regulatory
elements, as a consequence of variable transgene copy number or due to inhibitory
effects of surrounding chromatin structures in which the transgene has randomly
integrated.
One solution to overcome these problems, is to employ gene targeting which
uses the cellular DNA repair mechanisms to introduce, by homologous
recombination (HR), a transgene (provided that it contains homologous sequence to
the target locus) into a specific site in the genome known to be appropriately
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regulated. The advantage of using gene targeting at a known locus is that the
transgene will be inserted as a single-copy, and will be equipped with the appropriate
chromatin structure and regulatory elements therefore eliminating the silencing
effects of multi-copy arrays and chromosomal position. Additionally, a site known
for high level of transgene expression can be targeted repeatedly by HR providing a
useful tool for transgenic approaches (Wallace et al., 2000). Recombinase mediated
cassette exchange (RMCE) constitutes an alternative approach to targeting repeatedly
a locus with a single-copy transgene (Baer and Bode, 2001). In a first step, a cassette
flanked by heterospecific lox sites (small prokaryotic palindromic DNA sequences
which can only recombine between themselves) is introduced at a specific locus by
HR. In the second step, the cassette can be exchanged with another cassette, also
flanked by heterospecific lox sites, by site-specific recombination catalysed by Cre
recombinase.
This PhD will address the possibility of generating a human ES cell line
engineered to obtain predictable levels of transgene expression that can be used for a
variety of applications. To achieve this aim, the advantages of homologous
recombination with site-specific recombination will be combined to introduce a
marker gene at the hypoxanthine-guanine phosphorybosyl transferase (hprt) or
/3-casein locus by RMCE. Following the desired recombination event, engineered
cells will be characterised for their ability to provide reproducible tissue-specific
transgene expression in hES cells.
The hprt gene, which is ubiquitously expressed, represents a good candidate
locus for several reasons. Its disruption can provide a model for Lesh-Nyhan
syndrome, which is a severe human genetic disease that is caused by the malfunction
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of the hprt gene (Stout and Caskey, 1988). Additionally, hprt is X-linked and
therefore a single targeted mutation in male hES cells, results in a complete loss of
function. Finally, the characteristics of the purine metabolism pathway in which the
HPRT enzyme is involved, provides a double selection system in which HPRT can
be selected for (HAT selection), or against (6-TG selection) its activity. Therefore
frequencies for a targeted event or correction event are easy to calculate at a
phenotypic level (Albertini, 2001).
P-casein is a milk protein gene with no essential function out-with the
mammary epithelium (Kumar et al., 1994). Hence, the disruption of both copies of
the gene, by transgene introduction, is very unlikely to have any detrimental effects
in other non-mammary cells types. Additionally, high targeting frequencies have
been achieved at this locus in mouse ES cells (Kumar et al., 1994; kolb, 2001),
suggesting that targeting the fi-casein gene in human ES cells should be reproducible.
The following introduction will describe the present problems associated with
transgene expression in mammalian cells, and some of the approaches that are
currently employed to tackle them. Genetic modifications in ES cells by HR, or site-
specific recombination, as well as the rationale behind designing gene targeting
vectors will be highlighted. Human ES cell characteristics and their wide potential in
research and medicine will also be reviewed. Within this context, this introduction
will also highlight the implications in research and medicine of engineering specific
genes such as the p-casein or hprt genes to generate a human ES cell line with
reliable transgene expression. Finally the main objectives of this project will be
outlined within this framework.
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1.2.1. Problems Associated with Transgene Expression
Over the last twenty years transgenic technology has revolutionised biological
research and a large number of transgenic plant and animal lines have now been
created. The production of transgenic mice by injection of transgenes into one
pronucleus of a fertilised zygote (Gordon et al., 1980), or by injection of genetically
modified embryonic stem (ES) cells into blastocysts or morula (Gossler et al., 1986),
has provided a powerful analytical tool for molecular biologists. Animal
transgenesis has been applied, for instance, to study the function of housekeeping
and developmental genes (reviewed by Melton, 1994; Shastry, 1998), to study gene
regulation (reviewed by Porter, 1998), to generate a gain of function mutation (e.g.
Ripps et al., 1995), to generate animal models of human diseases (reviewed by
Clarke, 1994; Dickinson et al., 1995), to produce recombinant proteins in the milk of
farm animals (Houdebine, 2000; Keefer, 2004), or to develop gene therapy strategies
(Kren and Steer, 2002). The success of the above transgenic applications relies on
the stability of integration, expression and inheritance of the transgene or
endogenous gene modification. However, variability of transgene expression is often
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observed mostly due to the site of integration in the host chromosome, and variable
transgene copy numbers. Transgenes may express poorly or not at all, and in some
cases, aberrant patterns of expression may be observed (reviewed by Gallie, 1998).
The problems associated with transgene expression present a serious drawback for
transgenesis and gene therapy, and the requirement to regulate genes appropriately
remains one of the main challenges.
1.2.1.1. The Influence of Integration Site
Transgenes integrated randomly into the host genome of cultured
cells (e.g. Feinstein et al., 1982; Butner and Lo, 1986) and animals (Jaenisch et al.,
1981; Lacy et al., 1983; Soriano et al., 1986; Al-Shawi et al., 1990) often display
poor levels of expression, or exhibit inappropriate patterns of expression in the form
of temporally and spatially (ectopic) aberrant expression. The primary reason for
such problems is the chromosomal position effect (Wilson et al., 1990; Clark et al.,
1994), whereby the particular genetic environment of the integration site is likely to
influence the expression of the integrated transgene. Repressive chromosomal
position effects are associated with the suppression of DNase hypersensitive sites
(DHS) formation (Huber et al., 1994; Festenstein et al., 1996; Pikaart et al., 1998),
nucleosome remodelling (Wallrath and Elgin, 1995), and histone deacetylation
(Pikaart et al., 1998). Chromosomal position effects form the basis of the "gene
trap" technique which is increasingly being used for detecting patterns of gene
expression (reviewed by Cecconi and Meyer, 2000; Stanford et al., 2001). The
general term gene trap refers to the random integration of a reporter gene construct
(gene trap vector) into the genome such that integration events will activate the
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reporter gene only if it is brought under the transcriptional regulation of an
endogenous gene. While the gene trap approach is commonly used to isolate and
mutate endogenous genes (Friedrich and Soriano, 1991; Wurst et al., 1995), it would
be relevant to take advantage of these "insertion sites" into genes for other purposes,
such as the generation of tagged loci, with reproducible transgene expression, that
can be repeatedly manipulated for a broad range of transgenic applications (Cobellis
et al., 2005).
Position effects are either stable, where transgenes are expressed in
every cell but at different levels (Lewis, 1950); or variegated (Henikoff, 1990),
where transgene expression level is maintained but only a proportion of genetically
identical cells express the transgene. Position effect variegation (PEV) results from
the integration of a transgene into a telomeric or centromeric region of
heterochromatin (condensed chromatin), rich in repeated sequences and poor in
functional genes (Straub, 2003). Mosaic transgene expression (expression levels
vary from cell to cell) arises as a consequence of variable heterochromatin spreading
into euchromatic regions (decondensed chromatin structure which contains most of
the genes) (reviewed by Henikoff, 1990; Karpen, 1994). The first description of
PEV was published over 75 years ago (Muller, 1930). It was first observed as zonal
variegation in the color of the facets of the eye of Drosophila that occurs when a
pigmentation gene is brought into proximity with a region of constitutive
heterochromatin by translocation, and was attributed to clonal variegation in the
"spreading" of heterochromatinisation into the translocated chromosomal region.
Since this early report, variegation has also been reported in plants (Matzke et al.,
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2001), yeast (Tartof, 1994), fungi (Cogoni et al., 1996), fish (Collas et al., 1999) and
mice (Sutherland et al., 2000).
1.2.1.2. The Influence of Copy Number and Methylation
Randomly integrated transgenes are usually present in the form of
multicopy arrays mainly in a head-to-tail fashion at one or, rarely, a few
chromosomal sites per nucleus (reviewed by Smith, 2001). High copy number is
more often associated with transgene silencing or variegated expression, as a result
of heterochromatinisation of the transgene array (Dorer and Henikoff, 1997; Garrick
et al., 1998; Henikoffs, 1998; Matzke et al, 1999; McBurney et al., 2002). In this
case, heterochromatin formation arises from the generation of secondary structures
through pairing of the copies of the transgene which results in the methylation of
cytosines by methyltransferases. Methylation, which is often associated with gene
silencing (Cedar, 1988), is involved as part of the genome defense system developed
against parasitic sequences, including transposable elements (TEs), viroid and RNA
viruses (Matzke et al., 1999, 2000), and also controls the temporal and spatial
expression of certain genes (Bird and Wolffe, 1999). Several mouse studies
provided some evidence of a negative correlation between the number of transgene
copies within an array, and the level of expression of the transgene (e.g. Garrick et
al., 1998; McBurney et al., 2002). Garrick and co-workers (1998) used site-specific
recombination (see section 1.3.4 for site-specific recombination) to generate
transgenic mouse lines in which different copy numbers of a transgene were inserted
at the same chromosomal location, thereby eliminating the contribution of position
effects and allowing analysis of the effect of copy number alone on transgene
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silencing. Using this approach, they showed that reduced transgene arrays, is
correlated with increased levels of transcription and expression, and is accompanied
by reduced methylation. Silencing of multiple copies has also been documented in
fungi (Faugeron, 2000), plants (Flavell, 1994), Drosophila (Dorer and Henikoff,
1994), and nematodes (Kelly and Fire, 1998).
1.2.2. Control of Transgene Expression
Several strategies have been devised to overcome position and multi-copy
array effects. In some cases, the solution lies with the vector design, for example by
ensuring that an appropriate enhancer sequence is included in the transgene, or by
including insulator elements to protect a transgene from position effect. Position
effect can also be avoided through the use of gene targeting or by the identification
of sites permissive for transgene expression. The section below focus on these
strategies.
1.2.2.1. Inclusion of Regulatory Elements
Genes are thought to be organised on chromosomes as contiguous but
independent units known as expression domains (Dillon and Grosveld, 1994). These
expression domains are believed to remain insulated from neighbouring sequences
and are thought to include all regulatory elements that are necessary for their correct
temporal and spatial gene expression. This concept was confirmed by experiments in
which either transgenes harboring the complete set of cis-regulatory elements
(Bonifer et al., 1990; 1994; Lien et al., 1997) or large genomic fragments in the form
of yeast or bacterial artificial chromosomes were analysed in transgenic mice. In
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each case, correct regulation was observed (Schedl et al., 1993; Strauss et al., 1993;
Lien et al., 1997; Nielsen et al. 1998).
Some regulatory elements are capable of counteracting position and
multi-copy array effects, and may be divided into two groups: dominant positive
regulatory elements that impose an active chromatin configuration even in
heterochromatic surroundings, and boundary elements that can physically block the
passage of signals (either positive or negative) from the surrounding chromatin.
Locus control regions (LCRs) and strong enhancers constitute the first group of
regulatory elements, while matrix attachment region elements (MARs) and
chromatin insulators belong to the second group.
LCRs are non-coding genetic elements that confer tissue-specific,
position-independent and copy number-dependent expression of linked transgenes in
the host genome (reviewed by Li et al., 2002). LCRs were first described in the
human [1-globin genes cluster (Forrester et al., 1987; Grosveld et al., 1987), which
is composed of five genes (s, Gy, Ay, § and (3), spread across 32 Kb ofDNA, and are
arranged in the order of their developmental expression. A 5' and 3' LCR lies at
both ends of the cluster. The existence of LCRs first came to attention with data
obtained from studies of Hispanic P-thalassemia patients, in which a large deletion
(encompassing the 5' LCR) upstream of the cluster led to suppression of the fi-globin
genes expression (Kioussis et al., 1983; Driscoll et al., 1989). LCRs are associated
with erythroid-specific DNase I hypersensitive sites (HSs), characterised by
distinguishable functions, including transcriptional enhancers, domain-opening and
tissue-specific elements. LCRs are either clustered as for the human (3-globin locus
(Grosveld et al., 1987) or scattered throughout the domain as exemplified by the
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chicken lysosyme locus (Bonifer et al., 1994). Although the human [1-glob in LCR is
the most extensively characterised element, other LCRs have also been described in a
broad spectrum of mammalian gene systems, including humans, mice, rats, chickens,
rabbits, sheep, and goats (reviewed by Li et al., 2002). The discovery of LCR
upstream of the human /3-globin genes, with its ability to confer copy number-
dependent gene expression independent of the integration site, originally made this
element a promising candidate for incorporation in vectors for transgenic and gene
therapy approaches (Grosveld et al., 1987; Sadelain et al., 1995). However, the use
of LCR regulatory elements is limited, as they are only known for a few genes, and
are tissue-specific. Additionally, their ability to reliably confer position-independent
expression of a linked transgene in cells and in mice is not always true (Alami et al.,
2000; Ellis and Panned, 2001).
MARs can be defined as cis-acting elements located at the two
boundaries of a transcription unit, which mediate the attachment of the chromatin to
the nuclear scaffold. Eukaryotic DNA is organized into higher order chromatin
structures, which in turn are periodically attached by MARs to a sub-nuclear matrix
to form a series of 30-100 kb loops. Recent data reinforce the idea that MARs are in
fact the elements that provide a higher order organization of the eukaryotic genome
by matrix attachment (Goetze et al. 2003). The binding affinity of MARs to the
nuclear matrix correlates with certain AT-rich motifs, which are thought to function
as DNA-unwinding elements (Michalowski et al., 1999; Bode et al., 2000a; Goetze
et al., 2003). Unlike LCRs, MARs are not bound by known transcription factors, and
instead are associated with by topoisomerases I and II, histone HI and a number of
proteins not known in other contexts. The first MAR element to be characterized
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was in the chicken lysosyme locus (Stief et al., 1989). The chicken lysosyme gene
was shown to be expressed in a position-independent manner in transgenic mice
(Bonifer et al., 1990). MARs have been shown to increase transgene expression both
in stably transfected cells and in transgenic mice, and are believed to collaborate with
enhancers to generate an extended domain of accessible chromatin. They have also
been shown to decrease de novo methylation of transgenes (Bode et al., 2000c; Dang
et al., 2000). The advantage of using MARs over LCRs, is that they are not tissue-
specific, however they do not confer convincing copy-number dependence
(McKnight et al., 1992) and reports have been inconsistent to date.
Insulators are boundary DNA elements that exert their function by
shielding genes from either the action of a distal enhancer and/or from the silencing
effects of condensed chromatin (reviewed by West et al., 2002; Burgess-Beusse et
al., 2002) (figure 1.1). Insulators were first studied in Drosophila and have now
been described in many other species including yeast, sea urchins, Xenopus,
chickens, mice and humans (West et al., 2002). In vertebrates, the first best-
characterised insulator is the constitutive 1.2 kb 5' HS4, which is located near the 5'
end of the chicken fi-globin locus (Chung et al., 1993). This element is located
within a constitutive DNase I hypersensitive site between an open chromatin
conformation and 16 kb of condensed chromatin (figure 1.2). Transgenes flanked
with copies of the 5'HS4 insulator has proven very useful in the generation of
transgenic mice (Wang et al, 1997; Potts et al, 2000), rabbits (Taboit-Dameron et al.,
1999) and cell lines (Pikaart et al., 1998; Inoue et al., 1999; Emery et al., 2000;
Rivella et al., 2000; Recillas-Targa et al., 2002) with uniform transgene expression
in all tissue type (reviewed by Recillas-Targa et al., 2004).
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I Barrier
Figure 1.1. Barrier and enhancer blocking function of insulators. (A) Some
insulators function as barrier against surrounding heterochromatin. (B) Some insulators function as
enhancer-blocking elements that prevent enhancer action when placed between enhancer and
promoter (tagged box) but not otherwise. I: insulator, E: enhancer. (Picture adapted from Burgess-
Beusse et al., 2002).
Chicken fi-globin Domain
LCR elements
< ► < ►
Condensed DNase I hypersensitive
Chromatin
(16 kb)
Figure 1.2. Chicken p-globill domain. The locus is characterised by four genes (8, pA, pH
and p), a strong enhancer (enh), LCR elements and the constitutive 5'HS4 insulator flanking 16 kb of
condensed chromatin.
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There are currently three models of insulator functions (Recillas-Targa and Razin,
2001; West et al., 2002; Burgess-Beusse et al., 2002). (i) The insulator actively
recruits histone acetylases (and perhaps other activities associated with active
chromatin), maintaining a histone acetylated (open) chromatin configuration within
the domain, (ii) the insulator captures or titrates DNA methyltransferases and/or
histone deacetylases and methylases, avoiding gene silencing within the protected
domain and thus preventing heterochromatin-mediated domain repression, and (iii)
the insulator relocates the gene away from heterochromatic regions to an active
subnuclear compartment, perhaps in association with the nuclear periphery and
nuclear pore components (Gerasimova et al., 2000; Ishii et al., 2002).
Although insulators represent a promising approach in animal
transgenesis and gene therapy approaches, it is likely that the use of complementary
chromatin elements such as LCRs and MARs, will be necessary to ensure reliable
transgene expression (Ramezani et al., 2003; Ma et al. 2003).
1.2.2.2. Gene Targeting Approach
An alternative transgenic approach to obtain reproducible transgene
expression is the use of gene targeting, in which transgenes can be introduced to a
precise location in the genome by homologous recombination (reviewed by Jasin et
al., 1996) (see section 1.3.1 for mechanisms). Gene targeting provides the advantage
that a single-copy of the transgene is introduced into a specific gene, therefore
eliminating the silencing effects of multi-copy arrays (Bronson et al., 1996).
Additionally, gene targeting allows the selection of the site of integration and so
overcomes the problems associated with position effects owing to random
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integration. Thus a site known for high level of transgene expression can be targeted
repeatedly providing a useful tool for a broad range of transgenic approaches
(Wallace et al., 2000). The ubiquitously expressed hypoxanthine phosphoribosyl
transferase (hprt) gene played an important role in the initial development of gene
targeting strategies in murine ES cells (Thomas and Capecchi, 1987; Doetschman et
al., 1987) because this gene provides a positive and negative selection system (see
section 1.4.4.2 for more details), and mice containing the disruption are viable
(Hooper et al., 1987; Kuehn et al., 1987). The hprt gene is located on the X
chromosome and is hemizygous in XY ES cells, thus integration of a transgene that
disrupts the hprt gene can be directly selected for in the appropriate media (Albertini,
2001). Bronson et al. (1996) restored an /^/-deficient ES cell line, which contains
a 5' gene deletion, by inserting a human or mouse fi-actin promoter driving the
murine bcl-2 cDNA upstream of the hprt locus. Both transgenes were highly
expressed in vitro and in mice, although the human fi-actin promoter directed
consistently a higher level of transgene expression. Although reproducible transgene
expression at the hprt locus has been observed on several occasions (Vivian et al.,
1999; Evans et al., 2000; Guillot et al., 2000; Cvetkovic et al., 2000; Minami et al.,
2002; Heaney et al., 2004), variegated transgene expression has also been reported
(Shaw-White et al., 1993; Evans et al., 2000).
Gene targeting has also been used to drive reliable transgene
expression from endogenous promoters. A promoterless lacZ transgene has been
frequently targeted into loci to serve as a tag to monitor the expression of the locus
(e.g. Mansour et al., 1990; Le Mouellic et al., 1990; Mountford et al., 1994;
Tajbakhsh and Buckingham, 1994; Weiler-Guettler et al., 1996). Variations of this
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approach include targeting a transgene into an endogenous locus to restrict its
expression to a certain cell type (Zhou and Palmiter, 1995), and to replace a mouse
gene with its human homologue (Stacey et al., 1994; Detloff et al., 1994).
The site-specific recombination system (Fukushije and Sauer, 1992;
Baubonis and Sauer, 1993; Kolb and Siddell, 1996) offers an alternative approach to
genetically manipulate ES cells and mice (see section 1.3.4). The introduction in ES
cells of a loxP site from bacteriophage PI, which is recognised by the site-specific
Cre recombinase, allows in a subsequent step (and in the presence of Cre
recombinase) site-specific insertion of transgenes which carry flanking loxP sites.
Used in conjunction with homologous recombination, site-specific recombination
allows transgenes to be targeted to a specific site in the genome. Rucker and
Piedrahita have exemplified this approach in 1997, with the introduction of a marker
into the whey acidic protein gene. In a later report, Kolb and co-workers (1999) used
a similar strategy to introduce a single copy of a promoterless luciferase reporter
gene under the control of the endogenous fi-casein promoter in murine ES cells.
Recently, Shmerling et al. (2005) used recombinase-mediated cassette exchange (see
section 1.3.4.1) and showed that several reporter genes could be reliably expressed
when placed under the transcriptional control of the endogenous /3-actin promoter in
murine ES cells.
A variation on the gene targeting approach involves an in vitro pre-
screen of tagged random sites permissive for reproducible transgene expression,
followed by the introduction of a single-copy transgene by gene targeting (Wallace et
al., 2000) or site-specific recombination (Fukushige and Sauer, 1992). Fukushige
and Sauer (1992) introduced a single copy of a promoterless lox-neo fusion gene into
Chapter I 16
two independent random sites in the genome of Chinese hamster ovary (CHO) cells.
Subsequent Cre-mediated site-specific recombination with a plasmid containing a
loxP site, a constitutive promoter and a /3-actin-lacZ transgene, was detected by the
activation of the neo marker. Highly reproducible lacZ expression was observed
among the site-specific integrants obtained at the same site. Variation in levels of
transgene expression was however dependent on the locus and the orientation of the
lacZ gene in the locus.
Similarly, Wallace and co-workers (2000) conducted an in vitro
screen for sites in mouse ES cells which allowed the expression of a PGK-hprt
selectable marker lying 5' to an oct-4-lacZ transgene. Hundreds of clones were
assessed in vitro for appropriate down-regulation of the lacZ transgene following
differentiation (since the oct-4 promoter is active in ES cells and inactive in
differentiated cells). Two clones, containing a single copy of the transgene, were
chosen which displayed appropriate and inappropriate lacZ expression. In a
subsequent step, the oct-4 promoter was sequentially replaced by three tissue-specific
promoters (thyroglobulin, Hox2.6 and Myf5) using homologous recombination, to
drive expression of lacZ. While one site provided reproducible transgene expression
with the three promoters in vitro and in vivo, the other site showed inappropriate
transgene expression.
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1.3.1. Homologous Recombination in Mammalian Cells
Homologous recombination (HR) refers to any process in which two similar
DNA sequences (e.g. a homologous chromosome or a sister chromatid) interact and
exchange genetic information. In addition to prokaryotic organisms, HR also occurs
in eukaryotic organisms during meiosis, mitosis and DNA repair (reviewed by
Bollag, 1989; Hooper, 1992). The process of HR repair provides a mechanism for
the error-free removal of damage present in DNA that has replicated (S and G2
phases). Thus HR acts in coordination with the S and G2 checkpoint machinery, to
eliminate chromosomal breaks on a DNA molecule using information from the sister
DNA molecule before the cell division occurs. HR may occur between two
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introduced DNA molecules (extra-chromosomal recombination), between
homologous sequences in the chromosomes (intra-chromosomal and inter-
chromosomal recombinations), and between an introduced sequence and a
chromosomal sequence (gene targeting). In contrast with yeast, where HR is the
primary mechanism of double-strand break repair (DSB), mammalian cells favour
the non-homologous recombination pathway. This pathway joins the two ends of a
DSB without regard to sequence homology. Although this process is more prone to
error than HR, it might have evolved to prevent hyperrecombination in the
mammalian genome, rich in DNA repeats.
The main current models ofHR are based on lower eukaryotes such as yeasts
and other fungi (Reviewed by Smith, 2002). All models involve the following
events: Initiation, repair and resolution. Initiation involves alignment of
homologous sequences, generation of cross-overs and branch migration. Repair
takes place after any change or loss of genetic information that occurs prior to or
during initiation, and involves mismatch repair or DNA synthesis. Resolution is the
excision of the cross-overs and separation of the two recombinant molecules.
The Holliday model (Holliday, 1964) involves homology pairing; single-
strand cleavage ("nicking") of both duplexes at a homologous site; strand invasion of
free ends between duplexes, such that the crossed strands unite the duplexes in a
structure called a holliday junction; branch migration of the holliday junction,
moving the crossover point away from its original position; and resolution of the
holliday junction by single strand nicking in either of the two senses observed in
nature: Cross-overs (splices) or patches (recombinant regions that have not
exchanged flanking markers) (figure 1.3). A modification of the holliday model,
Chapter I 19
Meselson-Radding model, suggests that only one of the two molecules initiates
recombination (Meselson and Radding, 1975). The initiator is nicked in one of the
strands, thus generating a 3' end for DNA synthesis. This reaction displaces the 5'
end, which then invades a homologue. This results in the formation of a holliday




Figure 1.3. The Holliday model. See text for details.
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The double-strand break repair model (Szostak et al., 1983) was proposed to
account for the observation that in many organisms, DNA DSBs enhance
recombination locally. Earlier studies on plasmid-chromosome recombination in
yeast (Orr-Weaver et al., 1981, 1983) established the recombinagenic nature of
DSBs and demonstrated the occurrence of gene conversion by double-strand gap
repair. In this model (figure 1.4), HR is initiated by homology pairing and DSBs of
the "receptor" duplex. 5'-3' exonuclease action results in the digestion of one of the
strands at both ends of the cut, generating a gap with 3' overhangs. One of these
invades the intact duplex ("donor"), creating a heteroduplex and displacing the
complementary strand of the "donor" duplex. This generates a "D loop", which is
subsequently expanded through DNA synthesis from the 3' end of the invading
strand. Eventually, the loop will be large enough to base-pair with the 3' end of the
receptor, which can then prime new DNA synthesis to reconstitute the missing strand
from the donor template. Migration of the invading 3' end creates a molecule with
two holliday junctions, that can be resolved in two ways to give either splices or
patches (figure 1.4).
At the moment, the molecular and biochemical details of HR are poorly
understood. Therefore it is not yet possible to decide which model is most accurate
(initiation by single-strand or by double-strand breaks). Indeed, it has been suggested
that multiple recombination pathways may exist (Sedivy and Joyner, 1993). Some
mutants of Drosophila (Carpenter, 1982) and yeast (Engebrecht et al., 1990) show
normal levels of meiotic gene conversion (the correction of one strand of
heteroduplex DNA to make it complementary with the other at mistmatch positions)
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but reduced levels of crossing over, suggesting that not all gene conversion events












Figure 1.4. Double-Strand Breaks model. See text for details.
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1.3.2. ES Cell Route to Transgenesis
The isolation of pluripotent murine ES cells (established in vitro from the
inner cell mass of explanted blastocyst stage embryos) that can contribute to all
tissues of the foetus (Evans and Kaufman, 1981; Martin, 1981) provides a route for
precise modification of the mouse genome by gene targeting (for review see Brandon
et al., 1995; Babinet et al., 2001). Genetic modification can be achieved in ES cells
by taking advantage of HR to target single copy transgenes to specific sites or to
modify existing genes in situ even down to the level of a single base pair substitution
(Hasty et al., 1991b). Genetically modified ES cells can then be returned to the
embryo by injection and introduced into surrogate dams where they resume their
normal programme of development (Gossler et al., 1986). The donor ES cells can
then contribute to a broad range of tissues including the germ cells. Breeding from
the chimaera produces heterozygous offspring that can be interbred to produce a pure
line of homozygous animals with the engineered modification (Capecchi, 1989). The
phenotype of novel mouse lines generated from targeted ES cells gives important
information about the function of specific genes for the physiology or development
of the mouse. This approach is vital for the generation ofmouse models of recessive




Two types of targeting vectors have been used to modify target genes
in ES cells (figure 1.5). Replacement vectors (Q type) typically carry a segment of
DNA homologous to the target locus, which is interrupted by a positive selection
marker gene. This marker is either inserted into the homology region, or
alternatively, replaces genomic sequence located between the homology arms.
Replacement vectors are linearised outside the region of homology. Such vectors
recombine with the target gene by double cross-over events leading to the
replacement of the chromosomal sequence with all the components of the vector
which are flanked on both sides by the homologous sequences. Heterologous
sequences at the ends of the vector homologies are excised from the vector during
the process of homologous recombination. In contrast, insertion vectors (O type) are
linearised within the region of homology. Such vectors are inserted entirely into the
target locus by a single cross-over event at the site of linearisation, resulting in a
duplication of the homologous DNA separated by the heterologous sequences in the
vector backbone. Positive selectable markers are essential components of both types
of targeting vectors, since they allow the isolation of rare transfected cells (typically
around 10"4 in mouse ES cells) from a predominantly untransfected population. A
commonly used selectable marker is neo, which confers resistance in vitro to the
synthetic aminoglycoside G418 (Southern and Berg, 1982), but other markers such
as hyg, conferring resistance to hygromycin B, and hprt minigenes (which function
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Figure 1.5. Integration patterns for a replacement and an insertion vector. (A)
Replacement vector: The homology (thick blue line) to the target locus (thin blue line) is interrupted
with the selectable marker (+) resulting in gene inactivation. The vector is linearised outside the
region of homology. A double-crossover event results in an exchange of vector sequence with the
chromosomal sequence. (B) Insertion vector: The region of homology (thick blue line) to the target
locus (thin blue line) is linearised. A single-crossover results in the duplication of the region of
homology interrupted by the vector sequence.
1.3.3.2. Screening for Targeted ES Cell Clones
Two types of screening procedures are used to identify ES cell
clones carrying a targeted integration of the construct: Polymerase Chain Reaction
(PCR) (Saiki et al., 1988) and Southern blot analysis (Southern, 1975). For PCR
analysis, two oligonucleotide primers are used to amplify a specific fragment created
by the HR event (Joyner et al., 1989; Soriano et al., 1991). One primer is
complementary to sequences unique to the target locus and the other is unique within
the targeting construct. PCR amplification of the expected fragment is possible only
when these primers are correctly juxtaposed by a HR event. To rule out the
possibility of PCR artifacts such as PCR jumping (Paabo and Wilson, 1988),
Southern analysis is usually used to confirm a targeted event. With the choice of
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restriction digests and probes for hybridization, the wild-type allele can readily be
distinguished from the targeted allele since predicted novel restriction fragments are
generated by the HR event. Southern analysis is usually performed with a probe that
is not contained in the targeting vector (external probe) in order to distinguish the
wild-type from the predicted targeted allele. In contrast, an internal probe can result
in many false positives, since it will detect the randomly integrated vector and some
of these insertions by chance will give the expected restriction fragment size and
appear to be targeted insertions. Ideally, both the 5' and 3' aspect of the targeted
locus should be analysed by using a 5' and 3' external probes. This will allow to
discriminate targeted integration of the entire vector or concatemers of the vector
from simple replacement events.
1.3.3.3. Parameters Affecting Targeting Frequency
One major factor affecting targeting frequency is the length of
homology to the target locus. Several groups have described a relationship between
the length of homology and targeting frequency (Thomas and Capecchi, 1987;
Shulman et al., 1990; Hasty et al., 1991a; Deng and Capecchi, 1992; Scheerer and
Adair, 1994). As a general rule the greater the length of homology the higher the
targeting frequency. However the exact relationship between the length of homology
and targeting frequency is yet unclear since differences have been observed between
experiments even in the same system. While a linear relationship was observed at
the hprt locus in murine ES cells using homologies ranging from 1.3 to 6.8 kb (Hasty
et al., 1991a), an exponential relationship was observed by other investigators at the
same locus using homologies between 2 kb and 18 kb (Deng and Capecchi, 1992).
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However, saturation of the mammalian HR apparatus appears to require
approximately 14 kb of homologous sequence in the targeting vector (Deng and
Capecchi, 1992). An exponential relationship between homology length and
targeting frequency was also observed by Scheerer and Adair (1994) at the adenine
phosphoribosyltransferase (aprt) locus in Chinese hamster ovary (CHO) cells using
homologies ranging in size from 896 bp to 3275 bp.
The use of isogenic or non-isogenic constructs is another important
determinant of gene targeting efficiency. An evenly dispersed 19 % mismatch
reduces the frequency of extrachromosomal recombination up to 15-fold in mouse
ES cells (Waldman and Liskay, 1987). Similarly, base pair mismatches have been
shown to strongly affect the frequency of HR in bacteria (Rayssiguier et al., 1989),
of intrachromosomal recombination in mammalian cells (Bollag et al., 1989) and of
gene targeting in embryonic stem cells (Deng and Capecchi, 1992; te Riele et al.,
1992; van Deursen and Wieringa, 1992). The number and extent of polymorphic
variation between two mouse strains in any given locus is usually unknown and may
vary widely from gene to gene. Such variation could account for high targeting
frequencies also observed in mouse ES cells without the use of isogenic DNA
(Zijlstra et al., 1989; Te Riele et al., 1990). Although it is now clear that the
existence of sequence mismatches between the homology in the vector and the target
locus usually reduces the targeting frequency in mouse ES cells, it has been
suggested that non-isogenic DNA does not affect targeting frequencies in human
cells (Sedivy et al., 1999). This is likely because the sequence divergence between
two human cell lines is much smaller than the difference between two mouse strains.
While single-nucleotide polymorphisms (SNPs) occur at a frequency of one per 500
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to 1000 bp in human cells (Wang et al., 1998; Sachidanandam, 2001; Zhao et al.,
2003), as many as 17 SNPs may occur in a 150 bp stretch of sequence (e.g. ckm
gene) between the 129 and BALB/C alleles (Van Deursen and Wieringa, 1992).
This would also be consistent with a previous report that suggested that
intrachromosomal recombination in mammalian cells increases with the amount of
uninterrupted homology available (Waldman and Liskay, 1988).
Locus-to-locus intrinsic variability has been extensively documented
to affect the overall targeting frequency. The level of expression of the target gene
may account for some of these observations. Early work in E. coli showed that HR
is highly enhanced by transcription (Ikeda and Matsumoto, 1979). Similarly, it has
been shown that transcription enhances HR in eukaryotes (Blackwell et al., 1986;
Thomas and Rothstein, 1989; Nickoloff and Reynolds, 1990; Nickoloff, 1992; Prado
et al., 1997), and that gene targeting frequency is significantly enhanced (3-fold to
>20-fold) in the presence of an agent that stimulates target site transcription in
cultured human fibrosarcoma cells (Thyagarajan et al., 1995). The direct correlation
between gene expression and HR suggests that actively transcribed hypomethylated
genes may be more accessible to the HR machinery (Blackwell et al., 1986).
Consistent with this hypothesis, is a recent report that showed a 2-fold increase in
gene targeting frequency in murine ES cells lacking the DNA methyltransferase 1
(Dnmtl), an enzyme involved in methylation (Dominguez-Bendala and McWhir,
2004). While there is evidence that transcription can stimulate gene targeting
frequency (Thyagarajan et al., 1995), it is also known that untranscribed genes can
be disrupted by gene targeting in murine ES cells with frequencies similar to
expressed genes (Roller and Smithies, 1989; Kumar et al., 1994; Kolb et al., 1999,
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Kolb, 2001). Thus the exact correlation between transcription and targeting
frequency (if any) remains to be explored.
1.3.3.4. Enrichment Strategies
The ratio between HR and illegitimate recombination (IR) may be as
low as 1:1000 (Bode et al., 2000b), it is therefore very common to use strategies to
enrich for targeted events. A widely applied approach includes the use of a positive-
negative selection (Thomas and Capecchi, 1987; Mansour et al., 1988) to reduce the
number of clones with random integration events in a cell population (figure 1.6).
The targeting construct is based on a replacement vector containing a positive
selection marker within the region of homology and the negative selection (e.g.
HSVtA:) at one or both ends of the homologous DNA. In a first step, the positive
selection is applied to select for cells that have integrated the targeting vector in their
genome. In the second step, the negative selection is applied only against cells in
which the entire targeting vector has integrated at random, since cells carrying a
targeted integration lose the negative selection marker during gene replacement
event. The enrichment achieved with a positive-negative selection may vary. While
a 2000-fold enrichment for HR events over illegitimate events was initially reported
(Mansour et al., 1988), usually enrichments between 2- to 20 fold (Hanson and
Sedivy, 1995) are observed. This is likely to be due to exonuclease degradation of
the negative selectable marker prior to integration of the plasmid into the genome.
Occasional loss of the negative marker in random integrants and metabolic exchange
between non-targeted and targeted cells may also account for a low enrichment.
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Figure 1.6. Positive-negative selection strategy. A targeted event results in the loss of the
negative selection marker (-) since it is located outside the regions of homology, and thus targeted
cells are resistant to both positive (+) and negative selections. In contrast, the integration of the
targeting vector into a random chromosomal site includes the negative selectable marker. Random
integrants are therefore resistant to positive selection but sensitive to negative selection. Thus
negative selection permits an enrichment for targeted events.
Enrichment for targeted events may be improved by using a promoter,
enhancer, or a polyadenylation trap targeting vector (Doetschman et al., 1988; Dorin
et al., 1989; Jasin and Berg, 1988; Sedivy and Sharp, 1989). Promoter and enhancer
trap vectors are designed to use the transcriptional activity of the endogenous target
gene to drive the positive selection cassette from the targeting construct. Such
constructs are thus restricted to genes which are transcriptionally active in the target
cells. For promoter trap strategies (figure 1.7), the positive selection cassette is
either cloned in-frame with the endogenous translated product, or the cassette may
encode its own translation initiation site and is positioned upstream or in place of the
nominal translational initiation site. Because in a promoter trap strategy targeting
vectors do not contain a promoter, the majority of random integrations will be
transcriptionally silent and therefore will not survive positive selection. Promoter
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trap selection will yield typically a 100-fold enrichment for targeting events and will
work for both insertion and replacement vectors (Schwartzberg et al., 1990). Good
candidate genes for a promoter trap strategy are those with high expression levels,
although genes with low expression levels have been successfully targeted with
promoter trap vectors (Jeannotte et al., 1991). Enhancer trap vectors may also be
used to enrich for targeted events. Such vectors use a selection marker with a weak
position-dependent promoter which can be activated if integration occurs in the
proximity of a transcriptional enhancer element. The enrichment factors achieved





Gene Targeting Random Integration
| Promoter')— r-r—i
Resistant to positive selection Sensitive to positive selection
Figure 1.7. Promoter trap Strategy. Targeted integration of the promoterless positive
selectable marker (+), with a polyadenylation signal, into an actively transcribed gene results in
expression of the marker, and thus targeted cells survive positive selection. In contrast, random
insertion of the vector does not usually result in expression of the marker, and therefore random
integrants do not survive selection.
Chapter I 31
Polyadenylation trap vectors are designed to use the transcription
termination/polyadenylation signals of the target gene to generate a stable hybrid
transcript composed of elements from both the target gene and the positive selection
marker. Such a vector contains its own promoter but no polyadenylation signal. In
contrast to promoter trap strategies, polyadenylation trap strategies may be used for
any gene irrespective of whether it is expressed in the cells. The best location for the
positive selection marker is in an exon of the target gene so that the splice donor
sequence of the disrupted exon can allow normal splicing to occur downstream of the
cassette. Typical enrichment factors achieved with such vectors vary between 5-to
50- fold (eg. Donehower et al., 1992) and work for both insertion and replacement
vectors.
1.3.3.5. Generation of Subtle Mutations
Several strategies have been designed to introduce subtle mutations
(e.g. point mutations) into a target locus without leaving a selectable marker in the
target gene, for the purposes of analysing gene function, correcting specific gene
defects, or preventing the possible interference of the selectable marker with
neighbouring genes (Clark et al., 1997). The "hit and run" or "in and out" approach
requires two steps of recombination and is based on an insertion-type vector
containing a subtle mutation in the homology and a positive-negative selection
marker in the plasmid backbone (Hasty et al., 1991b; Valancius and Smithies, 1991).
In the first step ("hit"), HR leads to the complete integration of the vector into the
target locus generating a partial duplication interrupted by plasmid sequence and the
two selection markers. Negatively-selected intrachromosomal recombination event
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("run") between the repeats leads to the correction of the target gene (along with the
subtle mutation) and loss of all heterologous sequences. The hit-and run technique
has been successfully used to generate mutations in ES cells in the hprt locus
(Valancius and Smithies, 1991); the hox-2.6 locus (Hasty et al., 1991b), the
P-amyloid precursor protein locus (Gschwind and Huber, 1998); the G(i2)2a locus
(Rudolph et al., 1993) and the cystic fibrosis transmembrane conductance regulator
(Cftr) locus (Dickinson et al., 2000) (with germ-line transmission of the mutated
allele being demonstrated in the latter two examples).
The "tag and exchange" (Askew et al., 1993) or double replacement
(Wu et al., 1994) strategy also involves two sequential gene targeting steps but uses
two different replacement type vectors. In a first step a selectable marker is inserted
in the target locus. In a second step, homologous recombinants are transfected with a
targeting vector which replaces the selection cassette in the targeted locus with a
non-selectable (e.g. point) mutation. This technique was successfully used to
introduce subtle mutations in mouse ES cells in the Colla-1 gene (Wu et al., 1994),
a.2 Na,K-ATPase gene (Askew et al., 1993), the Huntington's disease homolog (Hdh)
gene (Cearley and Detloff, 2001), and to replace the murine |3-lactalbumin gene with
its human homologue (Stacey et al., 1994). The advantage of this technique is that
any transgene can be used in the second step to generate a range of mutation at the
same locus. For instance, this technique has been used in ES cells to generate a
series of different targeted alterations to the prion protein gene (Moore et al., 1995).
A variance of this strategy is the "plug and socket" approach
developed by Detloff and co-workers (1994). In a first step, a functional neo and a
partial hprt minigene ("the socket") are targeted to a specific locus in hprt-deficient
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ES cells. In a second step, a second targeting vector ("the plug") that supplies the
remaining portion of the hprt minigene, generates a functional cassette upon HR with
the integrated socket. Using this method, the murine fi-globin gene was replaced by
its human equivalent (Detloff et al., 1994).
1.3.4. The CrelLoxP System
1.3.4.1. CrelLoxP Site-Specific Recombination Mechanism
The simplest site-specific recombination systems are comprised of
two elements: the recombinase enzyme and a small stretch of DNA specifically
recognised by the recombinase. These two elements work together to either delete,
insert, invert, or translocate associate DNA. Two such recombinase systems include
the Cre-loxP system from the bacteriophage PI and the Flp-FRT system from the
budding yeast S. cerevisiae and have been shown to function in bacteria, fungi, plant
and mammalian cells (reviewed by Kilby et al., 1993). The Cre protein (38 kDA) is
encoded by the E.Coli phage PI which is present inside E.Coli as a single copy,
circular DNA plasmid molecule. Cre activity catalyses the exchange and separation
of copies of PI that arise after its replication in order to allow partitioning of the two
PI molecules at each cell division (Sternberg and Hamilton, 1981; Hoess and
Abremski, 1984). The target site of Cre is the 34 bp loxP (locus of cross-over x)
sequence, characterised by two 13 bp inverted repeats flanking an 8 bp core sequence
(figure 1.8.A). Two Cre molecules bind to each loxP sites, one on each half of the
palindrome to form a tetrameric complex bringing two lox sites into proximity (van
Duyne, 2001). Cleavage, exchange, and ligation of one DNA strand forms a
Holliday intermediate; cleavage, exchange, and ligation of the second strand resolve
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the Holliday intermediate into two recombinant molecules (van Duyne, 2001). The
final outcome is the exchange of the symmetry arms of the two loxP sites and the
core regions of the two recombinants heteroduplex. This recombination reaction is
carried out with absolute fidelity, such that not a single nucleotide is gained or lost
overall. The orientation of a loxP site on a segment of DNA directs the type of
recombination between loxP sites. Cre catalyses both inter-molecular DNA
exchanges and intra-molecular excision or inversion (figurel.8.B). Two sites
orientated in the same direction on a DNA segment, lead to excision and
circularization of the DNA between the sites (Sauer and Henderson, 1989; Baubonis
and Sauer 1993) leaving a single loxP on the DNA segment and on the resulting
circular DNA. The reverse reaction may also occur, with the integration of the
circular DNA into a single loxP site. Upon targeted integration of the circular DNA,
the loxP site is however duplicated, leading to the highly favored intra-molecular
excision (Araki et al., 1997).
Alternative strategies have subsequently been devised in order to
create higher frequency and stability of insertion events. Several mutant lox sites
(mutation present in the 8 bp core region), that recombine efficiently with an
identical lox site but very inefficiently with loxP, were identified (Lee and Saito,
1998; Langer et al., 2002) (figure 1.8.A). The identification of these mutant lox sites
led to the development of the recombinase-mediated cassette exchange (RMCE)
approach (reviewed by Bode et al., 2000b; Baer and Bode, 2001) in which
heterospecific lox sites flanking a transgene, are introduced randomly in the genome
(Bethke and Sauer, 1997; Bouhassira et al., 1997; Feng et al., 1999; Trinh and
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Figure 1.8. The Cre/loxP system. (A) DNA sequences of wild type loxP site and a mutated
lox site, lox2272 site. The 8 bp core is represented in red and the mutations in the lox2272, in blue.
(B) Excision/integration: Cre-mediated recombination between two directly repeated loxP sites on a
linear DNA molecule leads to the excision and circularisation of the loxP flanked DNA insert. One
loxP site remains on each of the reaction products. In the reverse reaction a loxP containing circle is
integrated into a linear DNA molecule. Inversion: Cre-mediated recombination between inverted loxP
sites leads to a 50:50 probability of insert inversion. (C) RMCE: Heterospecific lox sites (e.g. loxP
and lox2272) flanking an insert can be used to swap a pre-inserted cassette in the genome (cassette 1)
for a targeting insert (cassette 2) that is flanked by the same lox sites. This double replacement occurs
with a 50:50 probability.
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In a subsequent Cre-mediated recombination step, transgenes flanked by the same set
of heterospecific lox sites can be exchanged by a double-reciprocal recombination
event with the previously introduced transgene (figure 1.8.C). Once a locus is tagged
with heterospecific lox sites, RMCE can be used to generate a broad range of
mutation at the same locus.
1.3.4.2. Applications
Site-specific recombination mediated by CrdloxP approach allows
researchers to control not only site-specific integration and copy number of
transgene, but also to replace or delete precisely any sequence within a targeting
locus (Gu et al., 1994; Kolb et al., 1999; Kolb, 2001). For instance, the cre/loxP
system can be used to remove selection markers, after conventional gene targeting in
order to avoid interference with the expression of the targeted gene or a neighbouring
transgene (Wang et al., 1999; Kolb, 2001). Moreover, Cre-mediated site-specific
recombination can be used to manipulate gene expression in a cell type specific or
inducible manner at the stage of development, which needs to be investigated
(Schwenk et al., 1995; Sauer, 1998; Metzger and Feil, 1999). Another application of
this system has been to induce a variety of chromosome rearrangements (deletions,
inversions, duplications, and translocations) in ES cells that can be selected and then
used to produce ES-derived mice (Smith et al., 1995; van Deursen et al., 1995;
Ramirez-Solis et al., 1995). This technology known as "chromosome engineering",
has successfully generated numerous mouse models that accurately recapitulate
human chromosomal rearrangements (e.g. Lindsay et al., 1999; Tsai et al., 1999;
Buchholz et al., 2000; Collins et al., 2000).
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1.4.1. Human ES Cells
1.4.1.1. Origin
The derivation of hES cells arose from the graduated progress which
started more than 40 years ago with the isolation of embryonic carcinoma (EC) cells
from mouse testicular teratocarcinomas (Kleinsmith and Pierce, 1964). This early
report led to the first derivation of murine ES cells (Evans and Kaufman, 1981;
Martin, 1981), followed by human EC cells (Andrews et al., 1984; Thompson et al.,
1984), murine embryonic germ (EG) cells (Matsui et al., 1992) and primate ES cells
(Thomson et al., 1995). Although these cell lines differ in their phenotype, they all
share common properties ofmultipotency and immortality.
Human embryonic stem (hES) cells were initially isolated by J.
Thomson and co-workers in 1998 (Thomson et al., 1998). Human ES cells are
derived from the inner cell mass (ICM) (cells that are destined to develop into the
embryo proper) of the blastocyst of excess embryos produced for clinical in vitro
fertilisation. After mechanical or immunosurgical (Solter and Knowles, 1975)
separation of the ICM from the trophoblastic cells, the isolated ICMs are
subsequently plated onto a supportive matrix, such as mouse embryonic fibroblasts,
or human embryonic fibroblasts. Colonies of appropriate undifferentiated
morphology are subsequently selected and expanded to form established human ES
cell lines. Since this first report, a large number of hES cell lines have been isolated
(e.g. Reubinoff et al., 2000; Lanzendorf et al., 2001; Richards et al., 2002; Hovatta et
al., 2003; Mitalipova et al., 2003; Pickering et al., 2003; Cowan et al., 2004).
Chapter I 39
1.4.1.2. Properties
The most important property of hES cells is their pluripotency, a
common characteristic shared with mES cells and human EG cells (Shamblott et al.,
1998). When grafted into severe combined immunodeficiency disease (SCID) beige
mice, hES cells give rise to teratomas containing derivatives of all three primary
embryonic germ layers (Thomson et al., 1998; Reubinoff et al., 2000). These
include gut epithelium (endoderm); cartilage, bone, smooth muscle and striated
muscle (mesoderm); and neural epithelium, embryonic ganglia and stratified
squamous epithelium (ectoderm) (reviewed by Przyborski, 2005). In addition, hES
cells in suspension can also differentiate spontaneously into cells of the three germ
layers when allowed to aggregate and form spheroid clumps termed embryoid bodies
(EBs) (Itskovitz-Eldor et al., 2000). After several days of differentiation, the EBs
contain cells from various tissues including muscle, bone, kidney, blood cells, skin,
liver (Schuldiner et al., 2000), P cells of the pancreas (Schuldiner et al., 2000;
Assady et al., 2001), and a large number of neurons (Reubinoff et al., 2000;
Itskovitz-Eldor et al., 2000; Schuldiner et al., 2001; Carpenter et al., 2001). In some
cases, the cells have been shown to be functional as in the case of cardiomyocytes
(Itskovitz-Eldor et al., 2000; Kehat et al., 2001), neurons (Carpenter et al., 2001) or
endothelial cells (Levenberg et al., 2002). Spontaneous differentiation into various
cell types may also occur without aggregation into EBs (Reubinoff et al., 2000;
Reubinoff et al., 2001).
Like their murine counterparts, hES cells have also the capacity of
self-renewal and can be propagated in culture indefinitely while maintaining a
normal karyotype (Thomson et al., 1998; Amit et al., 2000). Recent reports however
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showed that chromosomal abnormalities such as translocations, deletions and
duplications, may occur in prolonged culture (Draper et al., 2004; Inzunza et al.,
2004; Rosier et al., 2004; Mitalipova et al., 2005; Maitra et al., 2005; McWhir et al.,
unpublished data). Undifferentiated hES cells are characterised by the expression of
several ES specific molecular markers such as the transcription factor Oct-3/4
(Nichols et al, 1998), the cell surface markers SSEA-3, SSEA-4, Tra-1-60 and
Tra-1-81, telomerase and alkaline phosphatase (Thomson et al., 1998; Xu et al.,
2001; Amit et al., 2000; Draper et al., 2002). Undifferentiated proliferation of hES
cells relies mostly on the presence of a mouse (Thomson et al., 1998) or human
(Richards et al., 2002; 2003; Amit et al., 2003; Cheng et al., 2003; Hovatta et al.,
2003; Lee et al., 2005; Yoo et al., 2005) fibroblast feeder layer, which produces a
matrix required to allow adherence of the cells, and secretes factors maintaining
pluripotency and self-renewal potential (Thomson et al., 1998). Alternatively, the
feeder cell layer can be replaced with matrigel, an extracellular matrix (ECM)
preparation, and conditioned medium from the feeder cell layer (Xu et al., 2001). In
addition to the important role of the feeder cells in maintaining pluripotency, is the
use of basic fibroblast growth factor (bFGF) (Thomson et al., 1998) for the
propagation of hES cells. Despite the wide knowledge gained on the importance of
leukemia inhibitory factor (LIF) (Moreau et al., 1988; Smith et al., 1988) in
maintenance of mES cells, evidence from hES cell lines indicates that LIF does not
play a critical role in sustaining undifferentiated growth (Thomson et al., 1998,
Reubinoff et al., 2000).
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1.4.1.3. Applications
Given the properties of hES cells, the potential applications are many
(figure 1.9). Human ES cells will be useful for the study of gene function and for the
development of in vitro human disease modelling (see section 1.4.2.5). These cells
could also provide new information about the cellular and molecular basis of
commitment and differentiation events during embryonic human development and
disorders, such as birth defects and embryonal tumours, as these issues cannot be
addressed in the human embryo for ethical reasons. Additionally, hES-derived cell
lineages could provide a novel source for cell replacement therapy addressing the
chronic shortage of tissue for transplantation in the treatment of a wide range of
diseases such as type I diabetes, cardiovascular disease, Parkinson's disease, and
blood cell diseases. Human ES cells could also be a potential answer to an end to the
use of immunosuppressive therapy in transplantation, if cloning techniques can be
used to derive stem cells from a patient's own tissue or if genetic modification
strategies are established to render hES derivatives invisible to the immune system
(see section 1.4.2.4). Human ES cells will also have widespread applications in the
areas of drug discovery and drug development (reviewed by Pouton and Haynes,
2005). Cell types such as cardiomyocytes and hepatocytes generated from hES cells
could provide an ideal source of cells for predictive toxicology. These cells could
reveal the toxicity of certain drugs that might not be detected using conventional
assays that rely on animal models. Other applications could be made possible such
as an investigational tool for the discovery of novel growth and differentiation
factors that might find application in tissue regeneration and repair; and new delivery






















Figure 1.9. Potential use of hES cells in basic research and medicine. See text for
details. SCNT: somatic cell nuclear transfer (cloning).
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1.4.1.4. Ethical Considerations
Despite the potential applications of hES cells mentioned above, these
cells are surrounded by a number of controversies, the extent of which is partly
dependent on their source (Frankel, 2000). Human ES cell lines are derived from
"excess" embryos from in vitro fertilization (IVF) clinics. This is not acceptable to
many people including ethicists, religious and political leaders who consider full
human life as starting with conception (i.e. the formation of a zygote). The
establishment of human somatic cell nuclear transfer (SCNT) technology (transfer of
a nucleus of a somatic cell into an enucleated egg) and the derivation of hES cell
lines may lead to the reality of "therapeutic cloning" (Colman and Kind, 2000).
This raises even more ethical concerns because embryos will be specifically created
and destroyed for the purpose of deriving hES cell lines for different applications
(e.g. "autotransplant").
The use of human adult stem cells in cell-based therapy would be a
solution to the present ethical concerns. Several investigators have reported the
isolation of primitive human adult multipotent cells from different tissues.
Subpopulations of human mesenchymal stem cells (hMSCs) exhibiting features of
primitive adult pluripotent or multipotent stem cells have been described (Young et
al., 1998; Pittenger et al., 1999; Colter et al., 2000; Reyes et al., 2001; Jiang et al.,
2002; Gronthos et al., 2003). Adult stem cells have also been found in umbilical
cord blood (Erices et al., 2000), peripheral blood (Huss et al, 2000; Kuci et al.,
2003), adipose tissue (Zuk et al., 2001), skeletal muscle and dermis (Young et al.,
2001), as well as other tissues (Asakura and Rudnicki, 2002). Although these
primitive adult cell subpopulations have been shown to give rise to multiple lineages,
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they are not pluripotent and have usually less self-renewal ability than hES cells.
Recently however, Catherine Verfailllie and colleagues (Schwartz et al., 2002; Jiang
et al., 2002a; Jiang et al., 2002b) have isolated multipotent adult progenitor cells
(MAPCS) from mesenchymal cell cultures obtained from rodent and human bone
marrow. These MAPCS were capable of in excess of a hundred population
doublings and could be induced to differentiate into mesenchyme, endothelia,
neuroectoderm (neurons, astrocytes and oligodendrocytes) and endoderm
(hepatocytes) lineages. Similarly, D'lppolito et al. (2004) described a unique
subpopulation of human marrow stromal cells, MIAMI (marrow-isolated adult
multilineage inducible) that could give rise in vitro to cell types of the three germ
layers and that could be expanded for more than 50 population doublings. The
advantage of these adult bone marrow cells over hES cells is that the former can be
derived from autologous adult bone marrow, circumventing the problem of immune
rejection in the context of transplantation, and ethical issues raised by the use of hES
cells. Although these data raised hopes that these cells would be as useful for
therapeutic purposes as hES cells, many questions remain concerning the nature and
status of adult stem cells both in vivo and in vitro and their proliferation and
differentiation/transdifferentiation capacity (Wurmser and Gage, 2002; DeWitt and
knight, 2002; Holden and Vogel, 2002; Wells, 2002; D'Amour and Gage, 2002).
One issue in particular has been raised based on in vitro co-culture experiments with
mES cells and adult neural stem cells (Ying et al., 2002; Pells et al., 2002) or with
mES cells and adult bone marrow stem cells (Terada et al., 2002) suggesting that
fusion between adult bone marrow stem cells and differentiated cells rather than
transdifferentiation, occurs in vivo. Regardless of the present issues, the potential
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applications of both human adult and embryonic stem cells cannot be ignored, and it
is likely that both fields of research will be mutually beneficial.
1.4.2. Genetic Modification of HES Cells: Applications
1.4.2.1. Directed Differentiation and Purification
While some present differentiation protocols have been shown to
enrich for a particular cell type such as mature neurons (Reubinoff et al., 2001;
Zhang et al., 2001; Schuldiner et al., 2001; Carpenter et al., 2001), motor neurons
(Singh Roy et al., 2005; Shin et al., 2005; Li et al., 2005), astrocytes,
oligodendrocytes (Zhang et al., 2001), osteoblasts (Sottile et al. 2003; Karp et al.,
2005), skin cells, liver cells, and adrenal cells (Schuldiner et al., 2000), they do not
induce a single differentiation pathway. Thus the main challenge will be to purify
homogenous populations of terminally differentiated functional cells or their
progenitors. One way to address this issue would be to genetically modify hES to
express master genes that promote commitment to a desired lineage pathway. For
instance, directed differentiation towards a chondrocyte phenotype was accomplished
in murine embryonic mesenchymal cells by expressing the human bone
morphogenetic protein-2 (BMP-2) cDNA (Carlberg et al., 2001). Similarly,
expression of HoxB4 transgene in mouse ES cells was shown to induce
differentiation towards haematopoietic stem cells (Kyba et al., 2002). Likewise, in
vitro differentiation towards a hepatocyte phenotype was achieved in mES cells by
overexpressing the hepatocyte nuclear factor 3 beta (Kanda et al., 2003).
Human ES cells could also be genetically modified to express a
lineage-specific selectable marker which would allow the purification of a defined
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cell population using drug ablation (Klug et al., 1996) or FACS/MACS separation
(Li et al., 1998; Muller et al., 2000). This strategy was first demonstrated by Klug et
al., in 1996 who engineered mES cells to express a neo marker under the control of a
cardiac-specific promoter. Following differentiation, an enrichment of more than
99% of cardiomyocytes was achieved by subjecting the mixed differentiated cell
populations to G418. Similarly, Muller et al. (2000) showed that 97 % of mouse
ES-derived cardiomyocytes, engineered with a cardiac-specific promoter driving a
GFP marker, could be purified using percoll gradient centrifugation and subsequent
fluorescence-activated cell sorting. Harvesting a single population of cells could be
further improved by using an antibody against a tissue-specific membrane protein
present in the differentiating cells of interest. Such a procedure was demonstrated
for the purification of hES-derived endothelial cells using a fluorescent-activated cell
sorter (FACS) (Levenberg et al., 2002) and hES-derived hematopoietic cells using
Magnetic Column Separation (MACS) (Kaufman et al., 2001).
1.4.2.2. Protection Against Tumorigenesis
The ability of undifferentiated hES cells to form tumours in
histocompatible animals is well documented (e.g. Thomson et al., 1998; Reubinoff et
al., 2000). Therefore, efforts need to be made to ensure that the cell graft is depleted
of any undifferentiated hES cells before transplantation. Elimination of
undifferentiated hES cells could be achieved by expression of a negative selectable
marker from an undifferentiated hES cell-specific promoter. A "suicide" gene
therapy described for treating cancer (Freytag et al., 2002) could be adapted for hES
cells with less complexity as the cells would be modified in vitro to express the
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suicide gene without the requirement of targeted delivery in vivo. Towards this end,
hES cells have already been modified to constitutively express the herpes simplex
virus thymidine kinase (HSV-t&) suicide gene which resulted in the ablation of
HSV-tk+ hES cells in vitro and their derivatives in vivo in SCID mice with the drug
ganciclovir (Schuldiner et al. 2003). For this application a suicide gene targeted to a
locus known to be permissive for transgene expression, would be the method of
choice to ensure the complete elimination of the potentially tumorigenic
undifferentiated hES cells from a differentiated cell population.
An alternative approach would be to target a tetracycline "on/off " inducible tk
transgene (Lewandoski, 2001) to a locus known to be permissive for transgene
expression. This strategy would allow the engineered-derived tissue of interest,
grafted into a patient, to be eliminated with tetracycline in the event that tumorigenic
cells developed within.
1.4.2.3. Long-Term Survival and Functionality of the Graft
Success in regenerative medicine will depend upon the functional
integration of the graft into host tissue. This will require the long-term survival of
the grafted cells, the presence of a critical tissue mass, the appropriate alignment of
the donor cells and their structural and functional integration within the host tissue.
Several questions and issues remain to be addressed in this area. Cell death
occurring after engraftment will be a major problem as it is believed to have a
negative impact on the size of the graft (Zhang et al., 2001; Muller-Ehmsen et al.,
2002). Hence, cell survival following transplantation may depend on adequate
vascularisation of the graft, which may require additional revascularisation
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procedures or induction of angiogenesis. In that respect, the ability to genetically
modify hES cells may be used to produce derivatives that are more resistant to
ischemia or apoptosis, that can display larger proliferative capacity, that can secrete
angiogenic growth factors such as VEGF (Rio et al., 1999), or may be coupled with
ES cell-derived endothelial progenitors.
1.4.2.4. Immunotolerance
Rejection of stem cell-derived grafts by an allogeneic host could be
circumvented in a number of ways (reviewed by Bradley et al., 2002). One solution
may be to render hES cells and their derivatives "invisible" to the immune system.
To this end, hES cells could be genetically modified to create a "universal donor"
hES cell line, which could escape or inhibit the host immune response. HLA-A, -B
and -C antigens, responsible for immunogenicity, could be suppressed by gene
targeting to prevent expression of major histocompatibility class (MHC) I molecules
(Bradley et al, 2002). In the mouse model, skin from mice that are deficient for both
MHC class I and II antigens grafted to recipients that differ by just a few MHC
antigens survives for a longer period of time, but eventually is rejected (Grusby et
al., 1993). This is likely because MHC antigens initiate rejection, although residual
MHC antigens might contribute also (Lee et al., 1997). A drawback to this strategy,
however, is the risk of susceptibility to tumorigenesis, as some of the most
aggressive malignancies are those that evade the immune system by a lack ofMHC
expression (Restifo et al., 1993; Cromme et al., 1994; Hicklin et al., 1998). Human
ES-derived tissues lacking MHC class-I-dependent defence system would also be
more susceptible to viral infection as there would be no MHC class I molecules to
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present viral peptides to virus-specific cytotoxic T cells (Zeidler et al., 1997).
Nevertheless, the host defence has evolved to counter these survival strategies with
the presence of NK cells that effectively lyse cells that have no MHC class-I-
mediated protection (Storkus et al., 1987). Thus protection of hES-derived
"universal-donor" cells from NK cells will be required, possibly by harnessing
immune-evasion strategies. For instance, hES cells could be further genetically
modified with transgenes that express certain viral genes which have evolved to
escape the host immune system (Arase et al., 2002).
While the idea of creating a MHC-deficient cell line might sound
attractive, such hES cells-derived grafts would likely still encounter rejection just as
it has been described for tissue grafts from MHC-/- mice (Grusby et al., 1993). Thus
alternative strategies, such as the generation of individualised ES cell lines through
SCNT and tolerisation approaches, may be more realistic. In the former approach,
the cells used for transplantation would be identical to those of the patient, thereby
overcoming the problem of graft rejection (Colman and Kind, 2000). An ethical and
practical limitation of SCNT is the requirement of oocytes. The derivation of
oocytes from ES cells may however provide a solution to this problem (Hubner et
al., 2003). The latter approach involves tolerisation of the patient's immune system
to the graft by the establishment of a chimeric immune system upon transplantation
of hES cell-derived hematopoietic stem cells (Bradley et al., 2002).
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1.4.2.5. In Vitro Modeling of Human Diseases
Modifying specific genes for in vitro studies in hES cells will be
important for learning more about the pathogenesis of diseases for which mouse
models are not appropriate. In the context of this project for instance, the hprt gene,
whose dysfunction in humans leads to Lesh-Nyhan Syndrome (LNS), would be a
good candidate. LNS is a severe genetic disease syndrome which is characterised by
excessive levels of uric acid in the blood, which eventually leads to kidney damage
(Stout and Caskey, 1988). LNS may also lead to physical and mental retardation,
nephrolithiasis, urinary tract stones and may impact brain development. It is still
unclear how the HPRT-deficiency leads to the neurological symptoms, although it
has been reported that dopaminergic neurons are affected in LNS patients (Visser et
al., 2000; Saito and Takashima, 2000). Urbach et al. (2004), have recently
demonstrated that a targeted mutation in the hprt gene in hES cells, mimic some
clinical features associated with LNS such as the abolishment of HPRT activity, and
a higher rate of uric acid accumulation (a characteristic never observed in the mouse
model). Thus their data point to the relevance of hES cells in complementing murine
models for the study of human genetic diseases. In vitro studies of HPRT-deficient
hES-derived dopaminergic neurons as well as transplantation of these cells to an
animal model should therefore provide useful clues regarding the etiology of the
neurological deficit, and may provide new means of drug development for the
neurological symptoms.
The study of genetic diseases, in which mutations are associated with
a gain of function such as the SOD1 gene, in the case of motoneuron disease (also
known as amyotrophic lateral sclerosis (ALS)) (Rosen, 1993; Shaw et al., 1998),
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could be further improved by introducing a disease-linked mutation into a
chromosomal locus known for reproducible transgene expression in hES cells,
followed by in vitro differentiation and subsequent analysis of the affected cell type.
1.4.2.6. Gene Correction
Breakthroughs in adult somatic nuclear transfer (Campbell et al.,
1996) and human ES cell derivation (Thomson et al., 1998) have raised the
possibility of using both techniques to generate unlimited sources of autologous cells
for tissue repair. Known as "therapeutic cloning", it might be possible to combine
this technique with gene therapy to derive hES cells from a patient with a specific
genetic defect, correct the gene by gene targeting, and return the derivatives of the
genetically-matched corrected cells to the body of the patient, such that repopulation
by the corrected cells repairs damaged and diseased tissues (reviewed by Colman and
Kind, 2000). This strategy has previously been exemplified in immune-deficient
Rag2'f' (recombination-activating gene 2) mice (Rideout et al., 2002). These authors
used immune-deficient Rag2~'~ mice as nuclear donors for transfer into enucleated
oocytes, and isolated ES cells from the NT-derived blastocysts. One of the mutated
alleles in the Rag2" ES cells was genetically repaired by HR, and hematopoietic
precursors were derived by in vitro differentiation and engrafted into Rag2~'~ mice.
Mature myeloid and lymphoid cells and immunoglobulins became detectable 3-4
weeks after transplantation, demonstrating the potential of this therapeutic approach.
In the face of the ethical and practical problems associated with therapeutic cloning
and subsequent gene correction in humans, it seems likely however, that a transplant
derived from normal, but allogeneic hES cells, will be less problematic.
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1.4.3. Methods for the Genetic Manipulation of HES Cells
1.4.3.1. Additive Transgenics in Human ES Cells
Developing improved technology for the genetic manipulation of hES
cells will be crucial for their effective application in research. The generation of
stable transfectants has now been achieved by electroporation (Eiges et al., 2001;
Zwaka and Thomson, 2003), Chemical methods (Eiges et al., 2001; Urbach et al.,
2004), or viral transduction with lentiviral (Pfeifer et al., 2002; Gropp et al., 2003;
Ma et al., 2003) and adenoviral (Smith-Arica et al., 2003) vectors. Transfection
efficiencies are however not as high as with mES cells which likely reflect a lack of
optimal culture conditions. Different cell culture regimes have been employed by
laboratories developing transfection procedures. These include mechanical
disaggregation of hES cells (Gropp et al., 2003), trypsin-based disaggregation (Eiges
et al., 2001), collagenase-based disaggregation (Thomson et al., 1998),
feeder-dependent (Eiges et al., 2001), and feeder-free cultivation (Xu et al., 2001).
Problems generating single-cell suspensions, poor plating efficiencies, and low
cloning efficiencies have hampered progress in developing efficient transfection
procedures. However, more laboratories are using trypsin-based disaggregation of
hES cells, allowing single-cell suspensions which are more effective for
electroporation.
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1.4.3.2. Gene Targeting in Human ES Cells
Gene targeting has now been reported in hES cells at the hypoxanthine
phosphoribosyl transferase (hprt) (Zwaka and Thomson, 2003; Urbach et al., 2004),
and the oct-4 genes (Zwaka and Thomson, 2003) with frequencies similar to those
observed in mouse ES cells. The work described in this thesis began one year before
these reports. For targeting hprt, Zwaka and Thomson used a targeting construct
containing 12 kb of homology, achieving transfection efficiencies of 2.3 x 10"5 and a
targeting frequency (measured as a proportion of transfectants) of 2 % using an
electroporation method in a subclone of the male HI hES cell line. Urbach et al.
(2004) used a targeting construct containing 8.5 kb of homology, resulting in
transfection efficiencies of 10"6 and a targeting frequency of 1 % using a chemical
method in the male HI3 hES cell line. Gene targeting has also been recently
exemplified by adeno-associated virus (AAV) transduction at the hprt locus in the
HI hES cell line with frequencies much greater than with plasmid-based vectors
(Thomson et al., unpublished data). Karyotypic stability, pluripotency, and sternness
of the hES-targeted cell lines are however issues that are yet to be addressed for these
cells to fulfill their role in research and medicine.
Gene targeting can also be achieved indirectly by targeting the
transcript through the use of short interfering (si) RNA. The new field of RNA
interference has provided a powerful tool for assessing the consequences of the
down-regulation of specific genes. Several recent reports have now shown that this
technique can be used to knockdown gene expression in hES cells (Hay et al., 2004;
Vallier et al., 2004; Liu et al., 2005). A downside of this approach, however, is the
transient nature of siRNA permitting only temporary gene knockdown.
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1.4.4. Engineering p-casein and hprt Genes in HES Cells
Many of the applications described in section 1.4.2, such as the modeling of
human diseases (in the case of LNS), reduction of immunogenicity of hES
cell-derived transplants, protection against tumorigenesis and directed differentiation,
could be achieved at the hprt and /?-casein genes in hES cells.
1.4.4.1. P-Casein Gene as a Target Locus: Characteristics &
Advantages
P-casein is a major protein component of mammalian milk and is
assembled into micelles in conjunction with other caseins (for review see Ginger and
Grigor, 1999). Caseins are a heterogenous group of phosphoproteins whose primary
function is to provide the suckling infant with essential amino acids, calcium and
phosphate, which are crucial elements for bone development in neonates. Caseins
are encoded by single-copy genes comprising a multigene family. Although caseins
have the same biological function in all mammals, their numbers vary widely among
species; bovine milk, for instance, contains four caseins: asi, as2, P and k, whereas
mouse milk contains five caseins: a, k, y, 8 and (3. Human milk, on the other hand,
contains only three caseins: p, k and asi. P-casein is the major casein and represents
about 30% of the protein mass in human milk. In contrast, the amount of a-CN in
human milk is very little (Rasmussen et al., 1995).
The P-casein gene represents an attractive candidate locus for
targeting transgenes as it was previously shown that the disruption of the p-casein
gene by gene targeting in mouse ES cells generated viable and fertile homozygous
P-casein mutant mice, and that homozygous females can lactate and successfully rear
young, although the growth of pups feeding on their milk, was reduced when
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compared to those feeding on the milk of wild-type mice (Kumar et al., 1994).
These results demonstrated that the fi-casein gene has no essential function out-with
the mammary gland. In addition, the fi-casein gene is only expressed in the lactating
mammary gland. Hence its dysfunction in non-mammary cell types by transgene
introduction is unlikely to have detrimental effects. The integration of transgenes
into pre-selected loci such as /?-casein also presents the advantage that both alleles
can be genetically modified without risks of insertional mutagenesis of essential
genes such as house keeping genes that are ubiquitously expressed. The attraction of
having two copies of the transgene lies in the low frequency with which both copies
could be lost or rendered dysfunctional. This is a particularly important
consideration where transgenes are introduced to provide protection against
tumorigenesis (eg. Tet-inducible tk transgene). Although unexpressed genes might
be more difficult to target in hES cells than expressed genes, it has been achieved in
mES cells (Johnson et al., 1989; Koller and Smithies, 1989) including the fi-casein
gene (Kumar et al., 1994; Kolb et al., 1999; Kolb, 2001), suggesting that it might not
be an issue in hES cells.
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1.4.4.2. Hprt Gene as a Target Locus: Characteristics &
Advantages
The hprt gene is a housekeeping gene, which is expressed at a low
level in most tissues with highest expression in brain and testes (Watts et al., 1987).
It is one of the three enzymes involved in the inosinate cycle (figure 1.10) (reviewed
by Stout and Caskey, 1988). The enzyme acts by salvaging hypoxanthine and
guanine by transfer of a phosphoribosyl group from the 5' phosphoribosyl-1-
pyrophosphate (PRPP) to generate inosine monophosphate (IMP) or guanosine
monophosphate (GMP), respectively. These mononucleotides exert a strong
feedback control on de novo synthesis pathway, which will be borrowed if purines
are not provided in the medium or if hprt is not functional. HPRT-deficiency results
in uric acid overproduction due to the inability to recycle either hypoxanthine or
guanine, which interrupts the inosinate cycle producing a lack of feedback control of
synthesis, accompanied by rapid catabolism of these bases to uric acid. PRPP not
utilised in the salvage reaction of the inosinate cycle provide an additional stimulus
to the de novo synthesis and uric acid overproduction.
The hprt gene has proved to be a very useful system in the
development of targeting strategies as well as in the study of HR in m ES cells
(Thomas and Capecchi, 1987; Doetschman et al., 1987). Two features make the hprt
gene a great tool for gene targeting strategies. Hprt is X-linked, therefore the
disruption of a single allele is sufficient to lead to complete loss of function in male
cell lines. Additionally, hprt is a selectable gene as its function may be selected
either for (HAT selection) or against (6-TG) in cultured cells by chemical selection
rendering targeting frequencies easy to calculate at a phenotypic level (Albertini,
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2001). The drug aminopterin is known to block the de novo pathway as well as the
thymidilate synthase reaction. Therefore in HAT (hypoxanthine-aminopterin-
thymidine) selection only wild type cells will be able to survive selection as they can
use the salvage pathway (Szybalski & Szybalska, 1962). In contrast, HPRT-deficient
cells have both routes affected and will die under HAT selection. HPRT is also
capable of phosphoribosylating the toxic guanine analogue 6-thioguanine (6-TG),
which will be fatal for wild type cells if this is added to the medium (Stutts &
brockman, 1963). Since HPRT-deficient cells are unable to salvage free purine
bases, they are not affected when 6-TG is added to the culture medium.
The hprt gene also provides the advantage that transgenes can be
introduced into a desirable chromatin environment with the appropriate regulatory
elements. Reproducible transgene expression has been previously demonstrated at
the hprt gene in a variety of cell lines including mES cells (Evans et al., 2000;
Guillot et al., 2000; Cvetkovic et al., 2000; Minami et al., 2002; Heaney et al., 2004)
and should therefore be a good candidate gene in hES cells for targeting transgene












Figure 1.10. HPRT in the purine salvage pathway. See text for details. PRPPS:
phosphoribosyl-l-pyrophosphate synthetase. PRPP: phosphoribosyl-1-pyrophosphate. PPi:
pyrophosphate. IMP: inosine monophosphate. GMP: guanosine monophosphate.
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1.5. Project Objectives
The aim of this project is to obtain a human ES cell line with predictable
levels of transgene expression at the /3-casein and hprt loci. Such cell lines will be a
critical tool in research and medicine. To achieve this aim, the objectives below are
to be followed:
1- To introduce heterospecific lox sites by homologous recombination into the
fi-casein and hprt genes in hES cells (Chapters 3 and 4).
2- To investigate whether a hES cell line targeted at the /?-casein or hprt genes,
retains a normal karyotype, can differentiate in vitro towards the three germ layers,
and express markers characteristic ofhES cells (Chapter 5).
3- To correct, by homologous recombination, the targeted mutation previously
generated in hES cells at the hprt gene, in a functional and structural levels (Chapter
6).
4- To introduce a series of lineage-specific markers by site-specific recombination
into the fi-casein and hprt genes in hES cells (Chapter 7).












2.1.1.1. Extraction of Genomic DNA from Human ES Cells


















2.1.1.1. Extraction of Genomic DNA from Human ES Cells
Genomic (g) DNA was extracted using a mammalian DNA isolation
procedure adapted from Laird et al. (1991). Lysis buffer was prepared by mixing
100 mM Tris-HCl pH8.5 (50 ml from 1 M Tris pH 8.5 stock), 5 mM EDTA pH 8.4
(5 ml from 0.5 M EDTA stock) and 200 mM NaCl (33.3 ml from 3 M NaCl stock),
for a total volume of 490 ml in distilled water. The solution was autoclaved and then
supplemented with 10 ml of 10% SDS (0.2 % final concentration (f.c)). Cells were
treated with lysis buffer (3 ml per 25 cm2 flasks) supplemented with Proteinase K
(Promega) (100 pg/ml f.c) prior to use. Lysates were subsequently transferred to a
suitable tube (depending on the sample volume) and incubated overnight at 55 °C.
The next day, lysates were incubated at 37 °C for 1 hour with ribonuclease A diluted
1:100 (32.5 mg/ml stock, Sigma) and a further 2 hours with 100 pg/ml Proteinase K
at 55 °C. One volume of isopropanol was added to each lysate and samples were
mixed until a white DNA precipitate was visible. For cell cultures with surface area
>10 cm , gDNA was recovered in an Eppendorf tube by fishing the precipitate with
an inoculating loop and needle (Nunc). Alternatively DNA precipitates, obtained
from culture vessels below a surface area of 10 cm2, were recovered by centrifuging
for 5 minutes at 14,000 x g in a table-top microcentrifuge (miniSpin plus,
Eppendorf). In both cases, gDNA was subsequently washed with 70% ethanol by
mixing the samples and centrifuged for 5 minutes at 14,000 x g. DNA pellets were
air-dried for 5 minutes, dissolved in a suitable volume of TE buffer (lOmM Tris-HCl,
pH 7.5, ImM EDTA) and incubated at 65 °C for several hours until the DNA was
dissolved properly.
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2.1.1.2. Extraction of plasmid DNAfrom bacteria
Minipreps
Small-scale extraction of plasmid DNA from bacteria were performed
using the QIAprep Spin Miniprep kit (Qiagen). Individual bacterial colonies were
picked and incubated overnight at 37 °C in 15 ml Falcon tubes containing 3ml of
autoclaved LB (Luria-Bertani broth) medium (10 g tryptone, 5 g yeast extract, 5 g
NaCl, 1 litre of distilled water, pH 7.5) supplemented with 100 pg/ml of ampicillin
or 50 pg/ml of kanamycin depending on the plasmid antibiotic resistance required.
1.5 ml of overnight cultures were transferred to Eppendorf tubes and centrifuged for
5 minutes at 14,000 x g. Bacterial pellets were resuspended in 250 pi Buffer PI (50
mM Tris-HCl, pH8.0; 10 mM EDTA, 100 pg/ml RNase A) and 250 pi Buffer P2
(200 mM NaOH, 1% SDS) was added to lyse the cells. Lysis reactions were stopped
with the addition of 350 pi of Buffer N3 (3.0 M potassium acetate, pH5.5), gently
mixed and centrifuged for 10 minutes at 17,900 x g. Resulting supernatants were
applied to a QIAprep Spin Column and centrifuged for 1 minute at 14,000 x g.
Columns were washed by adding 750 pi Buffer PE (1.0 M NaCl; 50 mM MOPS,
pH7.0; 15% isopropanol (v/v)) centrifuged for 1 minute at 14,000 x g. The
flow-through was discarded and columns were centrifuged for an additional 1 minute
to remove residual wash buffer. Columns were then placed in Eppendorf tubes and
DNAs were eluted with the addition of 50 pi Buffer EB (10 mM Tris-HCl, pH8.5) or
distilled water by centrifuging 1 minute at 14,000 x g.
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Maxipreps
The QIAGEN Plasmid maxi kit was used for the large scale extraction
of plasmid DNA from bacteria. Plasmid DNA prepared by this method was used for
stable and transient transfections and for the construction of the Southern DNA
probes. Typically, one individual bacterial colony was picked from a selective plate
into a 15 ml Falcon tube containing 5 ml of autoclaved LB medium supplemented
with the appropriate selective antibiotic and incubated for 8 hours at 37 °C at 225
rpm in a orbital shaker. Starter culture was diluted (1/500) into 200 ml of LB
complemented with the selective antibiotic in a 1 litre conical flask and grown
overnight at 37°C in a orbital shaker at 225 rpm. After 12 to 16 hours growth, the
bacterial culture was transferred into a 250 ml dry-spin1M bottle (Sorvall) and the
cells were harvested by centrifugation in a Sorvall RC-5B rotor at 6000 x g for 15
minutes at 4°C. After removing all traces of supernatant, the bacterial pellet was
resuspended in 10 ml of a Resuspension Buffer PI (50 mM Tris.Cl pH 8.0, 10 mM
EDTA, 100 pg/ml RNase) and 10 ml of a Lysis Buffer P2 (200 mM NaOH, 1%
SDS) was added with thorough mixing. The lysis reaction was carried out at room
temperature for 5 minutes. 10 ml of chilled Neutralization Buffer P3 (3.0 M
potassium acetate, pH 5.5) was added and the sample was incubated on ice for 20
minutes. The resulting precipitate was then centrifuged at 20,000 x g for 30 minutes
at 4°C. The supernatant containing the plasmid DNA was carefully filtered through a
filter paper (Whatman) into a 50 ml test tube. The resulting clear supernatant was
then applied to a QIAGEN-tip 500 previously equilibrated with 10 ml of Buffer QBT
(750 mM NaCl, 50 mM MOPS pH 7.0, 15 % isopropanol, 0.15% Triton X-100) and
was allowed to enter the resin by gravity flow. The QIAGEN-tip was washed twice
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with 30 ml of Buffer QC (1.0 M NaCl, 50 mM MOPS pH 7.0, 15 % isopropanol)
to remove all contaminants of plasmid DNA preparation and the DNA was eluted
with 15 ml of Elution Buffer QF (1.25 M NaCl, 50 mM Tris.Cl pH 8.5, 15 %
isopropanol) previously heated at 55°C. The eluted plasmid DNA collected in Corex
tubes was precipitated by adding 10.5 ml (0.7 volumes) of room-temperature
isopropanol and centrifuged at 15,000 x g for 30 minutes. The supernatant was
decanted carefully and the DNA pellet was washed with 5 ml of room-temperature
70% ethanol and centrifuged at 15,000 x g for 10 minutes. The supernatant was
decanted carefully and the DNA pellet was then air-dried for 10 minutes, dissolved
in 500 pi of TE buffer and transferred into a 1.5 ml centrifuge tube.
2.1.2. DNA Purification
2.1.2.1. Ethanol Precipitation
Purification of plasmids used for transfection experiments was carried
out as follows: Plasmid DNA in solution was precipitated by the addition of 1/10
volume of 3 M sodium acetate and 2.5 volumes of 100% ethanol. The sample was
then centrifuged for 10 minutes at 14,000 x g in a table-top microcentrifuge and the
resulting DNA pellet was washed in 500 pi 70% ethanol by centrifuging for 5
minutes at 14,000 x g. Excess ethanol was removed in a tissue culture hood to avoid
contamination and the pellet was air-dried and resuspended in distilled water to get a
final DNA concentration of lpg/pl.
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2.1.2.2. Gel Extraction
DNA was extracted and purified from standard or low-melting point
agarose (Invitrogen) gels using the QIAquick gel extraction kit protocol (QIAGEN).
A cut was made in the gel immediately in front of the fragment to be purified with a
clean, sharp scalpel. The gel slice was transferred to an Eppendorf tube and
weighed. Three volumes of Buffer QG were added to one volume of gel (100 mg ~
100 pi). The sample was incubated at 50°C for ten minutes in a water bath to melt
the gel slice. One gel volume isopropanol was added to the sample and mixed. The
sample was applied to a QIAquick spin column that was placed in a 2 ml collection
tube and centrifuged at 14,000 x g for one minute to bind the DNA. After discarding
the flow-through and placing the QIAquick column back in the same collection tube,
500 pi of Buffer QG was added to the column to remove all traces of agarose. The
column was centrifuged for 1 minute at 14,000 x g. 750 pi of Buffer PE
complemented with 100% ethanol was added to the column to wash the DNA and
the column was then centrifuged for 1 minute at 14,000 x g. The flow-through was
discarded and the column was centrifuged for an additional 1 minute in order to
remove residual ethanol from Buffer PE. The column was then placed into a sterile
1.5-ml Eppendorf microfuge tube and the DNA was eluted with 50 pi of elution
buffer EB by centrifuging the column for 1 minute at 14,000 x g.
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2.1.2.3. DNA Clean Up from Enzymatic Reactions
DNA clean up from enzymatic reactions were performed using the
same QIAquick gel extraction kit protocol but 3 volumes ofBuffer QG and 1 volume
of isopropanol was directly added to the enzymatic reaction. Subsequent steps were
carried out as described above.
2.1.3. DNA Quantitation
2.1.3.1. UV Spectrophotometer
Typically, 1:200 DNA dilution was used to determine the
concentration. Quantitation was conducted in an UNICAM 5625 UV/VIS
spectrophotometer at a wavelength of X = 260 nm. Since 1 unit of OD corresponds
to approximately 50 pg/ml of double-stranded DNA, concentrations could be
determined using the following formula:
pg DNA/ pi = OD x dilution factor x 50
2.1.3.2. Gel Quantification
When there was not sufficient material for spectrophotometer analysis,
the DNA was quantified by loading an aliquot on an agarose gel supplemented with
ethidium bromide along with 5 pi Bioline DNA hyper ladder molecular marker.
DNA concentration could be determined by comparing the intensity of the bands




All PCR products produced for the construction of plasmids were first
cloned into the Invitrogen pCR2.1-Topo TA vector (appendix 1, section 2.1) prior to
subsequent cloning steps. Tag-amplified PCR products are characterised by a single
3'-adenosine (A) overhangs on both ends. The linearised pCR2.1-Topo TA vector
contains 3'-thymidine (T) overhangs and two topoisomerase I covalently bound to
the vector (referred to as "activated" vector) that enable the direct ligation of PCR
inserts. Typically, 4 pi of purified PCR product was used in a Topo cloning reaction.
1 pi of salt solution and 1 pi of pCR2.1-Topo TA vector were added to obtain a final
volume of 6 pi. Reactions were mixed and incubated for 5 minutes at room
temperature (RT), and 2 pi of each reaction was used for subsequent transformations
ofDH5a competent cells (see section 2.1.4.5).
2.1.4.2. Blunting
When required, blunt ends were generated with the DNA polymerase I
large fragment (klenow). Klenow fragment (New England Biolabs) is a proteolytic
product of E.coli DNA polymerase I which retains 5'-3' polymerisation and 3'-5'
exonuclease activity but lacks 5'-3' exonuclease activity (Joyce and Grindley, 1983).
Typically, 1 to 5 units of klenow and 1.65 pi of 1 mM dNTP mix (33 pM f.c) was
added to the purified DNA and the reaction was incubated at room temperature for
15 minutes. The reaction was subsequently inactivated by incubation at 75 ° C for
20 minutes and DNA was purified using the QIAquick gel extraction kit protocol.
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2.1.4.3. Dephosphorylation
Prior to ligation between the vector and insert DNA, the linearised
vector DNA was dephosphorylated with shrimp alkaline phosphatase (SAP) (Roche),
to prevent self-religation of DNA ends. 1 unit of SAP was used to catalyse the
dephosphorylation of up to 1 pmol 5'-terminal phosphorylated 5'-protruding or 5'-
recessive ends DNA vectors, and up to 0.2 pmol 5'-terminal phosphorylated blunt-
ended DNA vectors for 60 minutes at 37 0 C. The reaction was subsequently
inactivated by incubation at 65° C for 15 minutes and the vector DNA was purified
using the QIAquick gel extraction kit protocol.
2.1.4.4. Ligation
Ligations of sticky-end and blunt-end DNA fragments (200 ng
maximum) were performed using the Rapid DNA ligation kit (Roche). As most
plasmid construction involved blunting of both vector DNA and insert DNA, the
molar ratio of vector to insert DNA was usually between 1:3 to 1:10. For instance
for a 1:3 ligation, 100 ng of purified dephosphorilated vector DNA (10 kb) and 45 ng
of purified insert DNA (1.5 kb) were dissolved in lx DNA dilution buffer in a total
volume of 10 pi. After thorough mixing, 10 pi of 2x T4 DNA ligation buffer was
added to the vial and mixed thoroughly before adding 1 pi of T4 DNA ligase (5
units). Mixed ligation reactions were subsequently incubated for 5 minutes at room
temperature. Occasionally, when the total volume of DNA solution in lx DNA
dilution buffer was greater than 10 pi, the volume of all reagents in the reaction was
increased accordingly and the ligation reactions were incubated for 30 minutes at
room temperature. A maximum of one-tenth of the volume ligation reaction was
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used for the transformation of Subcloning Efficiency (SE) competent cells of the
DH5a bacterial strain (Life Technologies) to avoid an inhibition by a surplus of
DNA.
2.1.4.5. Transformation
The Escherichia Coli Subcloning Efficiency (SE) DH5a strain was
used for the routine propagation of all plasmids and DNA from ligation reactions.
SE DH5a competent cells were thawed on ice and typically, 50pl of cells were
incubated with 50-500 ng of plasmid DNA solution in a 1.5 ml pre-chilled
microcentrifuge tube for 30 minutes. Cells were heat-shocked for 20 seconds at
37°C and incubated on ice for 2 minutes. 900 pi of autoclaved room-temperature LB
was added to the mixture and the cells were grown for 1 hour at 37°C in a orbital
shaker at 225 rpm. Cultures were diluted as necessary and plated onto 90 mm agar
plates supplemented with 100 pg/ml of ampicillin or 50 pg/ml of kanamycin
(depending on the plasmid selective antibiotic) next to a Bunsen Burner to avoid
contamination. Plates were inverted and incubated at 37°C overnight.
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2.2. DNA Analysis
2.2.1. Agarose Gel Electrophoresis
2.2.2. Restriction Enzymes Analysis
2.2.3. Polymerase Chain Reaction (PCR)
2.2.4. Southern Blotting
2.2.5. Cre Recombinase In Vitro Assay
2.2.1. Agarose Gel Electrophoresis
Agarose gels were prepared by dissolving agarose (BDH) at 0.8-1.5 % (w/v)
in IX TAE buffer (e.g. 980 ml dH20 + 20 ml 50 X TAE buffer (2.42 g Tris base +
57.1 ml glacial acetic acid + 100 ml 0.5M EDTA pH 8.0, in 800 ml dH20)) by
heating the suspension in a microwave oven. Ethidium bromide (0.5 pg/ml) (Sigma)
was added to the solution and poured into a gel mould. Once set, the gel was
submerged in IX TAE buffer in a gel tank and the DNA samples, containing 20%
DNA loading buffer, were loaded into the wells. Electrophoresis was carried out
either for 2 hours (80-120 Volts) or overnight (15-30 Volts). DNA was visualised by
illumination on a long wave UV light box and photographed. The size of the DNA
fragment was examined by comparison of their mobility to that of restriction
fragments ofknown size, typically DNA Hyperladder 100 lanes (Bioline).
2.2.2. Restriction Enzymes Analysis
Restriction enzyme digestions of plasmid and gDNA were performed
according to the manufacturer's instructions (Roche or New England Biolabs). DNA
was usually digested with a 10-fold excess of enzyme (typically 10 units of enzyme
which digests 10 pg of DNA in 1 hour was used to cut lpg of DNA) with a final
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volume of glycerol not exceeding 5% (v/v). The following example describes the
typical proportions of reagents and incubation time in a standard plasmid and gDNA
restriction analysis.
Plasmid DNA 1 pi (1 pg/pl)
10 x Buffer 2pi
Enzyme lpl (10 units: 1 unit digests 1 pg of DNA in 1 hour)
Distilled water 16pl
Total volume 30 pi
Incubation 1-4 hours at 37 °C
Genomic DNA 10 pi (1 pg/pl)
10 x Buffer 4 pi
Enzyme concentrated 1-2 pi (40-80 units)
Distilled water 25pi
Total volume 40 pi
Incubation overnight at 37 °C
For analysis of restriction digests, reactions were stopped by the addition of
DNA loading buffer to 20% (v/v) or by heat inactivation according to the
manufacturer's instructions.
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2.2.3. Polymerase Chain Reaction (PCR)
Polymerase chain reaction was performed using the Expand High Fidelity
PCR system (Roche) to amplify DNA fragments up to 6 kb. This system is
composed of a unique enzyme mixture containing thermostable Taq DNA
polymerase and Tgo DNA polymerase with proof reading activity, ensuring high
fidelity of gDNA (Barnes, 1994). Although PCR conditions had to be adjusted for
every individual experiment, a typical setting for DNA amplification of fragments of
up to 6 kb can be summarized as follows:
10 mM dNTP mix
10 pM downstream primer
10 pM upstream primer
Template DNA
Expand HF 10 x buffer with 15 mM MgC12
Autoclaved distilled water
Expand High Fidelity PCR enzyme mix
1.0 pi (0.2 mM final concentration)
1.5 pi (300 nM final concentration)
1.5 pi (300 nM final concentration)
1.0 pi (gDNA 500 ng; plasmid, 10 ng)
5.0 pi
39.25 pi
0.75 pi (2.6 units)
The reaction mix and the DNA were mixed together in 0.2 ml thermo-strip tubes
(Abgene) and the samples were placed in a Hybaid gradient thermocycler, which was
typically set using the following cycling parameters:
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lx denaturating step 94 ° C for 5 minutes
lOx cycle 1 Denaturation, 94 0 C for 20 seconds; annealing , 45-70°
C for 30 seconds; elongation, 72 ° C or 68 ° C (for PCR
products longer than 3 kb) for 1 to 5 minutes
20x cycle 2 Denaturation , 94 0 C for 15 seconds; annealing , 45-
70° C for 30 seconds; elongation, 72 0 C or 68 ° C for 1
to 5 minutes (+ 5 seconds increment/cycle to ensure
proper elongation as DNA concentration increases
overtime)
lx final elongation 72 ° C for 7minutes
Cooling 4 ° C for unlimited time
Annealing temperatures are dependent on the melting temperatures of the
primers used and are usually set 5 ° C below that of the melting point. There are
several ways to estimate the melting point temperatures of primers and one of them
is to add up 4 °C for every G+C and 2 °C for every A+T base pairs. The elongation
time was calculated depending on the length of the fragment to be amplified.
Typically, a 2 minutes elongation time was used to amplify a 3 kb DNA fragment.
For the generation of longer PCR products, the Expand Long Template PCR
system (Roche) was used to amplify DNA fragments above 3 kb. This system is
composed of an enzyme mix, containing thermostable Taq polymerase and Pwo
DNA polymerase with proofreading activity, which is designed to amplify DNA with
high fidelity. The PCR conditions usually used were as follows:
Chapter II 75
10 mM dNTP mix
10 pM downstream primer
10 pM upstream primer
1.0 pi (0.2 mM final concentration)
1.5 pi (300 nM final concentration)
1.5 pi (300 nM final concentration)
Template DNA 1.0 pi (gDNA, 500 ng; plasmid, 10 ng)
10 x buffer system 1 (with 17.5 mM MgC12) 5.0 pi
Autoclaved distilled water 39.25 pi
Expand long template PCR enzyme mix 0.75 pi (2.6 units)
Cycling parameters were as described above with the exception that elongation
temperatures were always maintained at 68 ° C.
Table 2.1. List of the PCR primers used in the course of this project. Primers were
designed (with the exception of T7 and T3 primers) using the Primer 3 program
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3 www.cgii and ordered through MWG.
Gene Size (bp) Primer name Sequence (5' to 3') Application
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2.2.4. Southern Blotting Analysis
Southern blotting (Southern, 1975) allows DNA fragments corresponding to a
particular probe to be identified directly from a restriction digest of gDNA. Since
DNA fragments cannot be handled directly in an agarose gel, it is necessary to
transfer them to a membrane (nitrocellulose or nylon) which provides a suitable
support. After immobilisation, the DNA can be subjected to hybridisation analysis,
enabling bands with identical sequence to a labelled probe to be identified. The
following protocol was adapted from Sambrook et al. (1989).
gDNA digests (5-10 pg) were loaded in a 0.8% agarose gel and run either for
3-4 hours at 100-120 Volts or overnight at 30-40 Volts. A UV photograph of the gel
next to a ruler (to determine the distance the fragments had run following
autoradiography) was taken before proceeding to denaturation, an essential step for
subsequent hybridisation of single strands DNA probes. Denaturing solution was
prepared by dissolving 87.66 g of NaCl (1.5 M final concentration) and 20 g of
NaOH (0.5 M final concentration) in 1 litre of distilled water (solution A); and 87.66
g of NaCl (1.5 M final concentration), and 500 ml of 1 M Tris HC1 pH 7.5 (0.5 M
final concentration) and 2ml of 0.5 M EDTA pH 8.0 (1 mM final concentration) in
one litre of distilled water (solution B). DNA fragments in agarose gels were
denatured by gently shaking the gel 2x15 minutes in solution A and 2x15 minutes in
solution B. The gel was then transferred to the blotting apparatus which was
assembled as follows: A glass plate was placed on top of a tank filled with 20 x SSC
buffer (876.5 g of NaCl and 441.0 g of tri-sodium citrate added to 4 litres of dH20;
pH 7.0). Two sheets of 3 mm Whatman paper were cut (as the width of the gel) and
placed over the glass plate such that the edges were submerged in 20 x SSC. The gel
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was carefully transferred wells side down onto the 3 mm paper and surrounded with
strips of parafilm such that the buffer is drawn from the tanks by capillary transfer
only through five 3 mm Whatman papers (two in direct contact with the buffer and
three gel-sized papers on top of the gel). One sheet of positively charged hybond
nylon membrane (Amersham International pic) was cut to the size of the gel, rinsed
in 3 X SSC using forceps and placed over the gel. Three sheets of 3 mm paper cut to
the size of the gel, comprising one sheet rinsed with 3 x SSC and two dry sheets,
were placed on top of the stack. Air bubbles were removed carefully between each
step. In the following order, paper towels evenly stacked, a glass plate and a 500 ml
filled bottle used as a weight were placed on top of the stack. The following day, the
nylon membrane was rinsed in 3 X SSC with the DNA transferred to it side up. The
membrane was then air dried on 3 mm paper, crossed linked in a UV stratalinker
1800 (Stratagene), wrapped in Saran wrap and stored at room temperature.
The membrane carrying the DNA was pre-hybridised for 1 to 2 hours at 65°C
in a hybridisation tube with 25 ml of a pre-hybridisation solution. Prehybridisation
solution was prepared with 50 ml of 1 M sodium phosphate (0.5 M final
concentration), 35 ml of 20% SDS (7% final concentration), 200 pi of 0.5 M EDTA
(1 mM final concentration) and 15 ml of deionised water.
DNA probes for hybridisation (-25 ng) were dissolved in 45 pi of 10 mM
Tris HC1 pH8.0 containing 1 mM EDTA (TE buffer), boiled for five minutes for
denaturation and snap cooled on ice for five minutes. The denatured DNA was
added to the labelling reaction tube (amersham pharmacia biotech) which consists of
a buffered solution of dATP, dGTP, dTTP, exonuclease free klenow enzyme and
random primers in a dried, stabilised form. Denatured probes were radioactively
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labelled with 5 pi of a 32 P-dCTP (Amersham International pic) for 10 to 30 minutes
at 37 ° C.
To separate labelled probes from unincorporated a 32 P-dCTP nucleotides, the
labelled reaction mixture was applied to a Pharmacia NICK column, in which the gel
was previously equilibrated with 3 ml of TE buffer pH7.5, and 400 pi of TE buffer
pH7.5 was added to the column. The first sample was collected into a test tube and
discarded into the radioactive waste. The purified sample was eluted with an
additional 400 pi of TE buffer into a fresh 1.5 ml Eppendorf tube to which 40 pi of
5M NaOH (40g/mol) was added for denaturation. The resulting hybridisation
solution was added to the tube containing the filter in prehybridisation solution and
was incubated at 65° C overnight in an oven with rotor.
The following day, the hybridisation solution was discarded and the filter was
washed at 65 ° C 2x15 minutes in solution 1 (2 x SSC and 0.1 % SDS) and 2x15
minutes in solution 2 (0.2 x SSC and 0.1 % SDS). The filter was carefully wrapped
in saran wrap and placed into a phosphor image cassette overnight. The next day, the
exposed screen was placed face down onto a Phosphorlmager to reveal the
autoradiography. Alternatively, the membrane was exposed to X-ray film (Fuji) at
-80° C during one week which was revealed in an autoradiograh.
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2.2.5. Cre Recombinase In Vitro Assay
Cre recombinase is a type I topoisomerase from bacteriophage PI that
catalyses the site-specific recombination ofDNA between loxP sites (Abremski and
Hoess, 1984). The enzyme requires no energy cofactors and Cre-mediated
recombination quickly reaches equilibrium between substrate and reaction products.
Recombination products depend on the location and relative orientation of the lox
sites. Cre recombinase can catalyse (i) the excision of DNA between two identical
lox sites in circular form, (ii) the fusion of two DNA species containing single lox
sites, (iii) the inversion of DNA between opposite lox sites with respect to external
sequences, and (iv) the reciprocal exchange of DNA flanked by heterospecific lox
sites between two DNA species provided that these are flanked by the same set of
heterospecific lox sites.
Prior to transfection, all plasmids, containing heterospecific lox sites, used for
recombinase-mediated cassette exchange experiments were tested in vitro with Cre
recombinase in the following manner: Two plasmids with the same set of
heterospecific lox sites were linearised with an appropriate restriction enzyme,
purified with the QIAquick gel extraction kit protocol and gel quantified. Typically,
100 ng of each DNA species were incubated along with 5 pi (1 unit/pl) of Cre
recombinase (New England Biolabs), 5 pi of 10 x Cre Recombinase buffer (New
England Biolabs) in a total reaction volume of 50 pi. Reactions were incubated for
30 minutes at 37 ° C followed by 10 minutes at 70 0 C to inactivate the enzyme. To
determine recombination between the two DNA plasmids (cassette exchange), 5 to
10 pi of the reaction was used as template in a PCR reaction using a primer set
specific to one of the recombination product only (table 2.1). The presence of a PCR
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product with the predicted size, indicating recombination, was subsequently
determined by agarose gel analysis.
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2.3.3. Construction of probes
2.3.3.1. 3' External (i-Casein Probe
2.3.3.2. 3' Internal Hprt Probe
2.3.1. Plasmid Material
The following commercial plasmids were used in this project:
pBlueScript II SK +/- (Stratagene) and pCR2.1-TOPO (Invitrogen).
The plasmids listed below were obtained from non-commercial sources:
pMMPoNeo (given by M. Marques), pEFGIN (given by Geron), pB-RMCE2272
(given by A. Kolb), phOCT-4-EGFP-l (given by D. Zhao), pLoxBSDIB and
pPGKGFP-SV40Neo (given by A. Thomson), pHS4PGKGFP-SV40Neo (given by
T. Lacroix), pNI-CD (given by A. West), pBSPGKNeo (given by E. Gallagher)
pE3ANeo (provided by A. Bradley), pTurboCre (gift from T. Ley), pHP-Hind/Xho




The targeting vector pCas-EfN (figure 2.1) was built as follows: The
5'arm of homology was generated by PCR amplification (from gDNA extracted from
the H9 female human ES cell line) of a 2371 bp fragment (3' end of the promoter
region) of the fi-Casein gene, using the 5' Cas-F and 5' Cas-R primers (table 2.1).
The resulting PCR product was subcloned into the pCR2.1-Topo TA vector
(appendix 1, section 2.1) to give pTopoCas5'. Similarly, the 3' arm of homology
was generated by PCR amplification of a 5449 bp fragment of the open reading
frame region of the gene (encompassing exon 2 to start of exon 8), using the 3' Cas-F
and 3' Cas-R primers (table 2.1). The resulting PCR product was subsequently
subcloned into the pCR2.1-Topo TA vector to produce pTopoCas3'. A 2388 bp
EcoRI fragment of pTopoCas5' containing the 5' genomic region of homology was
subcloned in the desired orientation into a EcoRI site in the multicloning site of the
pBlueScript II SK +/- (Stratagene) (appendix 1, section 2.2) to give pCas5'. A 5538
bp KpnI/XhoI fragment of pTopoCas3' containing the 3' arm of homology of the
fi-Casein gene was subsequently subcloned into a KpnI/XhoI-digested pCas5' in the
same transcriptional orientation as the 5' arm of homology, resulting in pCas5'/3'.
In a third step, the human EFl-a promoter was extracted from the plasmid pEFGIN
(appendix 1, section 2.3) as a 1511 bp Nhel/Sall fragment, blunted with the DNA
polymerase I Klenow fragment (New England Biolabs), and subcloned into the
Xhol-linearised and blunted pCas5'/3', to produce pCasEFla. As a final step, a
neoHGHpA cassette flanked by heterospecific lox sites (loxP and a lox2272) was
extracted as a 1775 bp NotI/Asp718 (Kpnl isoschizomer) from the plasmid
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pMMpoNeo (appendix 1, section 2.5), blunted with Klenow, and subcloned into
Sail-linearised and blunted pCasEFl-a, to generate the final version of the
fi-Casein targeting construct, pCas-EfN (14.2 kb).
Cas 5'
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Figure 2.1. Construction of the human p-Casein construct, pCas-EfN. The 5' and
3' regions of homology of the P-Casein gene (7909 bp in total), the EFla promoter, the neo cassette
flanked by heterospecific lox sites, and the pBlueScript II SK +/- backbone are indicated as dark blue,
light blue, pink and red lines, respectively. LoxP and lox2272 are represented as plain and white
arrows, respectively. The Xhol and Sail restrictions sites were eliminated following blunting, as




The human hprt targeting vector pHPRT-EfN (figure 2.2) is derived
from the pE3ANeo plasmid (appendix 1, section 2.6). The pE3ANeo plasmid (gift
from A. Bradley) contains a 6.9 kb Hindlll hprt fragment (Edwards et al., 1990)
comprising exons 2 and 3, intron 2 and fragments of introns 1 and 3. A MClweopA
cassette (Thomas & Capecchi, 1987) inserted at the Xhol site in exon 3, in the
opposite transcriptional orientation, divides the hprt homology into a 4.8 kb 5' and
2.1 kb 3' elements. To generate pHPRT-EfN, the MCIneo cassette from pE3ANeo
was extracted by restriction digestion with Ncol and Xhol. A 3.2 kb Clal/NotI
Klenow blunted EFla-LoxP-neopALox2272 from pCas-EfN (figure 2.1) was
subsequently subcloned into the NcoEXhoI-linearised and blunted pE3 (pE3ANeo
lacking the MClweopA cassette) to produce pHPRT-EfN.
1X1 a-loxP-neop\-lox22 72 3.2 kb
pE3ANeo
Hindlll yz6l ^Hol Hindlll (H kb)
4.8 kb V 2.1 kb
•< ► A ■* *■
5TfPRT^^|>
Lox 22 72 LoxP*
Hindlll
pHPRT-EfN
HindHI (131 kb )
Figure 2.2. Construction of the human hprt targeting construct, pHPRT-EfN.
The 5' and 3' regions of homology of the hprt gene (6909 bp in total), the floxed neo expression
cassette, and the pT218R backbone are indicated as dark blue, pink, and red boxes, respectively. The
EFl-a promoter is shown as plain light blue arrow. The IoxP and Iox2272 sites are represented as
small plain and white arrows, respectively. The MClneopA (in brown) was eliminated from
pE3ANeo by Xhol and Ncol restriction digestions, and the resulting pE3 plasmid was blunted with
Klenow, as described in the text. Hindlll digestion of pHPRT-EfN results in the relevant targeting
sequence used for the series of targeting experiments.
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2.3.2.3. pTopo-HPRT
To generate the pTopo-HPRT targeting vector, a 7.1 kb fragment of
the hprt gene was amplified by PCR from gDNA extracted from the HI male human
ES cell line, using the 5'ext hprt and 3'ext hprt primers (table 2.1). The resulting
PCR product was subcloned into the pCR2.1-Topo TA vector to give pTopo-HPRT.
The 7.1 kb of hprt homology comprises the 6.9 kb Hindlll hprt fragment included in







H indill 6 9 kb HindTlT
7.1 kb
flpri
Figure 2.3. Construction of the human hprt targeting construct, pTopo-HPRT.
The hprt homology (7.1 kb) and the backbone of pCR2.1-TopoTA are indicated as dark blue and red
boxes, respectively. Hindlll digestion of pTopo-HPRT results in the relevant targeting sequence used
for the targeting experiment.
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2.3.2.4. pfBSD-OctGFP
The ploxBSDIB plasmid (appendix 1, section 2.7), containing a
BSD-SV40pA under the transcriptional control of the SV40 promoter and flanked by a
loxP and lox2272 sites, was used to generate the pfBSD-OctGFP plasmid (figure
2.4). In a first step, the SV40 promoter was removed by Hindlll digestion, and the
resulting ploxBSDlBSV40" was religated. In a second step, a 5 kb Bglll/Sspl
oct-4-GFP cassette was extracted from the phOCT-4-EGFP-l plasmid, blunted with
the DNA polymerase I Klenow fragment, and subcloned downstream of the
BSD-SV40pA (in the same orientation) into the BamHI-linearised and blunted
ploxBSDlBSV40\ to produce pfBSD-OctGFP.
Hindlll Hindlll
pLoxBSDIB (5 kb)
pLoxBSDl BSV40" (4.5 kb)
* BSD Oct-4 ) GFP <| | pfBSD-OctGFP (9.5 kb)
Kpnl
Figure 2.4. Construction of the RMCE construct, pfBSD-OctGFP. The SV40
promoter, the BSD gene, the oct-4 promoter, the GFP, and the plasmid pBlueScript II KS +/-
backbone are indicated as yellow, purple, pink, green, and red lines, respectively. LoxP and lox2272
are represented as plain and white arrows, respectively. The Kpnl linearisation restriction site is
indicated in the final version of the pfBSD-OctGFP construct.
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2.3.2.5. pEfBSD-OctGFP
The plasmid pEfBSD-OctGFP was generated by subcloning the
human EFl-a promoter upstream of the loxP site in pfBSD-OctGFP, in the same
transcriptional orientation as the BSD gene (figure 2.4). The EFl-a promoter was
obtained by extraction from the plasmid pEFGIN (appendix 1, section 2.3) as a
1511 bp Nhel/Sall fragment, blunted with the DNA polymerase I Klenow fragment
(New England Biolabs), and subcloned into the KpnI-linearised and blunted







Figure 2.5. Construction of the pEfBSD-OctGFP plasmid. The BSD gene, the oct-4
promoter, the EFl-a promoter, the GFP, and the plasmid pBlueScript II KS +/- backbone are
indicated as purple, pink, blue, green, and red lines, respectively. LoxP and lox2272 are represented
as plain and white arrows, respectively. The Seal linearisation restriction site is indicated in the final
version of the pEfBSD-OctGFP construct.
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2.3.3. Contruction of Probes
2.3.3.1. 3' External fi-Casein Probe
To generate the /3-casein probe (figure 2.6) for Southern Blot analysis,
a 348 bp (encompassing region of exon 8 and 3' untranslated region of the P-casein
gene) was amplified by PCR from H9 gDNA using the P-cas probe-F and P-cas
probe-R primers (table 2.1), and subcloned into the pCR2.1-TopoTA vector to
generate pTopo-Cas. The probe was excised as a 365 bp EcoRI fragment, with the















Figure 2.6. Construction of the human 3' external p-casein probe. The p-casein
sequence (348 bp) and the backbone of pCR2.1-TopoTA are indicated as dark blue and red boxes,
respectively. EcoRI digestion of pTopo-Cas results in the production of the 365 bp 3' external
p-casein probe used for the Southern Blot analysis.
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2.3.3.2. 3' Internal Hprt Probe
The 3' internal hprt probe (encompassing regions of exon 3 and intron
3) used for Southern blot analysis was excised from a 1 % agarose gel as a 1193 bp
BamHI fragment from the plasmid pHP-Hind/Xho (gift from D. Russell), purified
with the QIAquick gel extraction kit protocol and gel quantified using 5 pi of Bioline
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HI and H9 cell lines were obtained from Geron (San Francisco, USA).
Human embryonic kidney (HEK) epithelium cells 293 were obtained from W. Cui
(Roslin Institute, Scotland) and the HPRT-deficient mouse ES cell line, HM1 was
provided by J. McWhir (Roslin Institute, Scotland). Mouse embryonic fibroblasts
(MEFs) were generated in the lab from 13 days postcoitum mouse embryos.
2.4.2. Maintenance of Mouse Embryonic Fibroblasts
2.4.2.1. Preparation of MEF Medium
MEF medium was prepared by filtering in a 500 ml filter unit (0.22
pm, corning, cellulose acetate, low protein binding), 450 ml Dulbecco's modified
Eagle's medium (DMEM, Gibco-BRL), 50 ml foetal calf serum (FCS, Gibco-BRL),
5ml L-glutamine (Gibco-BRL) (2 mM f.c) and 5 ml non-essential amino acids
(Gibco-BRL) (0.1 mM f.c). Medium was then stored at 4° C for up to one month.
2.4.2.2. Isolation of MEFs
Pregnant female mice were killed on the thirteenth or fourteenth day
of pregnancy. The abdomens were swabbed with 70 % ethanol and the abdominal
cavities were dissected to expose the uterine horns. Uterine horns were then placed
into a 10 cm bacteriological Petri dish containing 10 ml of Phosphate-Buffered
Saline (PBS) (Oxoid) supplemented with 0.25 ml penicillin
(5000 u/ml) / streptomycin (5000 pg/ml) (Gibco-BRL) and the embryos were
released into the saline by cutting open using fine scissors. The embryos were then
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removed together with the associated placentas and foetal membranes into a fresh
dish containing PBS. Placentas and membranes were removed using two pairs of
forceps and soft tissues (e.g. liver, heart and the other viscera) were separated from
individual embryos. The embryos were washed in two further changes of PBS and
placed individually into bijou tubes containing 2ml of TEG (3.15 g NaCl, 0.06 g
NA2HPO4, 0.108 g KH2P04, 0.166 g KC1, 0.45 g D-Glucose, 1.35 g Tris, 0.45 ml 1%
Phenol Red; add up to 400 ml distilled water; 50 ml of 10 x trypsin 2.5 %, 0.2 g
EGTA, 0.05 g PVA; adjust pH up to 7.6 and add distilled water up to 500 ml).
Tubes were incubated for 10 minutes at 37 0 C and the content was vortexed,
incubated for a further 10 minutes at 37 0 C and vortexed one more time. 3 ml of
MEF medium was added to inactivate the trypsin, the tubes were vortexed for a few
seconds and individual supernatants containing the cells were transferred into 75 cm2
flasks containing 12 ml PEF medium. Flasks were incubated at 37 0 C and the
medium was changed the following day to remove the cellular debris.
2.4.2.3. Passage of MEFs
Subconfluent 75 cm2 flasks were washed once with PBS and
incubated with 2 ml of TEG at 37 0 C (5 % C02) for 2-3 minutes. 9 ml of MEF
medium was added to the cells and those were split 1:2 into a 150 cm2 flask and
MEF medium was added up to obtain a final volume of 30 ml. MEFs could be
expanded for up to 4 passages before being discarded.
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2.4.3. Maintenance of Human ES Cells
2.4.3.1. Feeder-Free Human ES Cell Culture
Conditioned Medium Preparation
MEFs (150 cm2 flask) were used to prepare conditioned medium
(CM) by removing MEF medium and adding 50 ml of serum-free human ES medium
(80 % Knock-out DMEM (KO-DMEM, Gibco), 20 % serum replacement (SR,
Gibco), 0.1 mM non-essential amino acids, 2mM L-glutamine, 0.1 mM
(3-mercaptoethanol and 4 ng/ml basic fibroblast growth factor (bFGF, Invitrogen);
filter in a 500 ml filter unit (0.22 pm, corning, cellulose acetate, low protein
binding)). CM was collected from the feeder flasks the following day and replaced
with a further 50 ml of human ES medium. The same flask of feeders was used for
4-5 days, to generate 200-250 ml of CM. collected CM was either stored at -20° C
or supplemented with 4 ng/ml bFGF, filtered, and used for daily human ES cultures
maintenance.
Matrigel Coating for Human ES Cultures
Matrigel (Becton Dickinson) was thawed at 4 0 C for at least 2 hours
to avoid the formation of a gel. Matrigel was then diluted 1:100 in cold KO-DMEM
using a chilled pipette and typically 25 cm2 flasks were coated with 3 ml of the
solution. Flasks were either incubated at RT for 1-2 hours before use or stored at
4 0 C for no longer than 2 weeks. The matrigel solution was removed from the flasks
and washed with KO-DMEM before use.
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2.4.3.2. Passage Regime
When HI and H9 cells had reached 80-90 % confluence, the CM was
removed and cells were washed once with KO-DMEM. Typically, for a 25 cm2
flask, cultures were incubated with 1ml of TEG at 37 °C for 3-5 minutes and cells
were detached from the surface by shaking the flasks vigorously. 5 ml of
KO-DMEM was added to the cells and a single-cell suspension was obtained by
pipetting the cell suspension vigorously. Cells were then transferred to 15 ml falcon
tubes and centrifuged at 200 x g for 5 minutes. Supernatants were discarded and the
pellets were resuspended in fresh CM supplemented with 4 ng/ml bFGF and seeded
onto matrigel-coated 25 cm2 flasks as required (splitting usually between 1:3 and
1:4). Medium was changed the following day.
2.4.4. Maintenance of Other Cell Lines
HMl cells were grown at 37 °C (5 % CO2) on 0.1 % gelatin-coated flasks and
fed daily with mouse ES medium. ES medium was prepared with 450 ml Glasgow
modified Eagle's medium (GMEM, Gibco), 28 ml FCS, 28 ml new born calf serum
(NBCS, Gibco), 5ml L-glutamine (2 mM f.c), 5 ml non-essential amino acids (0.1
mM f.c), 5 ml sodium pyruvate (Gibco, 1 mM f.c), 1.1 ml 2-mercaptoethanol (0.1
mM f.c) and 280 pi of Leukaemia Inhibitory Factor (ESGRO-LIF, Chemicon, at
1 x 106 U/ml).
For passaging, subconfluent HMl cells were washed with PBS, trypsinised
with TEG for 1-3 minutes at 37 °C. After incubation, flasks were shaken vigorously,
an appropriate volume of ES medium was added to the cells, and a single-cell
suspension was obtained by gently pipetting. Cells were centrifuged at 200 x g for 5
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minutes and pellets were resuspended in ES medium and plated out onto 0.1 %
gelatin-coated flasks as required. HEK 293 cells were maintained as described above
but in MEF medium.
2.4.5. Cryopreservation and Thawing of Cell Lines
Cells were trypsinised and collected by centrifugation for 5 minutes at 200 x
g. Pellets were resuspended in the appropriate volume ofmedium and placed on ice.
One volume of ice-cold 2x freezing mix* was added progressively and the
suspension was gently mixed and aliquoted into pre-chilled cryovial tubes (1ml per
tube). Vials were stored at - 80° C for 24 hours and then transferred to - 150° C.
Cells were thawed by placing the vials in a 37° C water bath. 5 ml of appropriate cell
line medium was added to the contents of a vial in a 15 ml falcon tube and
centrifuged at 200 x g for 5 minutes. Supernatants were discarded and pellets were
resuspended in an appropriate volume ofmedium for plating out.
* For human ES cells, 2 x freezing mix was made by mixing 50 % CM, 30 %
SR and 20 % dimethyl sulfoxide (DMSO, Sigma). For MEFs, 2X freezing mix was
made by mixing 50 % MEF medium, 30 % FCS and 20 % DMSO. Freezing mixes
were filtered and stored at - 20° C.
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2.4.6. Subcloning, Cryopreservation and Thawing of HES
Clones
Plates containing H9 G418-resistant colonies, from /3-casein targeting
experiments, were washed with KO-DMEM and 10 pi of TEG was added onto each
colony. Plates were incubated at 37 °C for few minutes and the incubation was
stopped when the cells in the colonies started lifting up. Colonies were broken into
small clusters by adding 10 pi of CM and gently pipetting up and down. Clumps
were transferred into matrigel-coated 96-well plates containing CM supplemented
with bFGE. When reaching confluence after few days, colonies were trypsinised
with 25 pi of TEG, incubated at 37 °C for few minutes, and single cell suspension
was obtained by adding 50 pi of CM and pipetting up and down. Cell clones were
transferred into matrigel-coated 48-well plates containing 0.5 ml CM/bFGF. This
procedure was repeated until the clones were expanded up to two wells of a 12-well
plate for freezing and gDNA extraction. Using a protocol optimised by H. Priddle
(Roslin Institute) for in situ freezing and thawing of hES cells, subconfluent
individual colonies in 12-well plates were trypsinised with 200 pi TEG and a single
suspension was obtained by subsequently adding 400 pi of cold quench medium
(70 % KO-DMEM and 30 % SR). 600 pi of cold fresh 2x freezing mix was added to
each well and the plates were swirled gently until the DMSO was well diluted.
Plates were stored at -80 °C overnight and then transferred at 150 °C. When
required, H9 G418-resistant clones were thawed by adding 1.5 ml of warm
CM/bFGF to the well. Cell clones were subsequently transferred to two wells of a
matrigel-coated 12-well plate containing 1.5 ml of fresh CM/bFGF. For HI colonies
obtained from hprt targeting and RMCE experiments, cells were isolated and
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expanded the same way but clones were frozen and thawed as described in section
2.4.5.
2.4.7. In Vitro Differentiation of HES Cells
2.4.7.1. Generation of Embryoid Bodies
75 cm2 flasks of subconfluent H9 and HI cells received fresh medium
1 hour before use. Cells were then washed with KO-DMEM, trypsinised and
centrifuged as described in section 2.4.3.2. Each individual pellet was resuspended
in 5 ml CM/bFGF and transferred to a 10 cm bacteriological petri dish containing
20 ml of CM supplemented with bFGF. Resulting embryoid bodies (EBs) were
collected 48 hours later by transferring the contents of the dish into a universal tube
and allowing the EBs to sink to the bottom. The supernatant was discarded and EBs
were resuspended in 20 ml EB medium (90% KO-DMEM, 10% FCS, 2 mM
L-glutamine, 0.1 mM non-essential amino acids, 0.1 mM P-mercaptoethanol) and
transferred into a new bacteriological petri dish. EBs were maintained in suspension
for a further 2-3 days and then transferred onto 0.1 % gelatin-coated 24-well plates or
chamber well slides (-10 EBs per well) and cultured for an additional 21 days
before immunocytochemistry analysis.
2.4.7.2. Osteogenic Differentiation
HI and HI-derived cells were plated out at a cell density of 105 cells
and 104 cells per well in matrigel-coated 6-well (for Alizarin-Red S staining, see
section 2.4.9.5) and 96-well plates (for calcium assay, see section 2.4.9.6),
respectively. HEK 293 cells were seeded at a density of 104 cells per well in 0.1 %
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gelatin-coated 6-well plates and 103 cells per well in a 0.1 % gelatin-coated 96-well
plate. To induce osteogenic differentiation (work performed by Davina Wojtacha),
the CM was replaced 48 hours following plating with EB medium containing
osteogenic supplements (50 pM ascorbic acid phosphate, Wako; 10 mM
P-glycerophosphate, Sigma; and 100 nM dexamethasone, Sigma). Medium was
changed every 2 days and cultures were treated with or without osteogenic
supplements for the indicated time periods (9, 13, 16 and 20 days) before analysis.
2.4.8. Transfection
2.4.8.1. Eppendorf Multiporation
Exponentially growing cells received fresh medium 1 hour before
electroporation. Human ES cultures were trypsinised, resuspended in 10 ml CM, and
counted using a Neubauer haemacytometer (Weber, UK). 106 to 2xl06 cells were
resuspended in 750 pi of hypososmolar buffer (Eppendorf) and incubated for 20
minutes at RT. Linearised or supercoiled (for RMCE experiments) plasmids DNA
(50-138 pg) were diluted in 50 pi of distilled water and mixed with the cells in a
0.4 cm electrode Gene Pulser Cuvette (BioRad). Cells were electroporated with the
Eppendorf Multiporator at 300 V and 100 ps and incubated for 5 minutes at RT.
Cells were then resuspended in CM/bFGF, plated at a density of 5x10s cells per
matrigel-coated 10 cm or 15 cm dish, and incubated at 37 0 C in a humid 5% CO2




Cells were prepared as described in section 2.4.8.1 but in this protocol,
cells were resuspended in 750 pi of PBS. Linearised or supercoiled (for RMCE
experiments) plasmids DNA (50-138 pg) were diluted in 50 pi of distilled water and
mixed with the cells in a 0.4 cm electrode Gene Pulser Cuvette (BioRad). Cells were
electroporated with a BioRad Gene Pulser II at 200 V / 950 pF or 320 V / 200 pF.
Cells were incubated for 10 minutes at RT and plated at a density of 5x10s cells per
matrigel-coated 15 cm dish.
2.4.8.3. Lipofection
Lipofections were performed using the Lipofectamine™ 2000 kit
(Invitrogen). 2 to 4 days prior to transfections, 1x10s to 4xl05 cells were seeded per
well in a 6-well plate. One hour before transfection, 50-95 % confluent cultures had
the medium changed and a typical lipofection mixture was prepared as follows:
Solution A: 2.5 pi purified uncut DNA (lpg/pl) or 2.5 pi dH20 (Mock) + 122.5 pi
Opti-Mem I (Invitrogen)
Solution B: 6 pi Lipofectamine + 119 pi Opti-Mem I
Solution A and B were incubated for 5 minutes at room temperature, mixed together
and incubated for 20-30 minutes at room temperature to allow the
DNA-lipofectamine complexes to form. The CM was then removed from the wells
and replaced with 2.25 ml of fresh CM in which the lipofection mixture was added.
Plates were gently mixed and the cells were incubated at 37°C (5% C02). After
6-12 hours incubation, cells were washed with KO-DMEM and the medium was
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replaced with fresh CM. Bright field and fluorescent images of GFP-expressing
cells were captured 48 hours following transfection with a Nikon microphot SA
microscope, camera and Digital Pixel software.
2.4.9. Analysis
2.4.9.1. Colony Staining
Colonies were washed with PBS and fixed for 10 minutes in
methanol. Methanol was removed and colonies were stained 10-15 minutes in a 10
% Giemsa R-66 solution. After staining, plates were gently washed with water and
air-dried.
2.4.9.2. Mitotic Spreads
Confluent human ES cells in 25 cm2 flasks were split 1:5, and 50 pi
of 10 pg/ml karyoMax colcemid solution (Invitrogen) was added per 5 ml culture 22
to 24 hours later (to ensure that most cells are in exponential growth). Colcemid
arrests dividing cells at metaphase of mitosis by preventing the formation of the
spindle apparatus responsible for cell division. This results in an accumulation of
metaphases. The medium was collected 2 hours later in a 15 ml falcon tube and the
cells were washed with 2 ml PBS which was collected in the same 15 ml falcon tube.
Cells were trypsinised and resuspended with the CM/PBS solution previously
collected and centrifuged for 5 minutes at 200 x g. The supernatant was discarded
and cells were resuspended in 8-10 ml fresh hypotonic solution (0.56 % w/v KC1 in
dH20) using a vortex. Cells were incubated for 8-10 minutes at room temperature
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and centrifuged for 5 minutes at 200 x g. The supernatant was decanted and the cells
were fixed by adding slowly, down the side of the tube, 2-3 ml of freshly made
ice-cold fixative (18 ml methanol and 6 ml acetic acid) and vortexing
simultaneously. Cells were then resuspended in a final volume of 8-10 ml of
fixative. Tubes were centrifuged at 200 x g for 5 minutes, supernatant was discarded
and cells were washed twice more in fixative. Pellets were then resuspended in 1 ml
of fixative for mitotic spreads analysis.
Glass slides were cleaned in cold 70 % ethanol, polished and air-dried
before use. A Pasteur pipette was used to release a single drop of suspension onto
each slide. Fixative was allowed to spread and was air-dried, and bright field images
of mitotic spreads were obtained using a Zeiss microscope and the AxioVision
software (Carl Zeiss, Jena, Germany).
2.4.9.3. Immunocytochemistry
Human EBs and undifferentiated hES cells were washed twice with
PBS, fixed with 4% paraformaldehyde (PFA, Sigma) (dissolve 4 g PFA in 100 ml
PBS by moderate stirring on a hotplate/stirrer at 60 °C, filter and store at -20 °C) and
incubated at RT for at least 20 minutes. Samples were washed three times with PBS,
permeabilised with 0.2 % Triton X-100 (Sigma) in PBS for 10-15 minutes at RT, and
washed twice with PBS. EBs were then incubated with 2% BSA/PBS (13.3 ml
7.5 % BSA and 36.6 ml PBS) for 1 hour at 37 0 C to block non-specific sites.
Samples were incubated with a 2 % BSA/PBS diluted primary antibody against
Troponin T (1: 50 from a 0.2 pg/pl stock, NeoMarkers), or a-fetoprotein (1:400 from
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a 9 pg/p.1 stock, Sigma), or (3-III-tubulin (1:200 from a 0.6 pg/p.1 stock, Sigma) for 1
hour at 37 ° C or overnight at 40 C. Cells were washed once quickly in PBS and then
twice by gently agitating for 20 minutes in PBS supplemented with 0.05 % tween 20
(Sigma). Cells were then covered with 2 % BSA/PBS diluted secondary fluorescein
anti-mouse antibody (1:1000 from a 1.5 p.g/p.1 stock, Vector Laboratories) and
incubated for 1 hour at 37 0 C in a dark place. Cells were washed once quickly in
PBS and twice for 20 minutes (with gentle agitation) in PBS/0.05 % Tween 20.
Samples were mounted with Vectashield mounting medium (Vector Laboratories)
for fluorescence microscopy analysis, or analysed directly without the mounting
medium (EBs grown in 24 well-plates). The bright field and fluorescent images
were obtained using a Zeiss microscope and the AxioVision software (Carl Zeiss,
Jena, Germany).
For oct-4 expression analysis, subconfluent HI and HI-derived cells
in chamber slides were washed twice with PBS, incubated with 4% PFA for 20
minutes at RT and washed three times with PBS. Cells were then incubated with
ethanol for 2 minutes for permeabilisation, washed twice with PBS for 5 minutes and
blocked for 1 hour at RT with blocking buffer (10% NGS/PBS/0.1% Tween 20).
Samples were incubated with a 0.1% NGS/PBS/Tween 20 diluted primary antibody
against OCT-4 (1: 200 from a 0.2 pg/pl stock, Santa Cruz) for 1 hour at RT. Cells
were washed twice with PBS for 5 minutes. Cells were then covered with the PBS
diluted secondary anti-mouse antibody conjugated to FITC (1:100, from a 5 pg/pl
stock, Sigma) and incubated for 1 hour at RT in a dark place. Cells were washed
twice in PBS for 5 minutes. Samples were mounted with Vectashield mounting
medium with 4'-6' Diamidino-2-phenylindole (DAPI) (Vector Laboratories).
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Fluorescent and merged images were acquired with an Axiovert SI00 microscope
(Carl Zeiss), and the AQMe imaging acquisition software using a high-resolution
black and white ORCal camera.
For flow cytometry analysis of human ES cell surface markers, HI
and Hl.HPRT-1 cells were trypsinised and resuspended to approximately
5x10s cells/sample in 50 pi blocking buffer (40% heat inactivated rabbit serum in
staining buffer). Blocking was carried out for 15 minutes on ice. Primary antibody
and appropriate isotype-matched control diluted in staining buffer (2% FCS in PBS
and 2mM EDTA) was added to each sample and incubation was carried out on ice
for 30 minutes. Mouse IgG3 (1 pg/pl stock, Sigma), mouse IgM (1 pg/pl stock,
Sigma), SSEA-4 (DSHB), SSEA-1 (DSHB), Tra-1-60 (1 pg/pl stock, Chemicon) and
Tra-1-81 (1 pg/pl stock, Chemicon) were diluted 1:100, 1:3, 1:100, 1:5, 1:12 and
1:20, respectively. Cells were washed with staining buffer, spin at 200 x g for 5
minutes, resuspended with the secondary antibody diluted with staining buffer and
incubated for 30 minutes on ice in the dark. Staining with secondary antibody, was
carried out with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG3
(1:100 from a 5 pg/pl stock, Caltag laboratories) for IgG3 and SSEA-4, and with
phycoerythrin (PE)-conjugated goat anti-mouse IgM (1:100 from a 0.2pg/pl stock,
Caltag laboratories) for IGM, SSEA-1, Tra-1-60 and Tra-181. CD9 staining was
performed with PE-conjugated mouse-anti human CD9 (1: 5 dilution, BD
PharMingen). Cells were washed with PBS, spin for 5 minutes at 200 x g and
resuspended in 1ml PBS/0.1% PFA for flow cytometry analysis.
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2.4.9.4. Flow Cytometry
Flow cytometry was performed on a 488 nm laser FACScan (Becton
Dickinson). A 530/30 nm band pass filter was used to measure EGFP fluorescence
intensity or FITC-conjugated antibodies. A 585/42 nm band pass filter was used to
measure phycoerythrin-conjugated antibodies. For GFP analysis, detector settings
were adjusted with untransfected cells. For cell surface markers analysis, detector
settings were adjusted with both untreated and isotype controls. Analysis was
performed on CellQuestPro software (BD Biosciences). At least 10,000 "live" cells
were acquired for each sample. Forward size and side scatter plots were used to
exclude dead cells and debris from the histogram analysis plots.
2.4.9.5. Alizarin-Red S Staining
Cells in 6-well plates analysed for osteogenic differentiation were
washed twice with PBS and fixed in 95 % methanol (staining performed by Davina
Wojtacha). Alizarin-Red Staining, which forms a complex with calcium in a
chelation process, was performed for mineralised nodule detection as follows: Fixed
cells were incubated with a 1 % Alizarin-Red S (sigma) solution for 10 minutes and
washed twice in water. High-power and low-power bright field images were




Matrix-associated calcium deposition of HI, HI-derived, and HEK
cells was examined in a 96-well plate using a calcium colorimetric assay kit
(Randox) in quadruplet wells (assay and analysis performed by Davina Wojtacha).
The principle of this assay is as follows: Calcium in alkaline medium forms a purple-
red complex with ortho-cresolphthalein. Intensity of the developed colour is
proportional to the calcium concentration in the sample.
At each time point (9, 13, 16 and 20 days), medium was removed
from the quadruplet wells to be analysed and the cells were washed 3 times with
0.9 % NaCl. The 96-well plate was incubated at 37 °C until the final time point was
performed. Cells were then lysed by adding 50 pl/well of 0.1 M NaOH, and
neutralysed with 20 pl/well of 2 M HC1. The plate was air-dried at RT overnight.
The following day, 200 pl/well of assay buffer mix (containing 2-amino-2 methyl-
propan-l-ol and the chromogen) was added to each well and incubated for 10
minutes at RT. To calibrate the assay, a calcium standard curve was also performed
in a 96-well plate by applying a range of calcium standard (provided with the kit)
concentrations varying from 0 to 100 pM. After addition of 200 pl/well of assay
buffer mix to each well, the plate was incubated for 10 minutes at RT. Absorbance
of each well and standard was then read against a reagent blank at a wavelength of
575 nm using a spectra MAX plus spectrophotometer and a sofMax software.
Calcium concentrations using calibration were calculated as follows:
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Csample (mmol/1) (Asample / Astandard) X C standard (2.50)




Statistics for human ES cell surface markers flow cytometry analysis
were conducted based on three independent experiments. The mean value and the
standard deviation were calculated using Microsoft Excel. Means were compared
using the two-tailed student's T-test. Statistical analysis for the calcium assay was
performed by using a F-test with Genstat (version 8.1, Lawes Agricultural Trust,
2005) software. Statistics for mitotic spreads were carried out using a Chi-squared




Engineering the j3-Casein Gene in








The potential applications of hES cells include a source of tissue for
regenerative medicine, models to study human diseases and early human embryonic
development in vitro, and drug discovery and cytotoxicity testing. However, to bring
nonautologous hES stem cell therapies to the clinic, rejection of hES-derived grafts
by the patient's immune system must be avoided, directed differentiation to provide
therapeutically relevant cell types must be established and strategies to purify
differentiated cells from heterogenous populations, including potentially tumorigenic
undifferentiated hES cells (Thomson et al., 1998, Reubinoff et al., 2000), must be
developed. Genetic modification of hES cells could be the answer for many of these
issues. Gene targeting will be probably required for some applications such as the
modelling of human disease, the reduction of immunogenicity of hES cell-derived
transplants and the dissection ofpathways in developmental biology (for more details
see section 1.4.2, chapter I). Whilst random integration of transgenes can be
sufficient to provide stable transgene expression, for example to increase
commitment to a specific lineage, it may lead to insertional inactivation of coding
sequences, and/or reduced and aberrant expression of the transgene due to position
effects (Clark et al., 1994; Martin and Whitelaw, 1996). These problems can in
principle be overcome by the use of gene targeting to introduce a transgene to a site
known to be permissive for transgene expression (Wallace et al., 2000). Thus gene
targeting provides a safer and more effective route to stable transgene expression.
The mammary epithelium-specific /3-casein gene was chosen as a candidate
target site for reliable transgene expression in the H9 female hES cell line. The
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primary advantage of targeting this gene is that it has no essential function out-with
the mammary gland (Kumar et al., 1994). Thus the possibility of targeting both
alleles without risks of insertional mutagenesis of essential genes such as house
keeping genes, also provides a low frequency of losing both copies of a transgene.
This is an important consideration for strategies in which stem cells are manipulated
to express "suicide genes" such as HSV-tk to provide protection against
tumorigenesis (Bonini et al., 1997; Schuldiner et al., 2003). This gene was also
chosen because targeting frequencies of up to 8 %, using a positive and negative
selection (Capecchi, 1989), were achieved at this locus in mouse ES cells (Kolb,
2001).
Kolb (2001) introduced, by HR, a positive/negative /zprt-expression cassette
(Albertini, 2001) flanked by the loxP and lox2272 heterospecific lox sites (Lee and
Saito, 1998) at the [3-casein gene in the HPRT-deficient murine ES cell line HM1
(Magin et al., 1992). Because HM1 cells are HPRT-deficient, they are sensitive to
HAT selection (Szybalski & Szybalska, 1962) and resistant to 6-TG selection (Stutts
& Brockman, 1963) (see section 1.4.4.2, chapter 1, for details of the HPRT selection
system). As a result, HM1 cell clones targeted with the hprt cassette at the fl-casein
gene could be selected in HAT selection. Using Cre-recombinase-mediated cassette
exchange (RMCE) (Bethke and Sauer, 1997; Bouhassira et al., 1997; Seibler et al.,
1998; Feng et al., 1999; Trinh and Morrison, 2000) in a subsequent step, the
/i/irt-expression cassette from a targeted cell clone was then exchanged for a
promoterless fi-galactosidase gene and a PGK-hytk expression cassette flanked by a
loxP and a lox2272 site. Site-specific recombinants carrying the modification could
be recovered in hygromycin (Hy) and 6-TG (since these cells no longer expressed
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hprt). Using this positive/negative selection strategy, 100 % of the
6-TG/Hy-resistant colonies carried the desired modification.
We sought to characterise the fl-casein gene for its ability to provide
reproducible transgene expression in H9 cells. Based on the work conducted by
Kolb (2001), our objective was to tag, by HR, the same heterospecific lox sites
described by Kolb such that RMCE can be subsequently applied.
At the start of this project, there was no report of gene targeting in hES cells
and thus the establishment of a gene targeting protocol was a priority. Since then,
Zwaka and Thomson as well as Urbach et al. have reported gene targeting at the hprt
gene (Zwaka and Thomson, 2003; Urbach et al., 2004), and oct-4 gene (Zwaka and
Thomson, 2003) in hES cells. The first part of this chapter describes the targeting
strategy, the establishment of an efficient transfection protocol and the fi-casein
targeting experiments conducted in H9 cells. The second part of this chapter
describes a preliminary experiment in which the chicken HS4 insulator elements
(Chung et al., 1993) were tested in hES cells as an alternative approach to overcome
the problems associated with transgene expression, mentioned above. Insulators are
boundary elements that exert their function by shielding genes from either the action
of a distal enhancer and/or from the silencing effects of condensed chromatin. These
elements could be useful in protecting transgenes randomly integrated in the genome
for strategies that do not require gene targeting of hES cells. Additionally, insulators
could prevent transgene silencing at loci that are either expressed at low levels or
silent (such as the /3-casein gene), against a potential surrounding condensed




(i) To optimise the experimental conditions required for gene targeting
experiments in H9 cells, (ii) To introduce incompatible lox sites by HR into the /?-
casein gene in H9 cells, (iii) To test the ability of HS4 insulators to protect
transgenes from silencing in H9 cells.
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3.3.1.1. P-Casein Targeting Vector and Targeting Scheme
To introduce heterospecific lox sites into the ft-casein gene, a human
p-casein replacement vector pCas-EfN was generated (figure 3.1). This vector
consists of a 2.3 kb 5' arm and a 5.4 kb 3' arm of homology which were amplified
separately by "Expand™ High-fidelity PCR" (Roche) from H9 genomic (g) DNA.
The 5' element includes the 3' end of the promoter region (between -2602 and
-231 bp) and the 3' element includes most of the open reading frame of the gene
(from exon 2 to the beginning of exon 8). An expression cassette, composed of the
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human EFl-a (Elongation Factor 1-a) promoter (Mizushima and Nagata, 1990)
driving a neomycin (neo) gene flanked by heterospecific lox sites (loxP and lox
2272), was inserted between the two arms of homology. The human EFl-a promoter
(from pEFl/V5HisA, Invitrogen) was chosen to drive the neo cassette because of its
strong and ubiquitous transcriptional activity in human cells (Mizushima and Nagata,
1990). Targeting one of the fl-casein alleles with pCas-EfN would result in the
replacement of a 4.9 kb fi-casein sequence (spanning from the end of the promoter to
the end of intron 1) with a 3.4 kb EFl-a-loxP-neo-lox2272 cassette in the opposite
transcriptional orientation to the gene (figure 3.1). This transgene would allow
selection for both random and targeted events with the drug G418. Discrimination
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Figure 3.1. Schematic representation of the p-casein gene targeting in H9 cells.
The ^-casein promoter (9.4 kb) is represented by a box in a dark and light blue graduated shading.
The light graduated shading represents the 5'arm of homology included in pCas-EfN. The 8 exons of
the P-casein gene are presented as blue boxes with exon numbers indicated. The translational
initiation start (ATG) is shown above the second exon. The EFl-a promoter and the neo expression
cassette are indicated as a solid green arrow and solid pink box, respectively. The positions and
orientations of the loxP and lox2272 recombination sites are shown as a black and white arrow,
respectively. The Kpnl restriction site used to linearise pCas-EfN, prior to a targeting experiment is
also indicated. The black and red thick lines represent the sequence outside the P-casein locus, and
plasmid backbone, respectively. Cross-over recombination points between the targeting vector and the
p-casein chromosomal sequence are indicated by an 'X'. Following homologous recombination (HR)
a 4.9 kb P-casein sequence (spanning from the end of the promoter to the end of intron 1) is replaced
with a 3.4 kb EFl-a-loxP-neo-Lox2272 in the opposite transcriptional orientation of the gene,
disrupting the P-casein gene.
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3.3.1.2. Functionality of the Neomycin Expression Cassette
In order to verify the integrity of the neomycin expression cassette in
pCas-EfN, 107 HM1 mouse ES cells (Magin et al., 1992) were stably transfected by
electroporation with equimolar amounts of the KpnI-linearised pCas-EfN targeting
vector or KpnI-linearised pBS-PGKNeo using our standard mouse ES cell
electroporation conditions (800 V, 3 pF). A plasmid (pBS-PGKNeo) containing a
PGKneo expression cassette, was used as a positive transfection control in this study
because it was shown, in our hands, to be efficient in generating G418-resistant
colonies in HM1 cells. G418 selection (300 pg/ml) was applied the following day,
and 12 days after electroporation the resulting G418-resistant colonies were stained
with 10% Giemsa's stain solution (figure 3.2). HM1 cells transfected with
pCas-EfN, produced a very large number of G418-resistant colonies (>500),
rendering colony counting difficult. In contrast, HM1 cells transfected with
pBS-PGKNeo produced -135 colonies. Although this study suggests that the
transcriptional activity of the EFl-a promoter is stronger than the PGK promoter,
they could not be directly compared since different plasmids with different structures
were used in the transfection. A mock control, in which cells were electroporated
without DNA, did not yield any colonies, indicating that all the colonies obtained in
the experimental plates were actually G418-resistant.
These results demonstrate that the neomycin expression cassette in
pCas-EfN is functional and that the transcriptional activity of the EFl-a promoter is
very strong leading to a large number of G418-resistant colonies in mouse ES cells.
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Figure 3.2. Functionality of the neo expression cassette from pCas-EfN in HM1
cells. Giemsa staining of G418-resistant HM1 colonies 12 days after transfection with pCas-EfN
(left) or pBS-PGKNeo positive control plasmid (right).
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3.3.1.3. Functionality of the Lox Sites in pCas-EfN
The sequencing of loxP and lox2272 sites in the plasmid pCas-EfN
showed that both lox sites were intact (Appendix 1, section 1.1). However, it was
also necessary to test their functionality prior to performing a large scale targeting
experiment, as the subsequent RMCE step relies on their function. The plasmid
pCas-EfN was therefore assessed in an in vitro recombination assay (Kolb, 2001) for
its ability to recombine with pB-RMCE2272 (gift of A. Kolb, appendix 1, section
2.4), a plasmid containing the same pair of heterospecific lox sites. Site-specific
recombination between both vectors leads to reciprocal exchange of sequences
within the lox sites. The plasmids pCas-EfN and pB-RMCE2272 were linearised
with Kpnl and Seal, respectively, incubated with Cre recombinase (New England
Biolabs), and the reactions were used as the template in a PCR reaction with T7 and
T3 primers. These primers were selected because they should anneal specifically to
pB-RMCE2272 and one of the two recombination products only, resulting in the
amplification of 227 bp (from the pB-RMCE2272 plasmid) and 1850 bp if
site-specific recombination had occurred (figure 3.3 A & B). PCR results showed
the presence of the predicted bands when the two constructs were incubated along
with Cre recombinase (figure 3.3 B). In contrast, when the two plasmids were used
as template without prior treatment with Cre, only the 227 bp PCR product, arising
from the pB-RMCE2272 plasmid, was detected (figure 3.3 B). These results indicate
that cassette exchange was successful between the two plasmids in an in vitro assay,
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Figure 3.3. In vitro recombination assay between pCas-EfN and pB-RMCE2272.
(A) Schematic representation of relevant segments of the plasmids pB-RMCE2272, pCas-EfN, and the
potential recombination product arising from the recombination of each lox site with its counterpart.
Positions of the primers and PCR product sizes are indicated in red. (B) PCR analysis of Cre reaction
between plasmids pCas-EfN and pB-RMCE2272 treated with (+) or without (-) Cre recombinase
using T7 and T3 primers. The 1850 bp band, indicative of site-specific recombination, can only be
detected after Cre recombinase treatment of the two plasmids. M: Bioline hyperladder I.
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3.3.1.4. G418 sensitivity of H9 cells
G418 (also known as geneticin) is an aminoglycosidic antibiotic
commonly used for the selection of mammalian, plant or yeast cells transfected with
the neo gene. Geneticin is an analogue of neomycin sulfate that interferes with the
function of 80S ribosomes and protein synthesis (Daniels et al., 1973). The product
of the Tn5 or Tn601 aminoglycoside phosphotransferase gene (neo) confers
resistance to G418 by phosphorylating the antibiotic, thus blocking its action
(Southern & Berg, 1982). Prior to conducting a targeting experiment in H9 cells, it
was important to determine the minimum concentration of G418 required to kill all
the cells in a reasonable time (10 days). The working concentrations of G418 for
mouse ES cells are usually around 300 pg/ml. However, because of genetic
background variation and species differences, the H9 cell line might require a
different concentration of G418 in order to recover G418-resistant colonies. The
sensitivity of H9 cells to G418 was established by applying a range of G418
concentrations varying from 0 to 800 pg/ml to untransfected H9 cells. Ten days after
selection, the cells were fixed and stained with 10% Giemsa R-66 solution. Figure
3.4 shows that 100 pg/ml of G418 is the minimal concentration that efficiently kills
all untransfected H9 cells in 10 days and therefore was used for a subsequent
fi-casein targeting experiment in H9 cells.
Figure 3.4. G418 sensitivity of H9
cells. H9 cells were exposed to a range of
G418 concentrations (indicated in |ig/ml) and
after 10 days, were fixed and stained with 10 %
Giemsa solution.
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3.3.1.5. Establishment of a Transfection Protocol
Gene targeting by HR in murine ES cells is generally characterised by
low frequencies (as the ratio between the number of homologous recombinants and
the number of stably transfected clones) which vary between different target loci,
from as little as 1 in 20 000 (Johnson et al., 1989) to 1 in 3 (e.g. Te Riele et al.,
1992). Thus when an early report (Eiges et al., 2001) showed that high stable
transfection efficiencies (ratio between the total number of stable transfectants and
the total number of electroporated cells) were difficult to achieve in hES cells, it
became clear this would be a major obstacle to the routine isolation of gene-targeted
hES cells. Eiges et al. (2001) assessed a number of transfection techniques and
found the cationic polymer, ExGen 500 (Fermentas), to be most effective. This was
used to produce the first reported transfected hES clones (expressing GFP), with a
transfection efficiency of 3.3 x 10"5. Whilst chemical transfection efficiencies are
sufficient to generate transgenic hES cell lines, they would not provide sufficient
clone numbers to optimise the chance of identifying gene-targeted clones from a
transfection. Lipofection has also been shown to be less effective than
electroporation for the production of gene-targeted human somatic cells (Yanez and
Porter, 1999). Hence the focus of improvements for gene targeting in hES cells has
been on electroporation methods (Zwaka and Thomson, 2003).
To optimise transfection efficiencies in H9 cells, a protocol based on
standard mouse ES cell methods was first tested, with parameters adjusted to suit H9
cells (H. Priddle, unpublished data). In collaboration with A. Thomson (Roslin
Institute), a pilot fi-casein targeting experiment was conducted with the targeting
vector pCas-EfN. 106 H9 cells were stably transfected in HBS (10 mM HEPES,
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150 mM NaCl, pH 7.0) by electroporation (BioRad Gene Pulser II) at 200 V / 950
pF, with 50 pg of the KpnI-linearised targeting vector pCas-EfN (table 3.1). G418
selection (50 or 100 pg/ml) was applied 48 hours later and 11 days post-selection, 35
G418-resistant colonies were obtained with 50 pg/ml of selection, and 7 with
100 pg/ml of G418 (table 3.1). Therefore using this protocol, we obtained
transfection efficiencies (between 1.4xl0"5 and 7xl0"5) similar to those reported by





















Table 3.1. Pilot P-casein targeting experiment with pCas-EfN in H9 cells.
106 H9 cells were electroporated with 50 pg of pCas-EfN using the conditions indicated and were
maintained in G418 selection for 11 days.
Because these transfection efficiencies were too low to be practical in the
context of a targeting experiment, electroporation conditions were re-evaluated for
H9 cells using the Eppendorf Multiporator system. This protocol utilises a hypo-
osmolar buffer to expand the cell membrane and loosen its association with the
cytoskeleton, reducing the required voltage. The Multiporator also applies the
voltage in a shorter pulse, in the micro-second rather than milli-second range which
is claimed to be much "gentler" for the cells (see the Eppendorf Multiporator Basic
Applications Guide). By using this approach, stable transfection efficiencies of up
to 2.3xl0"4 were obtained in H9 cells with a PGK-neo plasmid (231 G418-resistant
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clones were obtained after transfection of 106 H9 cells) using electroporation
conditions of 300 V / 100 ps (H. Priddle, unpublished data). Therefore these
transfection conditions were adopted for a subsequent f3-casein targeting experiment.
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3.3.1.6. Validation of the p-Casein Southern Probe
Southern analysis allows DNA fragments corresponding to a specific
probe to be identified directly from a restriction digest of gDNA (Southern, 1975).
In order to identify a targeting event at the /?-casein gene in H9 cells by Southern
blotting, a 365 bp p-casein probe (amplified by PCR from H9 gDNA) was generated
and tested in a Southern screen with gDNA derived from wild-type H9 cells and
G418-resistant clones from the [3-casein pilot experiment. Figure 3.5 A shows the
Southern Pstl-diagnostic obtained with this probe with the wild-type allele (9.7 kb)
and the targeted allele (7.9 kb). The /?-casein probe was designed to recognise
chromosomal sequences just beyond the 3' arm of homology of the /3-casein gene
used in pCas-EfN, so that random integrants would not be detected. To validate the
probe, 10 pg of Pstl-digested gDNA from wild-type H9 and the 42 H9 G418-
resistant clones was analysed by Southern blotting. The presence of the predicted
9.7 kb Pstl-fragment from the wild-type allele was detected in all the samples
indicating that the probe was suitable for a fi-casein targeting experiment (figure 3.5
B). The absence of the predicted 7.9 kb PstI fragment from the targeted allele,
however indicated that none of the clones were the result of HR. Since targeting
frequencies usually vary between 1:400 to 1: 2000 in mammalian cells, these results
were expected as only 42 clones were analysed.
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Figure 3.5. Validation of the P-casein probe. (A) Map of the relevant segments of the
wild-type and targeted P-casein alleles showing the predicted PstI fragment diagnostics obtained with
a P-casein probe external to the homology included in pCas-EfN. The P-casein sequence is
represented as a thin blue line. The red line represents the sequence outside the P-casein locus. The
position of the probe is indicated as a red box with the size of the predicted PstI fragment shown
below. (B) Southern analysis of wild-type (wt) H9 and a representative subset of the 42 G418-
resistant H9 subclones. The unmodified P-casein allele yielded the predicted 9.7 Kb fragment but the
predicted 7.8 kb from the modified allele was not detected in any of the clones. The molecular ladder
(Hyperladder, Bioline) is indicated on the right.
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3.3.2. (i-Casein Targeting Experiments
3.3.2.1. /3-Casein Targeting Experiment I
Following the optimisation of experimental conditions in H9 cells, a
large-scale fi-casein targeting experiment was conducted. 106 H9 cells were
electroporated with the EppendorfMultiporator with either 50 or 100 pg of the Kpnl-
linearised targeting vector pCas-EfN (table 3.2). G418 selection (100 pg/ml) was
applied 48 h later and fourteen days after selection, 137 and 177 G418-resistant
colonies were produced with 50 and 100 pg of pCas-EfN, respectively (table 3.2). A
control plate in which H9 cells were transfected in the absence of the targeting
construct did not produce any G418-resistant colonies, indicating that those
generated in the experimental plates were actually G418-resistant. Therefore the
transfection efficiency obtained with this protocol was up to 13-fold greater than that
obtained in the pilot targeting experiment (table 3.2). As a result of bacterial
contamination, 48 clones were lost, therefore 266 G418-resistant clones were
expanded individually to two wells of a 12-well plate for freezing and gDNA
extraction.
Cell line Electroporation Number of pCas-EfN G418 G418r Transfection
Conditions cells treated (itg) (pg/ml) colonies efficiency
H9 300 V/100 ps 106 50 100 137 1.4xl0"4
106 100 100 177* "«*■o00r—•!
Table 3.2. p-casein targeting experiment I with pCas-EfN in H9 cells. * 48 clones
were discarded as a result of bacterial contamination.
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To screen for targeting events at the /?-casein gene, Pstl-digested
gDNA from each clone was analysed by Southern blotting using the external
fi-casein probe (figure 3.5.A). The probe was found to hybridise to the predicted
9.7 kb PstI fragment from the wild-type allele in all the clones. However, the
predicted 7.9 kb PstI fragment from the targeted allele was not detected in any of the
clones analysed indicating that none of them were the result of HR (figure 3.6).
These data show that the targeting frequency is below 0.38% since no targeting event
was detected in 266 H9 G418-resistant clones.
PstI
G418r H9 clones wt
mm* m-* «••»*>«* ktmi* m <-9.7 kb
Figure 3.6. Southern blot analysis of a representative subset of the 266 G418-
resistant H9 clones. The presence of the 9.7 kb PstI fragment from the wild-type allele can be
detected but the absence of the 7.8 kb PstI fragment from the targeted allele indicates that none of the
clones are the result of gene targeting at the /?-casein gene.
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3.3.2.2. (5-Casein Targeting Experiment II
Although no targeting event was detected in H9 cells in the previous
fi-casein targeting experiment, 266 clones might not have been sufficient to detect a
targeting event at the p-casein gene. Our strategy was therefore revised to increase
the number of G418-resistant colonies. Data from the pilot experiment showed that
using 50 rather than 100 pg/ml of G418 produced more colonies (35 versus 7)
suggesting that colonies expressing low levels of neo could survive at 50 jug/ml but
not at 100 pg/ml of G418. Because the fi-casein gene is not expressed in hES cells,
it is possible that the neo gene would be expressed at a low level at this locus due to a
potential surrounding condensed chromatin structure, often observed at a
transcriptionally inactive gene (Felsenfeld and Groudine, 2003). Based on this
hypothesis, selection with 100 pg/ml of G418 may have killed targeted cells,
whereas a primary G418 selection of 50 pg/ml might allow the survival of targeted
cells. It has been suggested that transcription itself leads to distinct changes (i.e.
"opening") in the structure of surrounding chromatin (Lee and Garrard, 1991). Thus
it is possible that initial transcriptional activation of the neo gene at 50 pg/ml may
lead to chromatin remodelling, thus rendering the ft-casein locus more permissive to
transgene expression. Allowing the transcription machinery to operate with a
primary lower selection regime, may therefore allow the survival of targeted cells
when G148 selection is subsequently raised to 100 pg/ml.
Based on this reasoning, another targeting experiment was conducted
in which 106 H9 cells were electroporated with 50 pg of the Kpnl linearised targeting
vector pCas-EfN using the Eppendorf Multiporator system (table 3.3). G418
selection (50 pg/ml) was applied 48 h later and seven days post-electroporation, the
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G418 concentration was doubled. This new selection regime produced 354 G418-
resistant colonies, an increase of transfection efficiency of up to 2.5-fold (table 3.3),
over the previous targeting experiment in which 50 pg of targeting vector was used
(table 3.2). All the colonies obtained in this experiment were the result of resistance
to the drug G418, as a mock control, in which cells were electroporated in the
absence of DNA, did not produce any G418-resistant colonies following the same
regime of G418 selection. The increase in G418-resistant colonies suggests that
either more colonies expressing low levels of neomycin survived selection, or that
this increase was the result of transfection efficiency variation between the two
targeting experiments. Fourteen days after G418 selection, the 354 individual clones
were picked and expanded up to 2 wells of a 12-well plate for freezing and gDNA
extraction for Southern analysis.
Cell Electroporation Number of pCas-EfN G418 G418r Transfection ETF
line conditions cells treated (pg) (pg/ml) colonies efficiency (%)
H9 300 V/100 ps 106 50 50 (5 days) 354 3.5xl0"4 <0.3
100 (9 days)
1
Table 3.3. fl-casein targeting experiment II with pCas-EfN in H9 cells. Effective
targeting frequency (E.T.F): ratio between the number of homologous recombinants and the numbers
of stable transfectants (see figure 3.7 for Southern analysis).
Pstl-digested gDNA from each clone was analysed by Southern
blotting to screen for targeted events with the external /?-casein probe. The 9.7 kb
PstI fragment from the wild-type allele was detected but not the 7.9 kb PstI fragment
indicative of a targeted allele, showing that none of these clones were the result of
HR at the f1-casein gene (figure 3.7). These data indicate that targeting frequency at
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the [3-casein gene in H9 cells is below 0.3 % (< 1/354) using these experimental
conditions, thus much lower than the 8 % reported by Kolb at the /?-casein gene in
mouse ES cells (Kolb, 2001). Kolb however, applied an enrichment strategy with
the use of a positive/negative selection vector (Capecchi, 1989).
PstI G418r H9 clones
<-9.7 kb
Figure 3.7. Southern blot analysis of a representative subset of the 354
G418-resistant H9 clones. The unmodified /?-casein allele yielded the predicted 9.7 Kb
fragment but the predicted 7.8 kb from the modified allele was not detected in any of the clones.
Failure to target the fi-casein gene in H9 cells might be due to two
possibilities; (i) The (1-casein gene is refractory to gene targeting in H9 cells and
therefore no targeting event has occurred; (ii) A targeting event has occurred but the
targeted cell was killed because the threshold of resistance to G418 provided by neo
expression was below 100 pg/ml. Because unexpressed genes (including the
fi-casein gene) have previously been targeted in mouse ES cells (Koller and
Smithies, 1989; Johnson et al., 1989; Kumar et al., 1994; Kolb et al., 1999; Kolb,
2001), it seems unlikely that hES cells are intrinsically refractory to gene targeting at
the fi-casein gene. If the neo gene was silenced at the fi-casein gene, one solution
would be to protect neo expression from the silencing effect of neighbouring
chromatin. The use of insulator elements such as the chicken HS4 (Chung et al.,
1993) may be a solution.
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3.3.3. Protective Effect of Insulators on Transgene
Expression in H9 cells
3.3.3.1. Strategy
Chromosomal position effects on transgene expression have been a
major problem in gene regulation studies in transgenic mice as well as in the
development of successful gene therapy strategies (Clark et al., 1994; Martin and
Whitelaw, 1996). A considerable effort has therefore been made to identify the cis-
regulatory requirements for tissue-specific, high-level and position-independent
expression of transgenes. The existence of insulators next to some genes was shown
to provide a barrier to shield the coding region from its surroundings, and as a result
has led to the development of strategies to overcome chomosomal position effects
(reviewed by Recillas-Targa et al., 2004). Insulators are DNA elements located at
the boundaries of a transcriptional domain. Their function is to shield a gene from
either the action of a distal enhancer or silencer, and/or from the silencing effects of
condensed chromatin (for more details, see section 1.2.2.1., chapter 1). As an
example, a 1.2 kb 5' constitutive DNasel-hypersensitive (HS) region with insulator
properties from the chicken fi-globin cluster was shown to protect endogenous gene
or transgene expression from chromosomal position effects in mammalian cells
(Chung et al., 1993). In a later report, Chung et al. (1997) showed that the activity of
the 1.2 kb HS4 fragment resides in a 250 bp core element which contains the
constitutive DNase I-hypersensitive site (5'HS4) and that the insulating activity of
the core element is multiplied when tandem copies are used on both sides of a
transgene. Ma et al. (2003) showed that the inclusion of the 1.2 kb HS4 fragment in
a EFla-GFP lentiviral vector, provides significantly reduced variability of GFP
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expression in the H9 cell line, compared with an EFla-GFP lentiviral vector lacking
the HS4 element.
Based on these data, we tested the ability of tandem copies of the
250 bp HS4 core elements to protect transgene expression in H9 cells. The
insulating properties of HS4 were tested by comparing GFP expression between a
plasmid containing a PGKGYV expression cassette (pPGKGFP-SV40Neo, given by
A.Thomson) and a similar plasmid with a PGKGFP flanked on both sides by the HS4
insulators (pHS4PGKGFP-SV40Neo, given by T. Lacroix) (figure 3.8). 106 H9 cells
were stably transfected with 50 pg of either Dralll-linearised pHS4PGKGFP-
SV40Neo or Dralll-linearised pPGKGFP-SV40Neo using the Multiporator protocol.
An SV40neo expression cassette was also included in the plasmids (figure 3.8) to
allow the generation of G148-resistant colonies 10 days later. Examination by
fluorescence microscopy 12 days post-electroporation, showed that few colonies
expressed GFP in both transfection experiments (data not shown). Additionally,
position effect variegation (PEV) was observed in most colonies. However, PEV
was minimal in clones derived from the transfection with pHS4PGKGFP-SV40Neo
(+ insulators) suggesting that insulators were able to protect GFP expression from
PEV. Colonies from both transfections were pooled and expanded to a T25 flask for
flow cytometric analysis to compare GFP expression levels.
Figure 3.8. Effect of HS4 insulators on GFP expression in H9 cells. Cells were
either transfected with Dralll-linearised pPGKGFP-SV40Neo (no insulators) or Dralll-linearised
pHS4PGKGFP-SV40Neo (+insulators). The SV40-neo cassette provides resistance to the drug G418.
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3.3.3.2. FACS Analysis
To compare GFP expression between the two transfections, cells were
collected and examined by flow cytometry. Flow cytometry offers a quantitative
way of assessing GFP expression levels in the cells. Untransfected H9 cells were
used as a negative control for GFP expression. In this analysis, only the live cells
were analysed. The dead cells were excluded based on their forward size scatter
(FSC-H) and side scatter (SSC-H) profile. A representative density plot showing the
region (Rl) which includes only the live cells analysed is illustrated in figure 3.9 A.
Quantification of GFP-positive cells showed that only 8.5 % of H9 cells transfected
with pPGKGFP-SV40Neo (no insulators) expressed GFP. In contrast, ~ 36 % of H9
cells transfected with pHS4PGKGFP-SV40Neo (+ insulators) expressed GFP (figure
3.9 B & C). Thus a 4-fold increase of GFP-expressing cells was observed when the
GFP expression cassette was flanked by FIS4 elements consistent with an increase of
protection of transgene expression. Among the GFP-positive population, ~ 3% (M2)
of these cells were found to express GFP at higher levels than cells transfected with
pPGKGFP-SV40Neo (figure 3.9 B). These preliminary data therefore suggest that
HS4 elements insulate a transgene in H9 cells and could be of use in preventing the
silencing of transgenes inserted at unexpressed or any other loci.
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A B
Sample % GFP + cells
Untransfected H9 — 0.77
H9 + pPGKGFP-SV40Neo — 8.51
H9 + pHS4PGKGFP-SV40Neo — 36.1
Figure 3.9. Flow cytometric analysis of pooled H9-GFP+ cells transfected with
pHS4PGKGFPSV40Neo or pPGKGFPSV40Neo. (A) Representative density plot
showing the region R1 containing the live cells analysed. (B) Histogram representation of
untransfected H9 cells (negative control) (red) and H9 cells transfected with either
pHS4PGKGFPSV40Neo (black), or pPGKGFPSV40Neo (green). Data were generated from the
analysis of at least 10000 viable cells. The gate Ml indicates the total number of GFP-positive cells
and the gate M2 indicates the 3% of pHS4PGKGFPSV40Neo transfected-H9 cells expressing GFP at







We sought to engineer the /3-casein gene in H9 cells by introducing, by gene
targeting, a selectable neo marker flanked by incompatible lox sites and driven by the
EFl-a promoter. Following gene targeting by HR, a promoterless selectable marker,
also flanked by incompatible lox sites, would be exchanged against the neo marker
by RMCE using a promoter trap strategy. Using an electroporation protocol,
transfection efficiencies obtained in these targeting experiments reached up to
3.5xl0"4 (table 3.3). This was 10-fold greater than the best transfection efficiency
achieved (using a chemical transfection protocol) obtained so far in H9 cells (Eiges
et al., 2001). Southern analysis however, showed that none of the 668 G418-
resistant colonies generated were the result of gene targeting at the [3-casein gene.
Failure to target the [3-casein gene in H9 cells could have been due to several
reasons; One possibility is that the)3-casein gene is less permissive to gene targeting
because of its transcriptionally-inactive status. It has been suggested that
transcription stimulates gene targeting frequency by creating a more favourable
target for recombination enzymes, through the introduction of topological changes
within the target (Thyagarajan et al., 1995). While there is evidence that
transcription can stimulate intrachromosomal HR (Nickoloff, 1992),
extrachromosomal HR (Nickoloff and Reynolds, 1990) and gene targeting in
mammalian cells (Thyagarajan et al., 1995), it is also known that untrancribed genes
can be targeted with frequencies similar to transcribed genes in murine ES cells
(Johnson et al., 1989; Roller and Smithies, 1989; Kumar et al., 1994; Kolb et al.,
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1999; Kolb, 2001). Thus these studies show that a low or nil transcription rate is
probably not a limiting factor in gene targeting frequency.
Another possibility is that gene targeting has occurred at the fi-casein locus
but the neo was silenced or otherwise down-regulated, perhaps by
heterochromatinisation of the locus, resulting in death of the targeted cells in the
presence of G418. Marques et al. (manuscript in preparation) have previously
attempted to target the fi-casein gene in sheep foetal fibroblasts, and although PCR
screening and restriction digestions of the PCR product indicated successful gene
targeting for some of the clones, Southern screening failed to provide evidence of
gene targeting in the candidate clones analysed. They claimed that targeted cell
clones were originally mixed with random integrants which eventually took over the
culture during expansion due to silencing of the selectable marker at the {3-casein
gene. Thus targeted clones could be identified by PCR but not by Southern analysis.
Their result is consistent with a previous report in which failure to detect a targeting
event in a human bladder carcinoma cell line was the result of cells not surviving
drug selection when the transgene was inserted into an inactive chromosomal locus
(Smithies et al., 1985). Another group recently reported the lack of expression of a
transgene targeted into the non-expressed immunoglobulin-/u and prion protein (PrP)
genes in bovine foetal fibroblasts, possibly due to silencing of the integrated
transgene as part of the silent locus (Kuroiwa et al., 2004).
Similarly, if neo silencing occurs at the fi-casein locus in H9 cells, targeted
clones would have eventually died and all of the G418-resistant clones would be
random integrants. It has been shown that targeted cells can be reliably identified by
PCR in pools in which non-homologous recombinants cells outnumber homologous
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recombinants by 100 to 1 (Kim et al., 1991). Hence screening for a targeting event
at the /3-casein gene in H9 cells could be facilitated by combining individual early
G418-resistant clones (obtained at 50 gg/ml G418) into small pools (<100 colonies)
for analysis by PCR (Hanson and Sedivy, 1995). If gene targeting was confirmed,
the targeting protocol could be modified by relaxing the selection as soon as colonies
become evident and to re-clone surviving colonies in the absence of selection in
order to identify targeted clones by Southern analysis.
The preliminary data presented in section 3.3.3 showed a 4-fold increase of
GFP-expressing H9 cells when a GFP transgene was flanked on both sides by HS4
insulators, indicating that these elements protect transgene expression from silencing.
Thus the addition of HS4 elements on both sides of the neo cassette in the fi-casein
targeting vector may be a solution in the future to improve targeting frequencies at
the fi-casein locus. A positive and negative selection could be employed (Mansour et
al., 1988; Capecchi, 1989) by including an HSVtA: (herpes simplex virus thymidine
kinase) (McKnight, 1980) expression cassette outside the regions of homology of the
targeting construct in order to reduce the number of clones with random integration
events in a cell population. In this enrichment scheme, G418 selection would be first
applied to select for cells that have integrated the targeting vector in their genome.
In a second step, the expression of the HSV/A: expression cassette, which converts
nucleoside analogues into toxic metabolites, would provide sensitivity to the drug
gancyclovir (St Clair et al., 1987). This selects against cells in which the entire
targeting vector has integrated randomly. On the other hand, cells carrying a targeted
integration should lose the HSVt£ cassette during HR and therefore survive selection.
Although a positive-negative selection strategy has been reported to produce modest
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enrichments, typically ranging from 2-to 10-fold (Hanson and Sedivy, 1995), the
addition of a second negative selection marker in the /?-casein targeting vector could
however increase this enrichment and should significantly ease the identification of













The X-linked hypoxanthine-guanine phosphoribosyl transferase (hprt) gene is
a housekeeping gene which is involved in the purine salvage pathway (Stout and
Caskey, 1988). We sought to engineer the hprt gene because it presents several
advantages: (i) The hprt gene is hemizygous in male cells and therefore a genetic
modification of a single allele leads to complete loss of function; (ii) HPRT activity
can be selected for or against (Albertini, 2001). HPRT catalyses the addition of
purines to the sugar intermediate 5' phosphoribosyl-1-pyrophosphate (PRPP) in
wild-type cells (for details of the HPRT selection system, see section 1.4.4.2). Either
in the absence of purines or when hprt is not functional, the cells are forced to follow
an alternative de novo synthesis pathway. Aminopterin selection inhibits the enzyme
dihydrofolate reductase, which is essential for de novo synthesis. Hence cells with
functional HPRT will survive Aminopterin selection if provided with Hypoxanthine
and Thymidine in the medium (HAT) (Szybalski and Szybalska, 1962). Because
wild-type cells are able to use the salvage pathway, they are not affected by the
presence of HAT in the medium, unlike HPRT-deficient cells that have both purine
ribonucleotide biosynthesis routes blocked and die in HAT. HPRT can also catalyse
the addition of a toxic purine analogue, 6-thioguanine (Stutts and Brockman, 1963;
Sharp et al., 1973, Wahl et al, 1975) to PRPP in the salvage pathway, resulting in
cell death. In contrast, HPRT-deficient cells do not show any alteration in their
metabolism in the presence of 6-TG, since these cells lack an active salvage pathway.
This ability to select for or against HPRT activity, therefore renders targeting
frequencies very easy to estimate at a phenotypic level (i.e. colony counting) in a
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male cell line (Albertini, 2001); (iii) The hprt locus is well known for its ability to
provide tissue-specific reproducible transgene expression in several cell lines (Vivian
et al., 1999; Evans et al., 2000; Guillot et al., 2000; Cvetkovic et al., 2000; Minami et
al., 2002; Heany et al., 2004) and therefore should be a good candidate gene for
reliable transgene expression in hES cells; (iv) The mutation of this gene in hES cells
would provide a model for Lesch-Nyhan syndrome (LNS). LNS is a severe human
genetic disease that is caused by the malfunction of the hprt gene (Stout and Caskey,
1988). Although the mouse model of LNS exhibits the same biochemical defect as
LNS patients, it does not mimic any of the behavioral symptoms associated with the
disease (Bedell et al., 1997; Elsea and Lucas, 2002).
Gene targeting has recently been described at the hprt gene in hES cells
(Zwaka and Thomson, 2003; Urbach et al., 2004). Zwaka and Thomson deleted
regions of the last 3 exons of the gene in a subclone of the HI male ES cell line
(Thomson et al., 1998) with a replacement construct using an electroporation
protocol. Their targeting protocol resulted in a targeting frequency of up to 2 % in
hES cells. Urbach et al., (2004) inserted a transgene in the exon 2 of the gene in the
H13 male ES cell line (Itskovitz-Eldor et al., 2000) with a replacement construct
using a chemical protocol which resulted in a targeting frequency of up to 1 %.
We sought to engineer the HI male ES cell line by introducing, by
homologous recombination (HR), a selectable marker flanked by heterospecific lox
sites (Lee and Saito, 1998) into exon 3 of the hprt gene. The insertion of lox sites
will permit the use of recombinase-mediated cassette exchange (RMCE) (Feng et al.,
1999; Trinh and Morrison, 2000; Kolb, 2001) to examine transgene expression at the
hprt gene (see chapter 7).
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4.2. Objectives




4.3.1. Targeting Scheme and Hprt Targeting Vector
4.3.2. G418 Sensitivity in H1 Cells
4.3.3. Hprt Targeting Experiments in H1 cells
4.3.4. Confirmation of a Targeting Event by PCR and
Southern Analysis
4.3.1. Targeting Scheme and Hprt Targeting Vector
To target the hprt gene in HI cells, we used a replacement targeting vector,
pHprt-EfN. Figure 4.1 shows the targeting scheme and the structure of the vector.
The hprt homology used in this construct is a 6.9 kb Hindlll fragment (Edwards et
al., 1990) comprising exons 2 and 3, intron 2 and fragments of introns 1 and 3. A
neomycin expression cassette was inserted at the Xhol site in exon 3, in the opposite
transcriptional orientation, separating the hprt sequence into 4.8 kb 5' and 2.1 kb 3'
elements. Following double reciprocal recombination between the targeting vector
and the hprt chromosomal sequences, a 3.4 kb EFl-a-loxP-neopA-lox2272
expression cassette is inserted in exon 3 of the hprt gene (see paragraph below for the
structure of pHprt-EfN). Thus this insertion permits selection for random and
homologous recombinants with the drug G418, and for homologous recombinants
alone with the drug 6-TG.
The pHprt-EfN targeting vector was used to introduce the loxP and lox2272
heterospecific lox sites (Lee and Saito, 1998) into the hprt gene such that RMCE
(Feng et al., 1999; Trinh and Morrison, 2000; Kolb, 2001) can be subsequently
applied. This construct is derived from the pE3Aneo vector (Zheng et al., 1991)
which contains the 6.9 kb Hindlll fragment (Edwards et al., 1990) with an
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HSWtkneopA expression cassette (Thomas & Capecchi, 1987) inserted at the Xhol
site in exon 3 of the hprt gene. The plasmid pHprt-EfN was generated by replacing
the HSWtkneopA with an EFl-a-loxP-neopA-lox2272 expression cassette such that
following HR, the hprt gene is tagged with heterospecific lox sites in the exon 3
(figure 4.1). Because the EFl-a promoter is not included between the lox sites, a
promoter trap strategy (Jasin and Berg, 1988; Sedivy and Sharp, 1989) can
subsequently be applied in an RMCE experiment. Following site-specific
recombination, the neo selectable marker between the lox sites is exchanged with a
promoterless selectable marker flanked by the same set of heterospecific lox sites
which will then be driven by the EFl-a promoter (see chapter 7). This enrichment
strategy therefore permits the direct selection of site-specific recombinants since the
majority of random integrations will be transcriptionally silent and not survive
selection. The ubiquitously expressed EFl-a promoter was chosen because it is a
strong promoter (Mizushima & Nagata, 1990) and because preliminary transfection
experiments in our laboratory showed that the transcriptional activity of this
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Figure 4.1. Schematic representation of the human hprt gene targeting in HI
cells. The structure of the relevant hprt sequence is represented by a thick blue line with boxes
above marking the exons with numbers indicated. The translational initiation start (ATG) is shown
below the first exon. The restriction sites Hindlll (H) and Xhol (X), divide the hprt homology
sequence into 4.8 kb 5' and 2.1 kb 3' arms. The EFl-a promoter is shown as a green solid arrow.
The neo expression cassette is shown as a solid pink box. The positions and orientations of the loxP
and lox2272 recombination sites are indicated as solid black and white arrows, respectively. The two
cross-over recombination points which take place between the targeting vector and the hprt
chromosomal sequence are depicted by an 'X'. Following FIR with the Flindlll-digested targeting
vector, targeted recombinants can be selected for, based on their resistance to 6-TG.
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4.3.2. G418 Sensitivity in H1 Cells
As previously described in section 3.3.1.4 of chapter 3, G418 is an antibiotic
which interferes with protein synthesis (Daniels et al., 1973) and whose action is
blocked by the expression of the neomycin gene (Southern & Berg, 1982). Targeting
experiments at the hprt gene require a rapid primary G418 selection to ensure that
targeted and non-targeted colonies are separated before adding 6-TG selection. The
proximity of non-targeted cells to targeted cells could favour the exchange of the
5' phosphoribosyl-1-pyrophosphate (PRPP) and 6-TG metabolites which may kill
targeted cells by a bystander effect or "kiss of death" (Andrade-Rozental et al.,
2000).
Although the G418 sensitivity threshold was previously determined in the
female H9 cell line, it was necessary to establish a sensitivity threshold in the male
HI cell line, because a different genetic background may have different drug
requirements to achieve the same effect. As a result, HI cells were seeded at low
density in a 6-well plate and exposed to a range ofG418 concentrations varying from
0 to 800 pg/ml (figure 4.2). Ten days after selection, the cells were fixed and stained
with 10 % Giemsa R-66 solution. As in H9 cells, this study showed that the
antibiotic killed all HI cells within 10 days at a minimum concentration of 100 pg/ml
(Figure 4.2). For the subsequent targeting experiments in HI cells, we chose to
apply G418 selection at 50 pg/ml for 5 days before increasing the concentration to
100 pg/ml because we wanted to follow a similar selection regime to that used by
Zwaka and Thomson in their hprt targeting experiment (Zwaka and Thomson, 2003).
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Figure 4.2. G418 sensitivity of HI cells. HI cells were subjected to varying concentrations
ofG418 (indicated in pg/ml) for ten days and were then fixed and stained with 10% Giemsa solution.
Chapter IV 147
4.3.3. Hprt Targeting Experiments in H1 Cells
To target the hprt gene with the pHprt-EfN replacement vector, three
different sets of electroporation conditions were compared in HI cells. The first
electroporation protocol (condition 1) was that established by Zwaka and Thomson
who successfully target the hprt gene in a subline of HI cells (Zwaka & Thomson,
2003). Using electroporation conditions of 320 V and 200 pF with the BioRad
Gene Pulser II, they obtained 350 G418-resistant colonies. Of these, 7 were the
result of gene targeting at the hprt gene (G418/6-TG-resistant). The two remaining
electroporation protocols were established in our laboratory for H9 cells (described
in section 3.3.1.5 of chapter 3) using the Eppendorf Multiporator (300 V / 100 ps)
(condition 2) and the BioRad Gene Pulser II (200 V / 950 pF) (condition 3).
106 HI cells were transfected with 50 pg of Hindlll-digested pHprt-EfN
using the three different electroporation conditions described above (table 4.1). The
cells were exposed to 50 pg/ml of G418 selection 48 hours later, and 5 days post-
transfection G418 concentration was increased to 100 pg/ml. 10 days post-
transfection 600, 488 and 380 G418-resistant colonies were produced with the
electroporation conditions 1, 2 and 3, respectively (table 4.1). A control experiment,
in which HI cells were electroporated without the vector pHprt-EfN, did not produce
any G418-resistant colonies, suggesting that those generated in the experimental
plates were actually G418-resistant. It is however not unlikely that in the
experimental plates some G418-sensitive cells which survived at 50 pg/ml of G418,
as shown on figure 4.2, would subsequently survive at 100 pg/ml by metabolic
cooperation if these were in the proximity of G418-resistant cells. As a result, G418-
sensitive cells surviving by metabolic cooperation may have killed some targeted
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cells by a bystander effect (see section 4.3.2) once 6-TG selection was applied. Thus
this selection regime may have affected targeting frequency.
6-TG (2.5 pg/ml) was applied 10 days post-transfection to select for
homologous recombinants. It is critical to maintain the cells for at least a week in
G418 selection before adding 6-TG selection, to clear residual hprt message and
protein in targeted cells that can no longer synthesise the HPRT enzyme (Thomas
and Capecchi, 1987). If 6-TG is applied too soon, residual HPRT enzyme will
phosphoribosylate the toxic 6-TG producing lethal levels of 6-ThioGMP which will
be fatal for targeted cells (described in section 1.4.4.2, chapter I). After 6 days of
selection in 6-TG, 1 G418/6-TG-resistant colony was recovered with each of the
electroporation conditions 1 (320 V / 200 pF) and 2 (300 V/ 100 ps) suggesting that
these clones were targeted at the hprt gene (table 4.1). The third electroporation
protocol (200 V / 950 pF) however, did not result in any 6-TG-resistant colony.
Although the two 6-TG resistant clones obtained in this experiment were likely to be
the result of a gene targeting event in the hprt gene, the possibility that a spontaneous
hprt mutation could have arisen during routine culture of the HI cells prior to the
targeting experiments needed to be ruled out. Since these cells were never in HAT
selection which would select for wild-type cells only, there might have already been
a sub-population of spontaneous hprt mutants in the culture. However, if
spontaneous mutation rates of hprt in hES cells are similar to those reported in
mouse ES cells (< 1CT8 /cell/generation) (Chen et al., 1998; Chen et al., 2000;
Munroe et al., 2000; Cervantes, 2002), it was unlikely that this was the case. In
order to distinguish between targeted and spontaneous mutation, these clones were
expanded and analysed by PCR and Southern to confirm targeting (see section 4.3.4).
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To confirm that targeting the hprt gene was reproducible in HI cells, another
targeting experiment was conducted with pHprt-EfN using the Eppendorf
Multiporator (300 V / 100 ps). The same experimental conditions described in the
first targeting experiment with pHprt-EfN were applied in this experiment. 233
G418-resistant colonies were obtained and of these, 1 was resistant to 6-TG selection
suggesting that the hprt gene was targeted (table 4.1). These results show that even
with decreased transfection efficiency (2.3x10"4 versus 4.9x10"4 in the first targeting
experiment), a 6-TG-resistant colony indicative of gene targeting at the hprt gene,
can be obtained. This clone was expanded for PCR and Southern analysis to confirm
a targeting event.
pHprt-EfN cell line/ Electroporation Number G418r G418r E.T.F A.T.F Transfection
(fig) Passage conditions of cells 6-TGr (%) efficiency
No
Hl/73 (1) 320V/200 pF lxlO6 600 1 0.16 lO"6 6.0xl0~4
50 Hl/73 (2) 300 V/100 ps lxlO6 488 1 0.20 10"6 4.9xl0"4
Hl/73 (3) 200V/950 pF lxlO6 380 0 0 0 3.8xl0"4
50 Hl/76 (2) 300 V/100 ps lxlO6 233 1 0.43 10"6 2.3xl0"4
Table 4.1. Hprt targeting experiments with pHprt-EfN in HI cells. E.T.F (Effective
targeting frequency): ratio between number of homologous recombinants and number of integrants
surviving selection (homologous and non-homologous). A.T.F (Absolute targeting frequency): ratio
between number of homologous recombinants and number of cells electroporated. Transfection
efficiency: ratio between number of integrants and number of cells electroporated.
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4.3.4. Confirmation of a Targeting Event by PCR and
Southern Analysis
To check that the G418/6-TG-resistant colonies were the result of gene
targeting events at the hprt gene and not spontaneous mutation, the 3 colonies,
obtained from the transfection of HI cells with pHprt-EfN were expanded and
characterised by PCR and Southern Blot analyses. The hprt gene inactivated by the
targeted replacement of endogenous sequence with the EF1a-LoxP-neo-Lox2272
cassette, produces a 6.7 kb PCR fragment with the two primers shown in figure
4.3.A. One primer anneals to the hprt sequence upstream of the 5' arm of homology
included in the targeting vector (external primer) and a second primer anneals to the
neo sequence (internal primer) (figure 4.3 A). gDNA was extracted from each cell
line and used as the template in a PCR reaction with the 5' ext hprt and neo primers.
The parental HI cell line was used as a negative control in the PCR analysis. All the
clones analysed produced the predicted 6.7 kb fragment expected for a gene targeting










Figure 4.3. PCR screening for a targeting event at the hprt gene of the three
G418/ 6-TG-resistant clones. (A) Map of the partial structure of the targeted hprt gene
showing the predicted size of a PCR product generated with a reverse primer within the selectable
marker (neo primer) and a forward primer 5' to the homology (5'ext hprt primer). (B) (C) PCR
analysis of the three G418/6-TG-resistant clones (Hl.HPRT-1, Hl.HPRT-2 and Hl.HPRT-3).
Presence of a 6.7 kb band indicates a targeting event at the hprt gene. (-): no DNA template.
M: 5 pi Hyperladder (Bioline).
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The PCR results were confirmed by Southern analysis of BamHI- and
EcoRI-digested gDNA from each clone. The probe (gift from David Russell) used
for the screen consisted of a 1193 bp of hprt sequence internal to the 3' arm of
homology included in the targeting construct. The wild-type allele is predicted to
produce a 8.4 kb EcoRI and 20 kb BamHI fragment (figure 4.4 A). Because the
EFla-loxP-neo-lox2272 cassette contains EcoRI and BamHI sites, its presence
introduces new restriction sites in exon 3 of the hprt gene, resulting in the production
of 6.9 kb EcoRI and 6.7 kb BamHI fragments (figure 4.4 A). As predicted from the
restriction map of the modified hprt gene, Southern blot analysis shows the presence
of 6.7 kb EcoRI and 6.9 kb BamHI fragments in the three clones recovered,
confirming that they were the result of gene targeting by HR (figure 4.4 B). Random
integration of the targeting vector should be detected as additional band(s)
hybridising to the internal hprt probe. There is however always a possibility that
random integration of the targeting vector may generate a band similar in size to that
of the targeted integration. In this analysis, two digests were examined and in each
case resulted in the detection of a single band. The probability that random
integration of the targeting vector has produced a band similar in size to the targeted
integration with both digests is therefore extremely low.
Together, these results show that transfection efficiencies of up to 6x10~4 and
gene targeting frequencies of up to 0.43 % can be obtained at the hprt gene in HI
cells with the replacement vector pHprt-EfN using two different electroporation
protocols.
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Hl.HPRT-1 Hl.HPRT-2 WT HI Hl.HPRT-3
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Figure 4.4. Southern screening for a targeting event at the hprt gene of the three
G418/6-TG-resistant clones. (A) Map of the relevant segment of the wild-type and targeted
hprt gene showing the predicted restriction fragments with an internal hprt probe. The hprt homology
is represented as a thin blue line. The exon 3 in which the transgene has integrated is indicated as a
blue box. The position of the hprt probe is shown as a red box with the size of the EcoRI and BamHI
fragments indicated below. RI: EcoRI, BHEBamHI. (B) Southern analysis of the 3 G418/6-TG-
resistant clones (Hl.HPRT-1, -2 and -3) obtained in the 2 targeting experiments with pHprt-EfN. The
presence of a 6.9 kb EcoRI and 6.7 kb BamHI fragment indicates a targeting event at the hprt gene.
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4.4. Discussion
We sought to engineer, by gene targeting, the hprt gene in HI cells by the
introduction of a neo marker driven by the EFl-a promoter and flanked by
heterospecific lox sites such that RMCE could be subsequently applied. We
generated three hprt-targeted cell lines using two different electroporation protocols.
The first, established in our lab for H9 cells, used the Eppendorf Multiporator
system, which produced transfection efficiencies of up to 4.9x10"4 and targeting
frequencies of up to 0.43 % in our targeting experiments. The second protocol,
established by Zwaka and Thomson (2003) for hES cells, used the BioRad Gene
Pulser II, which gave a transfection efficiency of 6xl0"4 and a targeting frequency of
0.16 % in our targeting experiment.
Using the electroporation conditions established by Zwaka and Thomson
(320 V / 200 pF), we obtained a transfection efficiency 26-fold greater (6x10~4) than
that reported by Zwaka and Thomson (2.3x10"5). Our transfection efficiencies were
up to 600-fold greater than those obtained by Urbach et al., (2004) (1(E6). However
Urbach et al. used a different male cell line (HI3) and a cationic reagent (ExGen
500) to transfect their cells both of which could have contributed to a low
transfection efficiency. The difference in transfection efficiencies between our work
and Zwaka and Thomson may reflect the use of a different culture system. They use
a collagenase passaging regime in their culture system, which permits the
disaggregation of hES cells into clumps of cells (Thomson et al., 1998). In contrast,
our culture system involves the use of trypsin-EGTA (TEG) which allows the
disaggregation of hES cells into a single cell suspension. Because Zwaka and
Chapter IV 155
Thomson electroporated their cells as clumps, it is possible that the uptake of DNA
has occurred in several cells in the clumps (i.e. multiple G418-resistant colonies may
have occurred within one clump) and as a result, fewer G418-resistant colonies were
detected. Alternatively, the difference of transfection efficiencies in both studies
could have been the result of a difference of cell survival following electroporation
due to experimental variations (e.g. passaging regime, number of cells
electroporated, and medium composition). It is also possible that the transfection
efficiency obtained in our work was much greater than Zwaka and Thomson because
we used a targeting vector with a stronger promoter (EFl-a) to drive the expression
of neo. Zwaka and Thomson used a targeting vector with the synthetic mutant
polyoma enhanced HSVt£ promoter (Thomas and Capecchi, 1987) driving neo,
which has been shown, in our hands, to work poorly in H9 cells (H. Priddle,
unpublished data).
Effective targeting frequencies (ratio between homologous recombinants and
total (homologous and non-homologous) integrants surviving selection) at the hprt
gene have been reported to reach 2 % using an electroporation approach in the male
Hl.l subline (Zwaka and Thomson, 2003) and 1 % using a cationic reagent in the
male HI3 cell line (Urbach et al., 2004). Our results showed that effective targeting
frequencies of up to 0.4 % could be achieved by electroporation at the hprt gene in
the HI cell line (table 4.1). Several experimental differences between these studies
could have accounted for this discrepancy. A major difference between our targeting
experiment and the data presented by Zwaka and Thomson, or Urbach et al., is that a
different hES cell line was used in each study. Zwaka and Thomson used a clonal
derivative of the HI cell line (subclone Hl.l). Thus the cells used in their study
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consisted of homogenous population which may have been more permissive to gene
targeting. In contrast, the parental HI cell line was used in our targeting
experiments, and since this cell line was not originally cloned from a single cell, the
possibility that there is some variation among the undifferentiated cells in spite of
their homogeneous appearance, cannot be ruled out (Thomson et ah, 1998). As a
consequence, not all the HI cells may have been permissive to the same extent to
gene targeting. The difference of targeting frequencies between our work and
Urbach's et al., could also be the result of cell line difference. However, because
there were so many experimental variations (e.g transfection conditions, hprt
homologies, selectable markers, and hprt mutations), between the two studies, a
single cause cannot be attributed. With only two published reports of gene targeting
in two hES cell lines, it is presently unclear whether similar targeting frequencies
will be obtained for the same gene between different hES cell lines.
The most likely explanation for the difference of targeting frequencies
between these three studies is that both groups used an hprt targeting vector with a
larger homology than we used to target the hprt gene. We used 6.9 kb of homology,
whereas 11.9 kb and 8.5 kb of homology was used by Zwaka, Thomson, and Urbach
et al., respectively. Several studies have shown that targeting frequency in
mammalian cells is dependent on homology length to some extent (Thomas and
Capecchi, 1987; Shulman et al., 1990; Hasty et al., 1991a; Deng and Capecchi,
1992). Thomas and Capecchi showed in the first hprt targeting study conducted in
mouse ES cells, a positive correlation between targeting frequencies and the length
of hprt homology in the replacement targeting vector employed (Thomas and
Capecchi, 1987). They observed a 16-fold increase of targeting frequencies with
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only a 2.25-fold increase in homology. Similarly, Zwaka and Thomson (2003)
achieved a 1.5-fold increase in targeting frequency at the oct-4 gene in hES cells,
when the total oct-4 homology in the targeting vector was increased from 7.9 kb to
12.8 kb. A positive relationship between targeting frequencies and the length of hprt
homology in the targeting vector was also observed in hES cells between our work
and the work conducted by Zwaka, Thomson, and Urbach et al. (figure 4.5).
However, the experimental conditions (i.e. cell line, transfection condition, and hprt
mutation) were different between studies and therefore, it can only be suggested that
an increase of homology in the targeting vector results in an increase of targeting










Urbach et al., 2004 8.5 1
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Figure 4.5. Gene targeting frequencies in hES cells at the hprt gene. Zwaka and
Thomson deleted regions of the last 3 exons of the hprt gene in the Hl.l subline using 40 gig of a
targeting construct containing 11.9 kb of isogenic hprt homology (by electroporation), resulting in an
effective targeting frequency (E.T.F) of 2 %. Urbach et al., introduced a mutation in exon 2 in the
H13 cell line using 3-4 pg of a targeting construct with 8.5 kb of non-isogenic hprt homology (with a
cationic reagent), resulting in an E.T.F of 1 %. We introduced a transgene in exon 3 in the HI cell
line using 50 pg of a targeting construct containing 6.9 kb of non-isogenic hprt homology (by
electroporation,), resulting in an E.T.F of 0.4 %.
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The use of isogenic DNA in Zwaka and Thomson's work could also have
resulted in an increase of targeting frequency. Several lines of evidence indicate that
the frequency ofHR is strongly affected by the presence of vector-target mismatches
in mouse ES cells. Te Riele et al. (1992) compared the frequencies of HR at the
retinoblastoma (Rb) susceptibility gene in a mouse 129-derived ES cell line with
isogenic (129-derived) and non-isogenic (BALB/c-derived) targeting constructs, and
observed a 20- to 50-fold increase in targeting frequency with the isogenic DNA
construct. The use of isogenic DNA was so efficient in recovering homologous
recombinants (1 in 3 resistant colonies) that an enrichment protocol was not
necessary. Similarly, Van Deursen and Wieringa (1992) showed that the mouse
creatine kinase M (ckm) gene, characterised by a 2% divergence for the 129 and
BALB/c alleles, can be targeted 25-fold more efficiently with isogenic DNA (129-
derived) than non-isogenic DNA (BALB-c-derived). In contrast, other studies have
shown high targeting frequencies without the use of isogenic DNA (Zijlstra et al.,
1989; Te Riele et al., 1990) showing that parameters other than isogenecity greatly
influence targeting frequency, or that some genes are more similar between mouse
strains than others. Unlike mouse ES cells, it has been suggested that isogenicity is
not important in human gene targeting (Sedivy et al., 1999). Sedivy et al. have
compiled gene targeting data in human cells including one study that featured the
targeting of the P53 gene in four different human cell lines using the same targeting
vector. The homologous sequence used in this vector was amplified from the LL1
human embryonic skin fibroblast cell line. The targeting frequencies obtained with
this vector in the LL1, LF1 (human embryonic lung fibroblast), TK6 (human
lymphoblast) and HCT116 (human colorectal adenocarcinoma) cell lines were 1.1 %,
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12 %, 0.8 % and 0.2 %, respectively. Thus targeting frequency was increased 11-
fold in the LF1 cell line compared to the LL1 cell line (to which the vector was
actually isogenic), suggesting that isogenicity was not a major issue in gene targeting
frequencies in human cells (Sedivy et al., 1999). Recently, Urbach et al. (2004) have
also demonstrated that the hprt gene can be targeted with non-isogenic DNA in the
H13 cell line at a similar frequency to that reported by Zwaka and Thomson in 2003
(figure 4.7), supporting the claims of Sedivy and collaborators. One possible
explanation for the differences between human and mice, in respect to the efficiency
of non-isogenic homologous recombination, is that the sequence divergence between
two hES cell lines is much smaller than the difference between two mouse strains.
Single-nucleotide polymorphisms (SNPs) in the human genome occur at a frequency
of one per 500 to 1000 bp (Wang et al., 1998; Sachidanandam, 2001; Zhao et al.,
2003). In contrast, SNPs are much more frequent in the sequences of different mice
strains. For example, in the ckm gene, as many as 17 SNPs occur in a 150 bp stretch
of sequence between the 129 and BALB/C alleles (Van Deursen and Wieringa,
1992). According to the National Centre for Biotechnology information (NCBI)
database, the hprt sequence used in the pHprt-EfN targeting construct contains only
10 SNPs distributed along the 6.9 kb sequence (~ 1 SNP every 700 bp). Based on
this information, it is less likely that the use of non-isogenic DNA in the context of
our experiments might have had a negative effect on targeting frequency.
To conclude, we have generated three HI-derived cell lines that carry a
positive selectable marker gene flanked by heterospecific lox sites at the hprt gene,
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Like their murine counterparts, hES cells are characterised by a stable diploid
karyotype and are capable of both self-renewal and differentiation into derivatives of
the three germ layers (Thomson et al., 1998; Schuldiner et al., 2000; Reubinoff et al.,
2000; Itskovitz-Eldor et al., 2000; Zeng et al., 2004). To fulfil their potential in cell-
based therapies, it is necessary that genetically-engineered hES cells retain these
properties after manipulation. There are currently two reports of gene targeting in
hES cells (Zwaka and Thomson, 2003; Urbach et al., 2004) but the ability of gene
targeted hES cells to retain a stable karyotype and to give rise to the three germ
layers has not been investigated.
This chapter examines whether a clonally-derived Hl.HPRT targeted cell line
retains (i) euploidy, (ii) the expression of stem cell markers, and (iii) multipotency.
A comparative study between the parental HI hES cell line and the Hl.HPRT-1
targeted cell line was conducted to address these questions.
5.2. Objectives
To compare ploidy, the expression of stem cell markers and multipotency




5.3.2. Analysis of Stem Cell Markers
5.3.2.1. Oct-4 Expression Analysis
5.3.2.2. Cell Surface Expression Analysis
5.3.3. Multipotency Analysis
5.3.3.1. Analysis of In vitro Differentiation
5.3.3.2.Osteogenic Potential of an H1.HPRT Targeted Cell
Line
5.3.1. Karyotypic Analysis
There is increasing evidence that hES cells propagated with enzymatic
methods (e.g. trypsin, collagenase) accumulate karyotypic abnormalities such as
translocations, deletions and duplications during long-term culture (Inzunza et al.,
2004; Draper et al., 2004; Rosier et al., 2004; Mitalipova et al., 2005; Maitra et al.,
2005; McWhir et al., unpublished data). The occurrence of chromosomal
abnormalities in hES cell lines destined for therapies is clearly a concern, given that
in vivo karyotypic changes are often associated with malignancy (reviewed by
Albertson et al., 2003). For the potential of hES cell-based therapy to be realised, it
is essential that these cells, including genetically modified cells, are shown to be
safe. This will require that they be karyotypically stable over long-term culture.
To investigate whether HI cells retain a diploid karyotype after a gene
targeting event and after propagation in culture, thirty chromosome spreads were
analysed from both the targeted Hl.HPRT-1 cell line (passage 85) and the parental
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HI cell line (passage 74), from which these cells were derived at the time of the
gene targeting experiment. Metaphase spread analysis showed that 67 % and 57 %
of the HI and Hl.HPRT-1 spreads, respectively, maintained a diploid male 46 XY
karyotype (figure 5.1 B). 33 % and 43 % of the HI and Hl.HPRT-1 spreads,
respectively, varied between 23 and 44 chromosomes (figure 5.1.B). The difference
between the two cell lines was however not statistically significant (p=0.6, %i =
0.28). Thus these data show that HI cells that have been subjected to gene targeting
procedures and that have been propagated in culture for 11 passages, retain a
predominantly diploid karyotype similar to the parental cells. Representative 46 XY



















Cell line HI HI.HPRT-1
Chromosomes numbers 46 (67%) 46 (57%)
(% ofmetaphase spreads) 23-44 (33%) 23-44 (43%)
Figure 5.1. Analysis of 30 metaphase spreads of the parental HI and the
HI.HPRT-1 cell lines. (A) High power magnification of a male diploid 46 XY karoytype from
HI and HI HPRT-1 cell lines. (B) Histogram representation of chromosome number for 30
metaphase spreads from HI and HI.HPRT-1 cell lines.
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5.3.2. Analysis of Stem Cell Markers
Two properties which characterise cells as embryonic stem cells are their
ability to self-renew and their capacity to remain in an undifferentiated state until
exposed to differentiation factors. Unless these criteria are fulfilled, cells cannot be
classified as ES cells. An essential indication of the undifferentiated state of the cells
is the expression of the transcription factor POU5F1 (also known as OCT-4), which
is associated with pluripotency (Nichols et al., 1998; Pesce et al., 1999).
Undifferentiated hES cells are also characterised by the expression of the cell-surface
Stage Specific Embryonic Antigens SSEA-4 and SSEA-3 and the keratan sulphate-
associated antigens TRA-1-81 and TRA-1-60 (Thomson et al., 1998; Amit et al.,
2000; Xu et al., 2001; Draper et al., 2002; Zeng et al., 2004). Upon differentiation,
hES cells lose expression of all these markers. The undifferentiated state of the HI
cell line has already been confirmed by us and other groups by examination of the
expression of these markers (Thomson et al., 1998; Amit et al., 2000; Xu et al.,
2001; Draper et al., 2002; McWhir et al., 2005, unpublished data). However, the
expression of these markers has not been investigated in HI-derived targeted cell
lines. We therefore sought to investigate whether the Hl.HPRT-1 targeted cell line
maintains the expression of stem cell markers.
5.3.2.1. Oct-4 Expression Analysis
The POU-domain transcription factor OCT-4 is highly expressed in
ES cells and has been shown to be essential for maintaining the undifferentiated state
of ES cells (for a review see Pesce et al., 1999). To assess the expression of Oct-4 in
both the parental HI cell line and the Hl.HPRT-1 targeted cell line,
immunofluorescence microscopy directed at OCT-4 was performed (staining
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performed by J. Fletcher, Roslin Institute). A clone derived from Hl.HPRT-1 cells,
H1.HPRT-1RMCE3, was used as a negative control as it exhibited a differentiated
morphology and was characterised by a very slow proliferation rate (chapter 7, figure
7.8). Results showed that most HI and Hl.HPRT-1 cells expressed the OCT-4
protein in their nuclei (green staining) consistent with maintenance of an
undifferentiated state (figure 5.2). A minority of cells did not detectably express the
protein suggesting the presence of differentiated cells among the undifferentiated
population. As predicted, oct-4 expression was down regulated in the
Hl.HPRT-l.RMCE-3 cell line as shown by the lack of green staining in the merged
picture. We conclude that the expression of the POU-domain transcription factor is
maintained in the Hl.HPRT-1 targeted cell line.
DAPI FITC MERGED















Figure 5.2. Oct-4 immunocytochemistry of HI and Hl.HPRT-1 cell lines. Oct-4
immnuohistochemistry analysis showing positive expression of the Oct-4 gene in the HI and
Hl.HPRT-1 cell lines (middle panels). Dapi (4'-6-Diamidino-2-phenylindole), which is a DNA
intercalating dye, can be observed in all nuclei (left panels). A merged picture of FITC (green) and
Dapi (blue) channels is presented on the right panels. Scale bars = 50 pm.
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5.3.2.2. Cell Surface Expression Analysis
Expression of the embryonic cell surface markers SSEA-4, TRA-1-60
and TRA-1-81 were analysed by flow cytometry in both the parental Ell and
H1.E1PRT-1 targeted cell line. The expression of SSEA-1, which is downregulated
in ES cells and upregulated upon differentiation (Andrews et al., 1996; Thomson and
Marshall 1998; Thomson et al, 1998), was also quantified in both cell lines.
Expression of a tetraspanin transmembrane protein, CD9, which is expressed in both
mouse (Oka et al., 2002) and hES cells (Carpenter et al., 2004) was also evaluated.
The HI and Hl.HPRT-1 cells were collected from a T25 flask and 5x10s cells were
stained with the appropriate antibodies. Isotype-matched controls (IgG3-FITC
(SSEA-4), IgM-PE (SSEA-1, Tra-1-60 & Tra-1-81) and IgGl-PE (CD9)) were
included to calibrate the instrument. In this analysis, only the live cells were taken
into account. A representative density plot showing the gate (Rl) which includes
only the live cells is illustrated in figure 5.3 B. Flow cytometry showed, over 3
independent experiments, that more than 98% of the cells for both cell lines
expressed the embryonic cell surface markers with no statistically-significant
difference between cell lines (P>0.05, two-tailed t-test) confirming the
undifferentiated phenotype for the majority of the cells (figure 5.3 A & C). Flow
cytometry also showed that 5.5% (Hl.HPRT-1) and 12 % (HI) of the cells examined
expressed SSEA-1, consistent with the presence of a small proportion of
differentiated cells among a largely undifferentiated population (figure 5.3 A & C).
The proportion of SSEA-1 positive cells was not significantly different between the
two cell lines (P>0.05, two-tailed t-test). These results show that the Hl.HPRT-1
cell line, which was subjected to gene targeting procedures, expressed markers of an
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undifferentiated ES phenotype (SSEA-4, TRA-1-60 and TRA-1-81) and
differentiation phenotype (SSEA-1) at similar levels to the parental HI cell line.
98.31% r.































Figure 5.3. Flow cytometry analysis of cell surface marker expression for both
the HI and Hl.HPRT-1 cell lines. (A) Representative expression analysis of SSEA-4,
TRA-1-60, TRA-1-81, SSEA-1 and CD9 markers demonstrating that targeted Hl.HPRT-1 cells are
positive for the ES-specific markers SSEA-4, Tra-1-60 and Tra-1-81 and largely negative for SSEA-1
expression. The high-fluorescent intensity peak (FL1 or FL2 channel) represents positive cells, while
the low-intensity peak represents background levels due to autofluorescence. Isotype controls: IgG3-
FITC (SSEA-4), IgM-PE (SSEA-1, Tra-1-60 & Tra-1-81) and IgGl-PE (CD9). Data were generated
from the analysis of at least 10,000 viable cells. (B) Representative density plot showing the region
R1 containing the live cells analysed in all fluorescence plots. (C) Histogram statistics of cell surface




5.3.3.1. Analysis of In Vitro Differentiation
Like their murine counterparts, hES cells spontaneously form three
dimensional aggregates of cells known as embryoid bodies (EBs) when grown in
suspension (Itskovitz-Eldor et al., 2000). After 4 to 5 days in suspension in the
absence of bFGF (required to keep the cells in an undifferentiated state), EBs may be
plated onto adherent culture surfaces to form a variety of ectodermal, endodermal
and mesodermal derivatives such as hematopoietic (Schuldiner et al., 2000),
endothelial (Levenberg et al., 2002), cardiac muscle (Itskovitz-Eldor et al., 2000;
Kehat et al., 2001, 2003; Xu et al., 2002) and neuronal cell lineages (Reubinoff et
al., 2000; Itskovitz-Eldor et al., 2000; Schuldiner et al., 2001; Carpenter et al.,
2001). Both the female H9 and the male HI cell lines have been shown to exhibit
these properties. Currently, there are no published reports regarding the potential of
a targeted hES cell line to differentiate into the 3 germ layers in vitro. This question
was therefore addressed with the Hl.HPRT-1 targeted cell line. Both the parental HI
and Hl.HPRT-1 cell lines were subjected to in vitro differentiation and
immunocytochemical analysis was performed to evaluate the expression of 3
lineage-specific markers: P-III-tubulin, a-feto protein (AFP) and troponin-T,
representative of the ectoderm, endoderm and mesoderm respectively. a-P-Tubulin
is an integral component of microtubules which are involved in several cytoskeletal
functions (Oakley, 1992). The isotype P-III-tubulin, is found in the brain and dorsal
root ganglia and appears to be localised to neurons of the central and peripheral
nervous system, where its expression seems to increase during axonal outgrowth.
AFP is a single-chain glycoprotein that is normally expressed in the fetal liver,
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gastrointestinal tract and yolk sac (Abelev, 1971). In early fetal life it is one of the
main plasma proteins. Anti-AFP was used to visualise endodermal cells in the
derivatives of HI cells. Troponin T is a microfilament protein closely associated
with actin and its microfilament accessory proteins that appear in skeletal muscle
myofibrils (Lin et al, 1984). Anti-troponin T was used to detect skeletal muscle
(mesoderm) in the differentiation cultures ofHI and Hl.HPRT-1 cell lines.
H9, HI and Hl.HPRT-1 cells were disaggregated from a T75 flask
with TEG into single cell suspensions. The H9 cell line was used as a positive
control in this study as it had already been shown, in our hands, to express these
lineage markers following in vitro differentiation. After 2 days of culture in
suspension in conditioned medium supplemented with bFGF, the EBs were
transferred to EB medium which contains serum but lacks bFGF. After 7 days in
suspension, the H9 cells had grown into robust spherical EB-like structures (figure
5.4). In contrast, HI and Hl.HPRT-1 cells rarely aggregated and the low number of
EBs generated (~5-fold fewer than H9) were very small and exhibited a less
spherical shape compared with H9 cells (figure 5.4).
To determine the in vitro differentiation potential of each cell line,
7-day old EBs were plated intact onto gelatin-coated chamber slides (~5 to 10 EBs
per well) and cultured for 3 weeks in EB medium before immunohistochemical
analysis. The plating efficiency of the HI- and Hl.HPRT-1-derived EBs was very
low relative to H9-derived EBs. Most H9-derived EBs adhered to gelatin very
efficiently. In contrast, most HI - and Hl.HPRT-1-derived EBs did not adhere to the
gelatin substrate in the chambers, resulting in a considerable loss of EBs following
medium replacement 24 hours later. After 21 days of differentiation, several cell
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types derived from H9 EBs could be observed, including areas of beating
cardiomyocytes (figure 5.4). In contrast the few remaining HI- and Hl.HPRT-1-
derived small EBs mostly differentiated into cells with an epithelial-like morphology
(figure 5.4).
Immunocytochemical staining for the expression of the lineage
specific markers P-III-tubulin (ectoderm), AFP protein (endoderm) and troponin-T
(mesoderm) revealed derivatives of the three germ layers in H9-derived EBs (figure
5.5). Elnlike H9-derived cells, AFP and troponin-T expression could not be detected
in HI- and Hl.HPRT-1-derived cells indicating that these cell lines did not
differentiate into these specific endodermal and mesodermal lineages. All the cells
present in the HI-derived and Hl.HPRT-1-derived cultures stained positively for
P-III-tubulin. A staining control in which the primary antibody was omitted did not
result in p-III tubulin staining indicating that the binding of the secondary antibody
was specific (data not shown). Although these results first suggested that the Hl-
derived and Hl.HPRT-1-derived cultures were capable of differentiating towards a
neuronal lineage, neither cell line exhibited a neuronal cell type morphology (as
determined by neuronal axon formation), and in this respect differed from the H9-
derived cells. Additionally, P-III tubulin expression was also found in both HI and
Hl.HPRT-1 undifferentiated cultures. Although P-III tubulin is considered a specific
neuronal marker, its expression has been previously reported in undifferentiated hES
cells (Zeng et al., 2004). Taken together, these results indicate a lack of neuronal
differentiation in both the HI and H1.HPRT1 cell lines (figure 5.5).
To conclude, the HI and Hl.HPRT-1 cell lines failed to express AFP,
troponin-T and neuronal P-III-tubulin markers. These results however, do not
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necessarily reflect the lack ofmultipotentiality of these two cell lines but possibly the
poor efficiency of robust EB generation.
Figure 5.4. In vitro differentiation of H9, HI and Hl.HPRT-1 cell lines.
Microscopic analysis of H9, HI and Hl.HPRT-1 derived EBs after 7 days in suspension culture (left
panels) and 21 days after plating onto gelatin-coated chamber slides (right panels). Black arrows






Figure 5.5. In vitro differentiation analysis. Immunohistochemical staining with anti-AFP
(endoderm) and Troponin-T (mesoderm) expression markers shows positive staining for these 2 germ
layers in H9-derived cells but not in HI and Hl.HPRT-l-derived cells. Unlike the H9-derived
culture, neuronal axon staining with p-Tubulin III (ectoderm) is absent in the Hl-derived and
Hl.HPRT-l-derived cultures indicating a lack of neuronal differentiation for these two cell lines.
Scale bars =100 pm.
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5.3.3.2. Osteogenic potential of the H1.HPRT-1 cell line
To demonstrate whether Hl.HPRT-1 cells could be induced to follow
a specific fate, a differentiation protocol, which does not require the EB stage, was
applied (work performed by D. Wojtacha, Roslin Institute). This protocol, recently
developed in our lab for hES cells, induces hES cells to differentiate towards bone
(Sottile et al., 2003). It consists of EB medium supplemented with the osteogenic
factors glucocorticoid dexamethasone, the extracellular matrix-promoting agent
ascorbic acid, and p-glycerophosphate, which induce nodule formation and mineral
deposition. The osteogenic differentiation potential of the Hl.HPRT-1 cell line was
compared to the HI parental cell line. In vitro osteogenic differentiation was
assessed at different time points over a period of 21 days by examination of
mineralised nodule formation staining with the alizarin Red S dye (Sigma). Mineral
deposition was measured using a quantitative calcium assay which had been
previously optimised and adapted for H9 and HI cells (Sottile et al., 2003). This
assay measures the calcium content of monolayer cultures using colorimetric
methods. Alizarin Red S staining, calcium assay and analysis were performed by D.
Wojtacha.
Undifferentiated HI and Hl.HPRT-1 cells were seeded at a density of
105 cells per well of a 6-well plate for the Alizarin Red staining, and 104 cells per
well of a 96-well plate for the calcium assay. Conditioned medium was replaced 48
hours later (day 0) with EB medium supplemented or not with osteogenic factors
(OS). The HEK 293 (human embryonic kidney) cell line (Graham et al., 1977),
which lacks osteogenic potential was used as a negative control in this experiment.
The HEK 293 cells are characterised by a high proliferation rate compared with hES
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cells. The HEK 293 cells were seeded at a density of 104 cells per well of 6-well
plate and 103 cells per well of a 96-well plate, in order to prevent cultures becoming
overconfluent and detaching over a period of 21 days (figure 5.6 A). Each cell line
was analysed by Alizarin Red S staining at days 9, 13, 16 and 20. Both the HI and
Hl.HPRT-1 cells formed nodules in response to OS treatment, which stained
positively with Alizarin Red at day 9 (figure 5.6. A & B), showing calcium
deposition. In contrast, no nodule formation was observed in cells cultured in the
absence of OS supplements. Unlike HI and Hl.HPRT.l cells, the HEK 293 cells did
not stain with Alizarin Red in the presence of OS treatment and nodule formation
was never observed (figure 5.6. A). The Hl.HPRT-1 cells showed an increased level
of nodule formation at each time point compared to the HI cells suggesting that these
cells had a greater osteogenic differentiation potential (figure 5.6. A & B). These
results show that both the HI and the Hl.HPRT-1 cell lines form nodules and
calcium deposits in vitro, consistent with osteogenic differentiation.
To quantify the mineralisation, cell matrix-associated calcium
deposition analysis was performed in 96-well plates using a calcium assay kit
(Randox). In this analysis, each cell line was seeded in 4 replicates and calcium
deposition was quantified at days 9, 13, 16 and 20 for each replicate. This assay
could not be performed on the HEK 293 cell line as they reached confluence very
quickly, resulting in the detachment of the cells from the tissue culture plastic during
the wash procedure. The results showed a significant (PO.OOl, F-test) increase in
calcium deposition over time in both the HI and Hl.HPRT-1 cells treated with
osteogenic factors (figure 5.7). In contrast, calcium deposition was minimal in the
absence of OS factors, and not significantly different between the two cell lines
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(P>0.05, F-test). The level of mineralisation in the OS-treated HI cells was
significantly lower (P<0.01, F-test) than that in the Hl.HPRT-1 cells. Additionally,
a delay in the onset of mineralisation in the OS-treated HI cells was observed with
respect to the Hl.HPRT-1 cells (day 6) (figure 5.7). The difference of level and
delay of mineralisation however, may reflect a difference in cell density rather than a
difference of mineralisation potential. Both cell lines may have responded
differently, in terms of proliferation, to the OS factors but because cell densities were
not examined at each time point prior to performing the calcium assay, this
possibility could not be excluded.
These data show that both the HI hES cell line and the targeted
Hl.HPRT-1 cell line, when exposed to osteogenic factors, produce mineralised












Figure 5.6. Osteogenic differentiation of HI and Hl.HPRT-1 cells in vitro. (A)
Alizarin Red S staining of HI, Hl.HPRT-1 and HEK 293 cells, nine days post-plating with or
without OS factors. Red areas indicate staining of calcium deposition. Scale bars =100 pm. (B) HI
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Figure 5.7. Quantitative mineralisation analysis. Time-course of calcium deposition of
HI and Hl.HPRT-1 cells treated ± OS supplements. A significant increase of calcium deposition is
observed in both HI and Hl.HPRT-1 cell lines treated with OS factors. However, the level of
mineralisation in the OS-treated HI cells is significantly lower than that in the OS-treated Hl.HPRT-1
cells. Data are presented as means ± SEM (N=4).
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5.4. Discussion
We investigated whether a hES cell line subjected to gene targeting
procedures would remain euploid and retain the stem cell markers expression and
multipotency of the parental HI cell line. The data presented in this chapter show
that, like the HI cell line, the Hl.HPRT-1 targeted cell line retains a diploid
karyotype and expresses markers of an undifferentiated ES phenotype (OCT-4,
SSEA-4, TRA-1-60 and TRA-1-81) and differentiated phenotype (SSEA-1) at
similar levels. Thus gene targeting and/or the extra culture required for the gene
targeting experiment did not affect the above properties.
In vitro differentiation analysis, failed to show multipotency of both the
parental HI and the Hl.HPRT-1 cell lines, when using a protocol that involved the
EB stage. It is likely that the problem resides in the poor efficiency of H1 cells in
producing robust EBs under the conditions tested, and in the inability of these EBs to
adhere to the gelatin substrate. This would be consistent with a previous report by
Reubinoff et al. (2000), in which hES-derived EBs failed to differentiate in vitro due
to extensive cell death and poor efficiency of good quality EB production. Since this
report, several laboratories have shown that the production of robust EBs could be
achieved, and that hES-derived EBs could differentiate into the three germ layers
(e.g. Itskovitz-Eldor et al., 2000). The inability of HI and HI-derived cells to
produce robust EBs raises the possibility that the trypsin-EGTA (TEG) passaging
regime used in our culture system does not allow the generation of three-dimensional
aggregates ofHI cells, since in our hands (data not shown) and in other labs (e.g. Xu
et al., 2002), good quality EBs can be generated from HI cells treated with
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collagenase. The TEG regime allows the disaggregation of hES cells into a single
cell suspension, unlike the collagenase treatment which permits the disaggregation of
hES cells into clumps of cells. Clumps of cells might therefore aggregate more
efficiently into robust EBs than single cells. Arguing against this hypothesis
however, is the ability of TEG-treated H9 cells to form robust EBs from single cell
suspensions, as shown in figure 5.4. This might however reflect the genetic
difference between the H9 and HI cell lines. It is possible that TEG treatment causes
the HI and Hl.HPRT-1 cells to lose their potential to aggregate and thus to
differentiate in vitro towards lineages of the 3 germ layers. Consistent with in vitro
differentiation data in HI cells treated with TEG, in vivo differentiation studies in
severe combined immunodeficiency (SCID) mice with TEG-treated HI cells do not
produce teratomas, unlike H9 cells treated with TEG (McWhir et al., unpublished
data). In contrast H9 and HI cells treated with collagenase produce teratomas when
injected into SCID mice (Thomson et al., 1998). Taken together, these results
suggest that TEG may affect the multipotentiality of HI and HI-derived cells by a
yet unknown mechanism.
The osteogenic differentiation experiment, which omits the EB stage, showed
that both the HI and the Hl.HPRT-1 cell lines, when exposed to osteogenic factors,
formed mineralised nodules in vitro, consistent with the ability of these cells to
differentiate into bone-forming osteoblasts (mesoderm). Thus these data showed that
gene targeting procedures did not affect the ability of HI-derived cells to form
mineralised nodules in vitro. Although the degree ofmineralisation was significantly
greater in the Hl.HPRT-1 targeted cell line than in the HI cell line, it is unclear
whether this was the result of cell line difference or a greater cell density of the
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Hl.HPRT-1 cells. The greater level of mineralisation of the Hl.HPRT-1 cell line
may be due to the fact that this cell line is a subclone of the HI cells. Thomson et al.
(1998) suggested that there may be some variation in the developmental potential
among the undifferentiated HI cells, in spite of their homogeneous appearance,
because these cells were not cloned from a single cell. If this was true, a difference
of developmental potential may have accounted for a reduced level of mineralisation
in the HI cells. In contrast, because the Hl.HPRT-1 cell line is clonally-derived
from HI cells and should be therefore homogeneous, all the cells in the population
would probably have a similar level of mineralisation.
Regardless of the difference between the two cell lines, further analysis
would be required in order to formally confirm the osteogenic differentiation of the
Hl.HPRT-1 cell line. X-ray diffraction analysis of hES-derived nodules would
show whether the diffraction pattern corresponds to that of hydroxyapatite crystals,
the principal mineral component of bone matrix (Heaney, 2002).
Immunocytochemistry and RT-PCR analysis would be required to show whether
osteoblast-specific markers such as osteocalcin, collagen I al and bone sialoprotein
(Sottile et al., 2003) are expressed in the Hl.HPRT-1 cell line.
To summarise, we have found no evidence that gene targeting procedures
affect the properties of hES cells, since both HI and HI-targeted cells retain
predominantly a diploid karyotype, express stem cell markers at similar levels, and
behave in a similar way in in vitro differentiation experiments. The difference
observed between H9 and HI cells in the in vitro differentiation studies indicates that
the genetic variation between hES cell lines may require the establishment of
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protocols specific to an individual hES cell line. These data therefore reflect the
challenges of optimisation that we face presently with human ES research.
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CHAPTER VI
Correction of an H1-Derived HPRT-








There are presently two published reports of targeted mutation by HR in hES
cells (Zwaka and Thomson, 2003; Urbach et al., 2004), but the correction of a
mutant gene by targeted HR has as yet not been accomplished in hES cells. While
genes can in principle be inactivated to create cellular models of genetic diseases in
hES cells (Zwaka and Thomson, 2003; Urbach et al., 2004), the ability to repair
mutated genes in hES cells could also have great implications for gene therapy.
Most gene therapy strategies are based on gene addition by virus-driven
random integration, in which a normal copy of a gene is transferred into the cell type
of interest, where it coexist with the mutant copy of the same gene. However, gene
addition remains a challenge owing to transgene silencing, inappropriate expression
or misintegration (Clark et al., 1994). An alternative approach has been the use of
targeted gene correction via HR, which enables the production of a normal protein
under the control of the cell's intrinsic regulatory signals. Some recent advances
have been made in this area of research in mammalian cells in vitro as well as
ex vivo (reviewed by Kren and Steer, 2002). A strategy based on the use of small
DNA fragments (SDFs) (few hundred nucleotides) homologous to the targeted
genomic sequence has been used to correct a deletion in the cystic fibrosis
transmembrane conductance regulator gene (cftr) in primary and transformed human
lung epithelial cells, reaching up to 1 % repair in the transfected cells (Goncz et al.,
1998). RNA-DNA oligonucleotide chimeratherapy is another technique that was
developed to target site-specific nucleotide base changes to homologous genomic
sequences. This technique was used to correct the sickle cell mutation in human
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lymphoblasts (Cole-Strauss et al., 1996). It has also been used to correct a
dystrophin point mutation in Duchenne muscular dystrophy skeletal muscles in mice
(Bertoni and Rando, 2002). Short single-strand oligonucleotide is an approach that
has also been explored to correct point mutations. For instance, Igoucheva et al.
(2001) showed that single-strand oligonucleotides (25-61 bases homologous to the
target sequence) were capable of correcting a single point mutation in the mutant
p-galactosidase gene in mammalian cells, with correction rate of 0.1 %. Another
approach that holds great promise in gene therapy is the use of zinc-finger nucleases
(ZFNs) (Kim et al., 1996), which have been shown to stimulate HR in human cells
(Porteus and Baltimore, 2003). These synthetic proteins are composed of a DNA-
binding domain, which recognises a specific site near a mutation, and a DNA-
cleaving domain, which introduces a double-strand break into the DNA, thus
promoting FIR. Urnov et al. (2005) have recently exploited this technology to
correct a mutation in the IL2Ry gene (which mutations cause X-linked severe
combined immune deficiency) (Cavazzana-Calvo et al., 2000) in transformed human
cells. The co-introduction of the ZFNs and the wild-type template resulted in the
correction of 15 to 20 % of the cells without the use of selection. Among these cells,
7 % acquired the desired correction on both X chromosomes. Additionally they
reported around 5 % correction in human T cells, where correction frequencies are
considerably lower without the introduction of double-strand breaks (-0.001%).
Lesch-Nyhan syndrome is a severe neurological disorder that is caused by the
malfunction of the hprt gene (reviewed by Stout and Caskey, 1988). The seriousness
of the disease makes it a candidate for eventual gene therapy. Several strategies have
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been developed to rescue an HPRT-deficient phenotype in a broad range of cell lines,
including the use of hprt minigenes (Selfridge et al., 1992), /z/jrt-expressing
adenoviruses (Southgate et al., 1999), and the use of an episomal transgene (Wade-
Martins et al., 2000). Gene targeting strategies have also been used to correct a
mutated hprt gene in several cell lines, including mouse ES cells (Doetschman et al.,
1987; Thompson et al., 1989; Koller et al., 1989; Reid et al., 1991; Magin et al.,
1992; Hatada et al., 2000; Heaney et al., 2004), and murine hematopoietic stem cells
(Hatada et al., 2000).
In this study, we sought to exemplify the correction of a mutated gene in hES
cells by gene targeting. This chapter describes a preliminary targeting experiment in
which a replacement vector was used to correct the targeted mutation in the HPRT-
deficient HI.HPRT-1 cell line (obtained by targeting HI cells with the pHPRT-EfN
targeting vector).
6.2. Objective
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6.3.2. Hprt Correction Experiment in H1.HPRT-1 Cells
6.3.3. Detection of a Targeting Event by PCR
6.3.1. Correction Scheme and Targeting Vector
The HI.HPRT-1 cell line obtained by targeting the hprt gene in HI cells with
the targeting vector pHPRT-EfN contains a 3.4 kb EFl-a-loxP-neopA-lox2272
cassette inserted in exon 3 in the opposite transcriptional orientation to the hprt gene
(figure 6.1). This cell line was used in a "correction" targeting experiment using the
targeting vector, pTopo-HPRT, which contains 7.1 kb of hprt homology comprising
exon 2 and 3, intron 2 and fragments of introns 1 and 3 (figure 6.1). Following
double reciprocal recombination between pTopo-HPRT and the hprt chromosomal
sequences, the chromosomal hprt sequence containing the 3.4 kb cassette is replaced
with native hprt sequence, thereby correcting the hprt gene structure and restoring
function. Because the hprt fragment only incorporates exons 2 and 3, it cannot
behave like an hprt minigene (Selfridge et al., 1992) to rescue HPRT-deficient cells
by random integration on its own. Therefore, the HPRT-deficiency phenotype can
only be rescued ifHR has taken place at the mutated hprt gene.
The pTopo-HPRT replacement targeting vector consists of 7.1 kb of hprt
homology comprising the 6.9 kb Hindlll hprt fragment included in the pHPRT-EfN
targeting construct (figure 6.1). The 7.1 kb hprt homology was obtained by using
long range PCR of gDNA from HI cells and subcloned into the Invitrogen
pCR2.1-Topo vector (appendix 1, section 2.1). The inclusion of a selectable marker
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in this vector is unnecessary because HPRT activity allows direct selection in HAT
medium (Albertini, 2001). HAT medium inhibits the de novo pathway of purine
synthesis and prevents growth of cells that lack an active salvage pathway (Szybalski
& Szybalska, 1962). The mutant cells proliferate in the presence of 6-TG (Stutts &
Brockman, 1963) and die in HAT medium while wild-type cells behave in the
opposite fashion. Therefore corrected HI.HPRT-1 cells can be directly selected in
HAT, rendering targeting frequencies easy to calculate at the phenotypic level.


















Figure 6.1. Schematic representation of the hprt gene correction by targeting in
the Hl.HPRT-1 mutant cell line. Partial structure of the hprt knock-out and corrected genes,
and the correction vector used to restore hprt function and structure in the Hl.HPRT-1 cell line. The
hprt homology (7.1 kb) in the pTopo-HPRT targeting construct is represented by a thick blue line with
blue boxes marking the exons. The pCR2.1 Topo vector backbone is represented as a thick red line.
The two cross-over recombination points which take place between the correction vector and the hprt
chromosomal sequence are depicted by an 'X'. Hindlll (H) digestion of pTopo-HPRT generates a
6.9 kb hprt fragment and following HR, targeted recombinants can be selected for based on their
newly-acquired resistance to HAT. The translational initiation start site (ATG) is indicated below
exon 1 in the hprt knock-out and corrected genes.
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6.3.2. Hprt Correction Experiment in H1.HPRT-1 Cells
To correct the hprt gene in the HI.HPRT-1 cell line, 106 HI.HPRT-1 cells
were stably transfected using the Eppendorf Multiporator (300 V / 100 ps) with
50 pg of Hindlll-digested pTopo-HPRT. HAT selection (0.1 mM hypoxanthine,
1 pM aminopterin, 10 pM thymidine) was applied 48 hours later to select for
homologous recombinants carrying a corrected hprt gene. After 8 days in selection,
3 HAT-resistant colonies were produced suggesting that hprt function was restored
in these clones by HR (table 6.1). A mock control transfection in which cells were
electroporated in the absence of DNA did not produce any HAT-resistant colonies
indicating that the HI.HPRT-1 cells were not contaminated with wild-type cells prior












HI.HPRT-1/96 300 V/100 ps 1x10s 50 3* 3xl0"6
Table 6.1. Targeted correction of the mutated hprt gene in Hl.HPRT-1 cells by
HR. ATF: Absolute targeting frequency: Ratio between the total number of homologous
recombinants and the total number of cells electroporated. * 1 colony was lost during expansion.
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6.3.3. Detection of a Targeting Event by PCR
To confirm that the two HAT-resistant colonies (one clone was lost during
expansion) were the result of a correction event at the hprt gene, gDNA was
extracted from each clone and used as the template in a PCR screen (PCR screen 1).
The corrected hprt or wild-type alleles should produce a 7 kb PCR fragment (since
the screen does not distinguish between wild-type and corrected alleles) with two
primers annealing to the hprt sequence 5' (5' ext hprt) and 3' (3' ext hprt) to the
homology included in the pTopo-HPRT targeting vector (figure 6.2 A). The HI
parental cell line and the HI.HPRT-1 cell line, from which the HAT-resistant clones
were derived, were used as controls in this analysis. PCR analysis showed that the
two HAT-resistant clones and the wild-type HI cells produced the 7 kb fragment
(diagnostic for a wild-type or corrected allele). In contrast, this band was not
detected with gDNA derived from the HI.HPRT-1 cell line (figure 6.2 B). Hence
these results show that the two HAT-resistant clones are the result of a targeting
correction event at the hprt gene.
A second PCR screen (PCR screen 2) was performed to check for any
possibility of contamination with HI.HPRT-1 cells (which may have survived by
metabolic cooperation) in the two hprt correctant cultures. In this screen, the
HI .HPRT-1 cells should produce a 6.7 kb fragment with the 5'ext hprt primer and an
internal neo primer (figure 6.2 A). In contrast, hprt correctant cells should not yield
any product because of the absence of the neo expression cassette to which the neo
primer anneals (figure 6.2 A). Results of the PCR showed the presence of the 6.7 kb
fragment (diagnostic for the uncorrected allele) for the HI.HPRT-1 cells but also for
the two hprt correctant clones (figure 6.2 B), indicating that both clones were
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contaminated with Hl.HPRT-1 cells. Survival of the Hl.HPRT-1 cells in HAT
selection may have been the result of positive metabolic cooperation ("kiss of life")
(Hooper, 1982). This effect has previously been reported in other correction
targeting experiments in the hprt gene in mouse ES cells (Thompson et al., 1989).
Because homologous recombinants were directly selected in HAT, all the
random integrants were eliminated, and as a result effective targeting frequency
(ratio between the total number of homologous recombinants and the total number of
integrants surviving selection) cannot be determined. The absolute targeting
frequency (ATF) however, can be determined as the ratio between the total number
of homologous recombinants (HAT-resistant clones) and the total number of cells
electroporated. The ATF obtained in this experiment (3xl0"6) (table 6.1) was similar
to that achieved for the targeted modification of the wild-type hprt gene (10"6) (see
chapter 4, table 4.1).
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Figure 6.2. PCR screening for a targeted correction event at the hprt gene of the
two HAT-resistant clones. (A) Partial structure of the hprt corrected and knock-out genes
showing the predicted size of a PCR product generated using two external 5' and 3' hprt primers
(7 kb) or the internal neo primer and the 5'external hprt primer (6.7 kb), respectively. (B) PCR
analysis showing the presence of a 6.7 kb and 7 kb band for the 2 HAT-resistant clones. The 7 kb
product shows correction event and the 6.7 kb product indicates that both clones are mixed with




In this study, we demonstrated that the targeted mutation in the Hl.HPRT-1
targeted cell line could be functionally and structurally corrected by targeted
replacement of the EFl-a-loxP-neopA-lox2272 transgene with the endogenous hprt
sequence. Using the pTopo-HPRT correction vector, we obtained three HAT-
resistant cell lines derived from the Hl.HPRT-1 deficient cell line (table 6.1)
consistent with the restoration ofHPRT activity in the Hl.HPRT-1 cells. In contrast,
untransfected Hl.HPRT-1 cells did not result in the generation of HAT-resistant
colonies, consistent with an absence of wild-type (wt) HI cells in the Hl.HPRT-1
culture. Subsequent PCR analysis confirmed the presence of hprt corrected structure
for the 3 HAT-resistant clones. Thus the data presented in this chapter strongly
support the idea that a correction event has occurred at the mutated hprt gene in
Hl.HPRT-1 cells.
The PCR analysis however showed that each HAT-resistant clone recovered
had both mutant and corrected DNA sequences, suggesting that the correctant clones
were contaminated with the Hl.HPRT-1 cells from which these clones were derived.
This is probably due to the persistence in the HAT-resistant culture of Hl.HPRT-1
cells surviving by metabolic cooperation (Hooper, 1982). Ten days after isolating
the HAT-resistant colonies, selection was relaxed and the clones were cultured in
non-selective medium for over 30 days before gDNA extraction, which would allow
uncorrected 6-TG-resistant/HAT-sensitive cells to expand along with the
targeted/corrected ones. This has been previously reported in mouse ES cells
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(Thompson et al., 1989). Subjecting each clone to renewed HAT selection at clonal
density should enable the subcloning of a pure corrected-HPRT cell line.
Although these preliminary data are very promising, Southern analysis will be
necessary to confirm a correction event at the mutated hprt gene. Furthermore, our
strategy could be refined to fully rule out the possibility that the generation ofHAT-
resistant colonies was the result of contamination with wt HI cells. In this present
study, the wt and corrected hprt structures cannot be distinguished because the
homology used in pTopo-HPRT is isogenic. According to the National Centre for
Biotechnology information (NCBI) database, the hprt homology used in the
pTopo-HPRT targeting construct contains ~10 SNPs distributed along the 6.9 kb
sequence (~ 1 SNP every 700 bp). Thus it may be possible to distinguish between a
corrected and wt hprt gene by using non-isogenic gDNA to the HI cell line, to
correct the hprt gene (e.g. hprt homology amplified from H9-derived gDNA).
Corrected clones would first be identified by PCR and Southern analysis. A
correction event would then be confirmed by sequencing of PCR amplified gDNA
flanking the polymorphic regions.
The targeted correction of the mutated hprt gene in HI-HPRT-1 cells was
achieved at absolute targeting frequency (ATF) of 3xl0~6 (table 6.1). Thus targeted
correction of the mutated hprt gene can be achieved with similar frequencies in hES
cells and murine ES cells (between 4xl0"8 and 2xl0"6) (Doetschman et al., 1987;
Thompson et al., 1989; Magin et al., 1992). These groups however used an insertion
vector to correct a defective hprt locus in murine ES cells. Other groups have
reported the use of a replacement vector to correct a defective hprt gene in the
E14TG2a (Reid et al. 1991) and HM1 (Hatada et al., 2000) mouse ES cell lines,
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resulting in much greater absolute targeting frequencies (between 10"5 and 2xl0"5)
than those achieved in our study. The inactivity of the hprt gene in both the
E14TG2a and HM1 cell lines is due to a spontaneous 55 kb deletion that includes the
promoter and exons 1 and 2 of the hprt gene (Tsuda et al., 1997). The pMP8 (Reid
et al. 1991) and pMP8neo (Hatada et al., 2000) targeting vectors used to correct both
cell lines, contained 4 kb of mouse gDNA 5' to the deletion, 1.8 kb of human hprt
gDNA including the promoter and exon 1, and 7 kb of mouse hprt gDNA including
intron 1, exons 2 and 3. All together 7.6 kb homology to the locus was used to
correct the hprt gene (Reid et al. 1991). We used a very similar length of homology
(6.9 kb). Thus the length of homology cannot account for the difference in targeting
frequency between our study and those reported by Reid et al., and Hatada et al.
The pTopo-HPRT correction vector used in our study to correct the mutated gene
contains hprt gDNA homology derived from HI cells. However, the homology used
in the pHPRT-EfN targeting vector to modify the hprt gene, was not isogenic. As a
result, the hprt homology used in pTopo-HPRT was non-isogenic to the mutated
locus. As previously discussed in section 4.4. (chapter 4), there is no evidence that
targeting frequency may be affected by polymorphic variation in human cells
(Sedivy et al., 1999). Additionally, the hprt gene has previously been targeted in
hES cells at similar frequencies with either an isogenic (Zwaka and Thomson, 2003)
or a non-isogenic targeting vector (Urbach et al., 2004). Thus it seems unlikely that
the use of isogenic DNA will increase targeting frequencies in hES cells.
Because there are so many experimental variations between our work and the
work reported by Reid et al., and Hatada et al. (e.g. cell lines, transfection
conditions, hprt homologies, and hprt mutations), it is presently unclear why ATF
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achieved in mouse ES cells is much greater than that achieved in our hands in hES
cells. It is however probable that targeting frequencies in hES cells will be further
improved with the establishment of optimal transfection conditions.
To conclude, these preliminary data support the exemplification of not only a
targeted correction by HR in a chosen gene in hES cells, but also repeated targeting
at the same locus. Thus this study demonstrates the feasibility of the gene targeting












Gene targeting and site-specific recombination are complementary strategies
that permit the alteration of specific genes in mammalian cells. The Cre site-specific
DNA recombinase from the phage PI specifically recognises a 34 bp recombination
site called loxP (locus of X-over of PI) and catalyses reciprocal DNA strand
exchange between two of these sites (Hoess and Abremski, 1984). By exploiting the
properties of the Cre/lox system, the pre-positioning of a loxP site into a specific
genetic locus, known for reproducible transgene expression, provides a means to
introduce any transgenes flanked by two unidirectional loxP sites. In a first step, a
loxP site is placed into a predetermined gene locus by HR. In a second step, a
transgene of interest flanked by two unidirectional loxP sites can be integrated, in the
presence of Cre, into the pre-existing loxP site (Kolb and Siddell, 1997; Kolb et al.,
1999). However, transgene integration is unstable because the plasmid can re-excise
itself following recombination between two unidirectional loxP sites (Araki et al.,
1997; Kolb et al., 1999). Since integrations are inter-molecular events while
excisions are intra-molecular events, excisions are strongly favored. Recombinase-
mediated cassette exchange (RMCE) is a method that aims at eliminating the
re-excision problem (Bethke and Sauer, 1997; Bouhassira et al., 1997; Seibler et al.,
1998). The RMCE approach is based on the observation that two recombination lox
sites that differ in their central 8-bp-spacer region do not recombine with each other,
whereas lox sites which possess the same spacer region recombine efficiently. By
taking advantage of these mutated lox sites, a transgene flanked by heterospecific lox
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sites (Lee and Saito, 1998) can be inserted by HR into a specific gene. This insertion
allows in a subsequent step, the exchange, by a double reciprocal crossover
replacement, of the transgene with a single copy of another transgene flanked by the
same heterospecific lox sites (Bethke and Sauer, 1997; Bouhassira et al., 1997;
Seibler and Bode, 1998; Feng et al., 1999; Trinh and Morrison, 2000; Kolb 2001; Li
et al., 2003; Cobellis et al., 2005). In ES cells, effective RMCE frequencies (ratio
between number of site-specific recombinants and number of integrants surviving
selection (random and targeted)) between 54 and 100 % may be obtained using a
negative and positive selection (Seibler et al., 1998; Kolb, 2001). Effective targeting
frequencies of 100% can be achieved by combining RMCE with a promoter trap
strategy (Baubonis and Sauer, 1993 ; Verhoeyen et al., 2001). As a result, the
RMCE procedure has emerged as a powerful tool for manipulation of the eukaryotic
genome and the production ofmultiple second-step modifications.
While the RMCE approach has now been used in a variety of cell lines
including mouse ES cells (Seibler et al., 1998; Feng et al., 1999; Kolb, 2001), it has
not yet been demonstrated in hES cells. The aim of the experiments described in this
chapter was to exemplify RMCE at the previously tagged hprt gene in hES cells, and
to test this locus for its ability to show reproducible transgene expression. Combined
with the RMCE approach, we used a promoter trap strategy, in which following the
desired recombination event, the reconstruction of a promoterless selectable marker
in exon 3 of the hprt gene, ensures only the selection of single-copy site-specific
recombinants.
The following study discusses the optimisation of the experimental
procedures required to achieve site-specific recombination at the hprt gene, and the
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assessment of transgene expression at the hprt gene in hES cells after site-specific
recombination.
7.2. Objectives
(i) To optimise the RMCE protocol and exemplify RMCE in the previously
tagged hprt gene in hES cells, (ii) To investigate whether site-specific recombinants
at the hprt gene are characterised by reproducible transgene expression.
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7.3. Results
7.3.1. Development of an RMCE Protocol
7.3.1.1. RMCE Scheme and RMCE Vector
7.3.1.2. Blasticidin Kill Curve for H1 Cells
7.3.1.3. Transient Recombination Assay in H1 Cells
7.3.1.4. RMCE Experiments by Electroporation
7.3.1.5. RMCE Experiments by Lipofection
7.3.1.6. Detection of an RMCE Event by PCR and Southern
Analysis
7.3.2. Transgene Expression Analysis of Site-Specific
Recombinants at the Hprt gene
7.3.2.1. GFP Expression Analysis
7.3.2.2. Oct-4 expression Analysis
7.3.1. Development of an RMCE Protocol
7.3.1.1. RMCE Scheme and RMCE Vector
A promoter trap strategy was employed to enrich for site-specific
recombinants at the previously tagged hprt gene. The general outline of the
approach, detailed in figure 7.1, is as follows: Targeted clones (HI.HPRT cell
clones) generated by HR in exon 3 of the hprt gene carry a neomycin (neo) gene
flanked by heterospecific lox sites in the opposite transcriptional orientation of the
hprt gene. The neo gene is under the transcriptional control of the EFl-a promoter,
which is excluded from the "floxed" cassette. Cre-mediated site-specific
recombination is performed by co-transfection of these clones with supercoiled
RMCE plasmid (pfBSD-OctGFP) and pTurboCre plasmid (gift from T. Ley,
Washington University, St. Louis, USA). The ere expression plasmid pTurboCre
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was used because its excision activity between two loxP sites has been shown on
several occasions in mouse ES cells (Westervelt et al., 2003; Lin et al., 2003; Engel
et al., 2004). Additionally, pTurboCre contains the strong ubiquitous CAG promoter
(Niwa et al., 1991), which produces high levels of Cre recombinase expression in
mammalian cells. The CAG promoter combines the human cytomegalovirus
immediate-early enhancer and a modified chicken (3-actin promoter and first intron
(Niwa et al., 1991).
The RMCE construct (pfBSD-OctGFP), consists of a promoterless
blasticidin (BSD) gene and the enhanced green fluorescent protein (EGFP) gene
under transcriptional control of the human oct-4 promoter (amplified by PCR from
H9 cells). In common with the modified hprt gene, the RMCE vector is flanked by
the same heterospecific lox sites. Because the EFl-a promoter is not included
between the lox sites in the targeted locus, a promoter trap strategy (Jasin and Berg,
1988, Sedivy and Sharp, 1989) can be applied in a subsequent RMCE experiment.
Upon site-specific recombination catalysed by Cre recombinase, the neo gene
between the heterospecific lox sites is lost, conferring G418 sensitivity, and the
promoterless BSD gene is now placed under the transcriptional control of the EFl-a
promoter, conferring resistance to blasticidin. This enrichment strategy permits the
direct selection of site-specific recombinants because the majority of random
















Figure 7.1. RMCE at the engineered hprt gene. Schematic representation of the hprt
gene targeting by site-specific recombination in Hl.HPRT targeted cells. The exon 3 of the hprt gene
is depicted by a blue box. The positions of the EFl-a, oct-4, and CAG promoters are marked as green,
orange and yellow arrows, respectively. The neo, BSD, GFP and ere genes are marked as a pink,
purple, green and red boxes, respectively. Positions and orientations of the loxP and lox2272
recombination sites are represented as solid and white arrows, respectively. The modified hprt gene,
which incorporates a neo gene flanked by heterospecific lox sites under the transcriptional control of
the EFl-a promoter, is used as the target for an RMCE experiment. Site-specific recombination at the
hprt gene leads to the loss of the neo cassette (1.8 kb) and the insertion of a BSD gene (1.5 Kb) and an
Oct-4GYV expression cassette (5 Kb). The BSD gene is inserted such that its expression is controlled
by the EFl-a promoter and stable site-specific recombinants can be selected directly in blasticidin
selection.
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7.3.1.2. Blasticidin Kill Curve for H1 cells
Blasticidin S is a peptidyl nucleoside antibiotic isolated from the
culture broth of Streptomyces griseochromogenes. It specifically inhibits protein
synthesis in both prokaryotes and eukaryotes through inhibition of peptide bound
formation in the ribosomal machinery (Yamaguchi et al., 1965). Expression of the
blasticidin S deaminase gene BSD from Aspergillus terreus confers resistance by
converting the antibiotic to an inactive deaminohydroxy derivative compound
(Kimura et al., 1994). Blasticidin S is used to select for transfected cells carrying the
BSD resistance gene.
An RMCE event with pfBSD-OctGFP in the Hl.HPRT targeted cell
lines results in the exchange of the neo gene with the BSD gene in exon 3 of the hprt
gene. In order to determine the optimal concentration of antibiotic required to
eliminate blasticidin-sensitive cells, a kill curve was calculated for untransfected HI
cells and for HI cells transfected with a BSD expression vector pEfBSD-OCTGFP (a
plasmid identical to pfBSD-OctGFP but in which the BSD cassette is under the
control of the EFl-a promoter). Because lpg/ml of blasticidin was sufficient in our
hands to completely kill H9 cells (data not shown), drug selection ranging from 0 to
1 pg/ml was tested in untransfected and transfected HI cells. Cells were cultured
with blasticidin for 7 days and were subsequently stained with 10 % Giemsa's
solution for colony counting.
As shown in table 7.1 and figure 7.2, concentrations between 0.4 and
0.8 pg/ml produced a similar number of resistant colonies in pEfBSD-OctGFP-
transfected HI cells, while fewer colonies were recovered at 1 pg/ml. Although
blasticidin-resistant colonies were never produced in untransfected HI cells (table
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7.1), patches of cells surviving blasticidin selection were detected at 0.4 and
0.6 pg/ml but not at 0.8 pg/ml (figure 7.2 B). Below 0.4 pg/ml, selection had little
effect on the cells. It was therefore decided that subsequent RMCE experiments
would be conducted at a blasticidin concentration of 0.8 pg/ml to select for
blasticidin-resistant site-specific recombinants.
Blasticidin concentration (pg/ml) /
Cell line Number Plasmid DNA Number of colonies recovered
ofcells (b8) 0 0.2 0.4 0.6 0.8 1
HI lx 106 No DNA * * 0 0 0 0
HI 1 x 10" pEfBSDOctGFP (50) * ; 23 27 24 11
Table 7.1. Blasticidin kill curve for HI cells and for pEfBSD-OctGFP
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0.4 0.6 0.8 1
Blasticidin concentration (MQ/rnl)
Figure 7.2. Blasticidin kill curve for untransfected HI cells and for HI cells
transfected with pEfBSD-OctGFP. (A) Graph representation of blasticidin kill curve for
untransfected HI cells (blue) and for HI cells transfected with pEfBSD-OctGFP (pink). Maximal
colony recovery was achieved with 0.6 pg/ml of blasticidin in HI cells transfected with pEfBSD-
OctGFP. However all the untransfected HI cells were killed at 0.8 pg/ml (see figure B). (B)
pEfBSD-OtGFP transfected (top panel) and untransfected (lower panel) HI cells were selected in
blasticidin for seven days and were subsequently stained with 10 % Giemsa's solution. Blasticidin
concentrations ranging from 0 to 1 pg/ml are indicated. Optimal colony recovery in HI cells
transfected with pEfBSD-OctGFP can be achieved with 0.8 ug/ml ofblasticidin selection.
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7.3.1.3. Transient Recombination Assay in H1 Cells
Sequencing of the hprt targeting vector (pHPRT-EfN) and the RMCE
vector (pfBSD-OctGFP) showed that both heterospecific lox sites were intact
(Appendix 1, sections 1.2 and 1.3). To confirm functionality of the lox sites, a
recombination assay was developed in HI cells using a lipofection protocol which
had been optimised for H9 cells (H. Priddle, unpublished data). HI cells were
transiently co-transfected with the circular plasmids pHPRT-EfN (1.17 |ig),
pfBSD-OctGFP (0.9 pg), and pTurboCre (3.2 pg), using lipofectamine 2000
(Invitrogen) (figure 7.3 A). A 3:1 molar excess of pTurboCre was used to ensure
that most of the cells transfected with pHPRT-EfN and pfBSD-OctGFP also
incorporated the ere expression plasmid. As a control reaction, HI cells were co-
transfected with pHPRT-EfN and pfBSD-OctGFP in the absence of pTurboCre.
Microscopic analysis performed 48 hours later showed that a large percentage of the
cells expressed GFP (arising from transient expression of pfBSD-OctGFP),
indicating DNA uptake (data not shown). gDNA was extracted for PCR analysis 48
hours post-lipofection to allow for expression of ere and cassette exchange between
the targeting and RMCE constructs. Site-specific recombination between both
vectors leads to reciprocal exchange of sequences within the lox sites, and produces
an 896 bp PCR product with the hprtloxM and GFP primers (designed to anneal to
one of the two recombination products only) (Figure 7.3 A and B). PCR analysis of
gDNA derived from cells treated with all three plasmids showed the presence of the
predicted 896 bp product arising from the recombination product A, whereas no
signal was detected in the absence of the pTurboCre (figure 7.3 B). These results
showed that cassette exchange had occurred between the hprt targeting and RMCE
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constructs in HI cells, thus confirming the functionality of the lox P and lox2272
sites. In addition, these data show that pTurboCre is not only able, but is required, to
direct site-specific cassette exchange of two plasmids flanked by heterospecific
lox sites in HI cells.
yhp?T neo
%. rFla 3'hprt



























neo [ Circular recombination product B
Lox2272 LoxP
896 bp
Figure 7.3. Transient recombination assay between pHPRT-EfN and
pfBSD-OctGFP in HI cells. (A) HI cells transiently co-transfected with superercoiled
plasmids pfBSD-OctGFP, pHPRT-EfN and pTurboCre. Transient expression of the pTurboCre
plasmid results in the generation of two recombination products (A and B) arising from the
recombination of each lox site with its counterpart. Position of the primers' binding sites are indicated
by red arrows. (B) PCR analysis of gDNA extracted from cells co-transfected with pHPRT-EfN,
pfBSD-OctGFP and pTurboCre (lane 1) or with pHPRT-EfN and pfBSD-OctGFP only (lane 2). The
896 bp band indicative of RMCE between pHPRT-EfN and pfBSD-OctGFP can be detected only in
the presence of pTurboCre. The sizes of the DNA fragments in the marker lane (M) (Bioline
hyperladder) are indicated.
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7.3.1.4. RMCE Experiments by Electroporation
To achieve RMCE in the Hl.HPRT targeted cell lines, we tested two
electroporation protocols that resulted in high transfection efficiencies in the hprt
targeting experiments previously conducted in HI cells (up to 6x10~4) (see chapter 4,
table 4.1).
An unknown parameter was the optimal molar ratio of
pTurboCre:pfBSD-OctGFP plasmids required for efficient RMCE. Three different
pTurboCre:pfBSD-OctGFP DNA molar ratios were tested, based on data obtained by
A. Kolb (2001) who achieved high recombination frequencies using a 2:1 to a 4:1
pCre:pRMCE DNA molar ratio in mouse ES cells (Kolb, 2001). Kolb introduced, by
HR, a PGK-hprt expression cassette flanked by heterospecific lox sites (loxP and
lox 2272) into the fi-casein gene in the HPRT-deficient mouse cell line HM1 (Magin
et ai, 1992). In a subsequent step, a series of RMCE vectors were tested for cassette
exchange by site-specific recombination at the modified fi-casein gene. Following
site-specific recombination, the PGK-hprt selection marker was exchanged for a new
selection marker, providing both a positive selection (presence of the new marker
gene) and negative selection (absence of the hprt expression cassette). Using this
enrichment scheme, absolute RMCE frequencies (ratio between the number of site-
specific recombinants and the number of cells electroporated) of approximately
3 x 10"6 were observed, with 100 % of the clones carrying the desired modification.
Based on Kolb's work, the first RMCE experiment was performed
using a 4:1 molar ratio of pTurboCre:pfBSDOctGFP. The Hl.HPRT-1 and
Hl.HPRT-2 cell lines were transiently co-transfected with 50 pg of supercoiled
pTurboCre and 25 pg of supercoiled pfBSD-OctGFP plasmids using the Eppendorf
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Multiporator (300 V/ 100 ps) (table 7.2, experiments 1). Both plasmids were
expected to remain episomal and maintain their expression for a few days before
being degraded, allowing sufficient accumulation of Cre for a site-specific
recombination event at the hprt gene. Supercoiled DNA was used to reduce the
possibility of random integration (Taniguchi et al., 1998).
Illegitimate recombination was measured by transiently transfecting
Hl.HPRT-1 and Hl.HPRT-2 cells with 25 pg of circular pfBSD-OctGFP in the
absence of pTurboCre. Blasticidin selection was applied 48 hours post-transfection
and after fourteen days in selection, none of the cells survived selection, suggesting
that cassette exchange had not taken place in both the Hl.HPRT-1 and Hl.HPRT-2
targeted cell lines (table 7.2).
In a second experiment, electroporation conditions (320 V/ 200 pF)
established in hES cells by Zwaka and Thomson (Zwaka and Thomson, 2003) were
also tested. Additionally the amount of pfBSD-OctGFP was increased to 50 pg to
ensure that there was sufficient RMCE plasmid for a site-specific recombination
event. Finally, two new molar ratios of pTurboCre:pfBSD-OctGFP (2:1 and 3:1)
were tested (table 7.2, experiment 2). An increase in cell death was observed 24
hours post-transfection with both sets of electroporation conditions, possibly as a
consequence of DNA toxicity due to an increase of total DNA transfected (up to
138 pg). Following blasticidin selection for 14 days, none of the cells survived,
suggesting that site-specific recombination had not occured at the hprt gene.
A third experiment was performed, in which a 3:1
pTurboCre:pfBSD-OctGFP molar ratio and a total DNA amount of 50 pg (to
minimise DNA toxicity) were used. The plasmid pfBSD-OctGFP was also
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transfected in the absence of pTurboCre to control for illegitimate recombination.
Blasticidin selection was applied 48 hour later, and 9 days following electroporation
1 blasticidin-resistant colony was obtained. The control reaction in which cells were
transfected with pfBSD-OctGFP did not produce any blasticidin-resistant colonies,
suggesting successful cassette exchange in the experimental plate (table 7.2,
experiment 3). To confirm that this clone was the result of RMCE rather than a
clone which had acquired resistance by integration downstream of a random
promoter, the colony was expanded for subsequent gDNA analysis (see section
7.3.1.6).
Experiment Electroporation Cell line/ Number pTurboCre: pCre: BSDr A.R.F
conditions passage no of cells pfBSDOctGFP pRMCE clones
molar ratio (qg)
1 300V/lOOps HI HPRT-1/88 lxlO6 4:1 50:25 0 0
HI HPRT-2/86 lxlO6 4:1 50:25 0 0
2 300V/100 ps 2:1 59:50 0 0
320V/200 pF HI HPRT-2/86 lxlO6 3:1 88:50 0 0
3 300V/100 ps H1HPRT-1/97 1x10s 3:1 31:19 1 10"6
Table 7.2. Summary of RMCE experiments in both the Hl.HPRT-1 and
Hl.HPRT-2 cell lines using electroporation. Absolute RMCE frequency (ARE): ratio
between the number of site-specific recombinants and the number of cell electroporated.
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7.3.1.5. RMCE Experiments by Lipofection
The recovery of a single blasticidin-resistant colony using an
electroporation protocol required a large number of cells and high amount of DNA.
Site-specific recombination has previously been demonstrated in mammalian cells
using lipofection (e.g. Baubonis and Sauer, 1993; Masui et al., 2005). It was
therefore decided to establish a lipofection protocol in order to scale down the
experiment such that more transfections could be performed simultaneously. In
order to optimise experimental conditions in Hl.HPRT targeted cell lines, three
independent experiments were performed and the variables cell density, total DNA
concentration and DNA molar ratio were investigated.
In the first experiment, Hl.HPRT-2 targeted cells were plated at a
density of 3xl05 cells per well of a 6-well plate and were transfected 48 hours later
(-90 % confluent) with 2.5 pg of supercoiled pTurboCre:pfBSD-OctGFP DNA at a
3:1 molar ratio (determined as the effective DNA molar ratio to produce blasticidin-
resistant colonies in the electroporation protocol) (table 7.3). 2.5 pg of total DNA
was used because an increase of cell death had been observed with greater amounts
of DNA (data not shown). Transient GFP expression (arising from the introduction
of pfBSD-OctGFP in the Hl.HPRT-2 cells) examined by fluorescence microscopy
48 hours post-lipofection, showed that only a small percentage of cells transiently
expressed GFP, indicating poor DNA uptake (figure 7.4).
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Figure 7.4. RMCE experiment 1 in the Hl.HPRT-2 cell line using lipofection.
Fluorescence microscopy (right panel) and phase-contrast microscopy (left panel) of Hl.HPRT-2 cells
transiently expressing GFP 48 hours following lipofection with supercoiled pfBSD-OCTGFP and
pTurboCre. The low number of Hl.HPRT-2 cells transiently expressing GFP show poor DNA
uptake. Scale bars = 200 pm.
Hl.HPRT-2 cells co-transfected with pTurboCre and pfBSD-OctGFP
were subjected to blasticidin selection 48 hours post-lipofection, resulting in the
recovery of 2 blasticidin-resistant colonies in the same well after 7 days in selection
(table 7.3). These results show that even with poor DNA uptake, the recovery of
blasticidin-resistant colonies is possible. A control experiment in which Hl.HPRT-2
cells were transfected with pfBSD-OctGFP alone did not produce any blasticidin-
resistant colonies (table 7.3). Together, these results suggest that the 2 blasticidin-
resistant clones recovered in the experimental plate were the result of cassette
exchange by site-specific recombination at the hprt gene rather than illegitimate
recombination. During the subcloning procedure, these 2 blasticidin-resistant
colonies were lost and thus cassette exchange could not be confirmed.
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Cell line / Number of Lipofectamine:DNA pTurboCre: pTurboCre: BSDr
passage cells seeded / ratio (pl:pg) pfBSD-OctGFP pfBSD-octGFP clones
number well molar ratio (Pg)
Hl.HPRT-2/ 3xl05 4.8:1 3:1 1.6:0.9 2
81 0:2.5 0
Table 7.3. RMCE experiment 1 in the Hl.HPRT-2 cell line using lipofection.
To determine whether the recovery of blasticidin-resistant colonies
was dependent on cell density at the time of lipofection and total DNA amount,
different cell densities and DNA amounts were tested in the Hl.HPRT-1 cell line.
105, 2xl05 and 4xl05 Hl.HPRT-1 cells were seeded per well of a 6-well plate,
resulting in ~50%, 80% and 100% confluent cultures, respectively, at the time of
lipofection (table 7.4). The Hl.HPRT-1 targeted cells were transiently co-transfected
with different amounts of the pTurboCre and pfBSD-OctGFP plasmids (3:1 molar
ratio) varying from 0 to 8 pg, and blasticidin selection was applied 48 hours post-
transfection. Following blasticidin selection for 9 days, 1 blasticidin-resistant colony
was recovered in each well treated with 1, 2 and 4 pg of total DNA, at a plating cell
density of 2X105 cells per well (80% confluent at the time of lipofection) indicating
that these experimental conditions were best suited for colony recovery (table 7.4).
No blasticidin-resistant colonies were produced when cells were transfected with
pfBSD-OctGFP alone, suggesting that the colonies recovered were the result of
cassette exchange at the hprt gene. Colonies were expanded for subsequent analysis.
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Cell line/ pTurboCre: Number Total DNA (pg)
Passage pfBSD-OctGFP of cells Blasticidin-resistant colonies
number molar ratio seeded per well 0 0.5 1 2 4 8
lxlO5 0 0 0 0 0 0
Hl.HPRT-1/ 3:1 2x10s 0 0 1 1 1 0
91 4xl05 0 0 0 0 0 0
Table 7.4. RMCE experiment 2 in the Hl.HPRT-1 cell line using lipofection.
A third experiment was performed to investigate whether an increase
of colony recovery was dependent on an increase of pfBSD-OctGFP DNA, while
maintaining the total amount of DNA at 2.5 pg. To address this question, a 2:1 and
3:1 pTurboCre:pfBSD-OctGFP molar ratio were compared (table 7.5). Cells were
seeded at densities of 105, 2xl05 or 4xl05 per well in duplicate such that prior to
transfection, they could be counted to determine the absolute RMCE frequency
(ARF) (ratio between the number of site-specific recombinants and the number of
cells treated). Hl.HPRT-1 cells were co-transfected with 2.5 pg of a 2:1 or 3:1
pTurboCre:pfBSDOctGFP molar ratio. Blasticidin-resistant colonies were recovered
at both DNA molar ratios and at both 2xl05 and 4xl05 plating cell densities (table
7.5). However, the highest number of colonies recovered was again at a plating cell
density of 2xl05 (-90% confluent at lipofection ) with a 2:1 molar ratio of
pTurboCre to pfBSD-OctGFP (2 colonies at 2:1 molar ratio versus 1 colony at 3:1
molar ratio). These results suggest that an excess molar ratio of the pTurboCre
plasmid over the RMCE plasmid may not be necessary to achieve site-specific
recombination in hES cells. These clones were expanded for characterisation.
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Cell line/ Total Number Number of BSDr ARF
Passage DNA of cells cells/well clones
number Gig) seeded lipofected 2:1* .3:1* 2:1* 3:1*
per well
lxlO5 3x10s 0 0 0 0
Hl.HPRT-1/ 2.5 2xl05 5x10s 2 1 4xl0"6 2x10
99 4xl05 7x10s 1 0 1.4xl0"6 0
Table 7.5. RMCE experiment 3 in the Hl.HPRT-1 cell line using lipofection. (*)
2:1 & 3:1 represent the pTurboCre:pfBSDOctGFP molar ratio. ARF (Absolute RMCE frequency):
ratio between the number of site-specific recombinants and the number of cells treated per well (see
section 7.3.1.6).
Given the data collected from three independent experiments, it was
concluded that the most efficient plating cell density was 2xl05, such that cells
would reach ~80 to 90 % confluency at the time of lipofection. A 2:1 or a 3:1
pTurboCre:pfBSD-OctGFP molar ratio using 2.5 pg of total DNA were both suitable
for colony recovery. It is very likely that further optimisation of experimental
conditions (e.g. optimal pTurboCre:pfBSD-OctGFP molar ratio, and transfection
efficiency) in the Hl.HPRT targeted cell lines will improve blasticidin-resistant
colony recovery and therefore RMCE frequencies.
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7.3.1.6. Detection of an RMCE Event by PCR and Southern
Analysis
Five blasticidin-resistant clones isolated from the electroporation and
lipofection experiments described in sections 7.3.1.4 and 7.3.1.5 (one from the
electroporation, two from the lipofection experiment 2 and two from the lipofection
experiment 3) were analysed by PCR amplification of gDNA. The hprt gene
modified by HR and subsequent site-specific recombination produces a 197 bp PCR
product amplified with the internal BSD primer and the external EFl-a primer
(figures 7.5 and 7.6). PCR analysis showed that all the clones yielded the predicted
197 bp fragment consistent with a site-specific recombination event at the hprt gene
(figure 7.6).
lox2272










(internal) 197 bP (external)
Figure 7.5. Map of the structure of the twice-modified hprt gene following
an RMCE event. The internal (BSD) and external (EFl-a) primers and the predicted size of
PCR product (197 bp) are indicated.
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HI. Hl.HPRT-l.RMCE
M HI HPRT-1 1 2 3 4 5
<«— 197 bp
Figure 7.6. PCR screening for an RMCE event at the modified hprt gene. PCR
analysis of five Hl.HPRT-l.RMCE clones obtained by electroporation (HI.HPRT-1.RMCE-1) and
lipofection (Hl.HPRT-l.RMCE-2, -3, -4 and -5). A 197 bp band can be detected as expected for an
RMCE event at the modified hprt gene. M: Bioline hyperladder.
To confirm that these clones were the result of site-specific
recombination at the hprt gene, EcoRI-digested gDNA from two clones
(Hl.HPRT-l.RMCE-2 and Hl.HPRT-l.RMCE-3) was analysed by Southern
blotting. The 1193 bp 3' hprt probe (used in the first targeted modification of the
hprt gene) was predicted to hybridise to a 8.4 kb EcoRI fragment from the wild-type
allele, a 6.9 kb fragment from the allele modified by HR and a 9.9 kb fragment from
the allele modified by site-specific recombination (figure 7.7 A). Southern analysis
showed the presence of the predicted 9.9 kb EcoRI fragment in both the
Hl.HPRT-l.RMCE-2 and Hl.HPRT-l.RMCE-3 clones, confirming that these clones
were the result of site-specific recombination at the modified hprt gene (figure 7.7
B).
Taken together, these data show that the promoter trap strategy
employed in this study allows the recovery of blasticidin-resistant colonies, ofwhich
100 % carry the desired modification at the hprt gene. In addition, absolute RMCE
frequencies of 10"6 and 4 x 10"6 (tables 7.2 and 7.5) can be achieved by
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electroporation and lipofection, respectively. Thus the RMCE frequencies obtained
in hES cells are in the range of those obtained in mouse ES cells using the same
heterospecific lox sites and a promoter trap strategy (between 2.4 x 10~6 and
1.6 x 10"5) (Kolb, 2001). Finally, absolute RMCE frequencies at the hprt gene can
compare to absolute targeting frequencies obtained in the first modification of the
hprt gene by HR in HI cells (10"6). It is probable that RMCE frequencies will be
further enhanced with the development of optimised transfection protocols.
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Figure 7.7. Southern screening for a site-specific recombination event at the hprt
gene. (A) Map of the wild-type, once-modified (by HR) and twice-modified (by site-specific
recombination) hprt gene showing fragments digests diagnostics using a 3' hprt probe. (B) Southern
analysis of Hl.HPRT-l.RMCE-2 and H1 .HPRT-1 .RMCE-3 clones obtained by lipofection. The
9.9 kb EcoRI fragment confirms that these clones are the result of site-specific recombination at the
hprt gene.
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7.3.2. Transgene Expression Analysis of Site-Specific
Recombinants at the Hprt Gene
7.3.2.1. GFP Expression Analysis
The aim of this project was to characterise transgene expression at the
hprt gene by combining gene targeting and site-specific recombination in hES cells.
All the site-specific recombinants contain an EF1 -a-BSD-oct-4G¥? transgene at the
hprt gene (figure 7.1). Because oct-4 is only expressed in undifferentiated ES cells
(Pesce et al., 1999), it was predicted that GFP would be expressed in undifferentiated
cells and progressively down regulated upon differentiation. To confirm that GFP
was expressed in the site-specific recombinants, GFP expression was examined in
undifferentiated ES cells by fluorescence microscopy and flow cytometry analysis.
Fluorescence microscopy showed that all the blasticidin-resistant
colonies generated by electroporation and lipofection expressed GFP 9 to 14 days
post-transfection. However, following this analysis, progressive down-regulation of
GFP expression was observed in all the blasticidin-resistant clones. By 4 to 6 days
following the first fluorescence microscopy analysis, no detectable levels of GFP
expression were observed. The fact that all the clones remained resistant to
blasticidin, indicated that the BSD-oct-4-GFP transgene was stably integrated in the
genome. Additionally, transient persistence of the pfBSD-OctGFP plasmid in the
cells was only expected for 2 to 3 days following lipofection. Since EGFP has a
half-life of 24 hours, it seems unlikely that progressive GFP silencing was due to
elimination of transient persistence of pfBSD-OctGFP in the blasticidin-resistant
clones. A representative fluorescence microscopy analysis is shown on figure 7.8 for
one blasticidin-resistant colony obtained by electroporation (Hl.HPRT-l.RMCE-1)
and two blasticidin-resistant colonies obtained by lipofection (Hl.HPRT-l.RMCE-2
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and Hl.HPRT-l.RMCE-3). These results suggest that either these clones have
spontaneously differentiated, and therefore oct-4 is down-regulated, or that GFP
expression is progressively down-regulated possibly by transcriptional interference, a
mechanism commonly observed in loci in which two independent transcriptional
units are introduced (Kadesch and Berg, 1986; Proudfoot, 1986).
Hl.HPRT-l.RMCE-1
Figure 7.8. Analysis of GFP expression of the hprt site-specific recombinants.
Fluorescence (top panels) and phase-contrast (bottom panels) microscopy showing down-regulation of
GFP expression in site-specific recombinants obtained by electroporation (Hl.HPRT-l.RMCE-1) and
lipofection (Hl.HPRT-l.RMCE-2 and Hl.HPRT-l.RMCE-3). The number of days following
transfection is indicated. Scale bars = 100 pm
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To confirm down-regulation of GFP expression, flow cytometry
analysis was performed on the Hl.HPRT-l.RMCE-2 and Hl.HPRT-l.RMCE-3 cell
clones that had been expanded over a period of 5 weeks. Untransfected HI cells
were used as a negative control for GFP expression. As a positive control for GFP
expression, pooled HI cells expressing an oct-4-GFP transgene (Hl.EfBSD-OctGFP
cells), were also sorted. The Hl.EfBSD-OctGFP cells were generated by stable
transfection of HI cells with the pEfBSD-OctGFP plasmid (a plasmid identical to
pfBSD-OctGFP but in which the BSD cassette is under the control of the EFl-a
promoter) (figure 7.9.A). Blasticidin-resistant colonies obtained with
pEfBSD-OctGFP were pooled ten days following selection and expanded over a
period of two weeks in blasticidin selection before FACS analysis. Pools rather than
subclones were studied to minimise transgene expression variation due to site of
incorporation. Fluorescence microscopy analysis of the pooled Hl.EfBSDOctGFP
cells showed variegated GFP expression as evident from the presence of cells not
expressing GFP in the pooled population (figure 7.9 B).
While FACS analysis showed that 15 % ofHl.EfBSD-OctGFP cells expressed GFP,
similar background levels of fluorescence between the wild-type HI cells and the
two hprt site-specific recombinants were observed, confirming down-regulation of







Figure 7.9. Flow cytometric analysis of GFP expression in the Hl.HPRT-
l.RMCE site-specific recombinants. (A) Schematic representation of the pEfBSDOctGFP
plasmid used to generate the pooled Hl.EfBSDOctGFP cells (positive control for GFP expression).
(B) Fluorescence (left) and phase-contrast (right) microscopy showing GFP variegation in the
Hl.EfBSD-OctGFP cells. Scale bars = 200 gm. (C) Flow cytometric analysis confirming down-
regulation of GFP expression for the two hprt site-specific integrants, Hl.FIPRT-l.RMCE-2 (blue)
and Hl.HPRT-l.RMCE-3 (pink). Data were generated from the analysis of at least 10, 000 viable
cells. The gate Ml indicates the total number ofGFP+ cells for each cell line in the graph and table.
Hl.EfBSD-OctGFP
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7.3.2.2. Oct-4 Expression Analysis
As described in section 7.3.2.1, the GFP gene is under the
transcriptional control of the ES-specific human oct-4 promoter in the hprt site-
specific recombinants. GFP silencing observed in the site-specific recombinants
may have arisen from spontaneous differentiation of the cell clones possibly as a
result of poor quality conditioned medium or as a result of the transfection
procedure. To rule out this possibility, endogenous oct-4 expression was examined
by immunocytochemistry (in collaboration with J. Fletcher, Roslin Institute) in the
Hl.HPRT-l.RMCE-2 and Hl.HPRT-l.RMCE-3 cell clones (figure 7.10). The
Hl.HPRT-l.RMCE-2 clone was chosen because it exhibits an ES-like phenotype,
and is representative of the remaining site-specific recombinants obtained in the
course of the RMCE experiments. In contrast, the Hl.FIPRT-l.RMCE-3 cell clone
was selected because it exhibits a differentiated morphology (figure 7.8), and it was
predicted that the endogenous oct-4 would not be expressed. The HI.HPRT-1 cell
line was used as a positive control for oct-4 staining as it was previously shown to
express oct-4 (see chapter 5, section 5.3.2.1). OCT-4 staining showed that the
Hl.HPRT-l.RMCE-2 cell line expressed the endogenous oct-4, suggesting that
down-regulation of the transgenic human oct-4 promoter was not the result of
spontaneous differentiation (figure 7.10). However, oct-4 expression was down
regulated in the Hl.HPRT-l.RMCE-3 cell line, consistent with the differentiated
cellular morphology previously observed by microscopy analysis (figure 7.8). It is
therefore very likely that GFP down-regulation was the result of spontaneous
differentiation in the Hl.HPRT-l.RMCE-3 clone. Because the remaining hprt site-
specific recombinants exhibited an undifferentiated phenotype throughout expansion
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(data not shown), these results argue that spontaneous differentiation was not
responsible for GFP silencing in the Hl.HPRT-l.RMCE-2 clone and in the
remaining hprt site-specific recombinants. Oct-4 expression analysis will however
be required to rule out the possibility of spontaneous differentiation in the remaining
hprt site-specific integrants.
Figure 7.10. Oct-4 immunocytochemistry of Hl.HPRT-1, Hl.HPRT-l.RMCE-2
and Hl.HPRT-l.RMCE-3 cell lines. Oct-4 immnuohistochemistry analysis showing
positive expression of the endogenous Oct-4 gene in the Hl.HPRT-1 and Hl.HPRT-l.RMCE-2 cell
lines, but not in the Hl.HPRT-l.RMCE-3 cell line (middle panels). Dapi (4'-6-Diamidino-2-
phenylindole), which is a DNA intercalating dye, can be observed in all nuclei (left panels). A
merged picture of FITC (green) and Dapi (blue) channels is presented on the right panels.
Scale bars = 50 pm.
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7.4. Discussion
It was demonstrated for the first time that RMCE can be successfully
achieved at the hprt gene in hES cells. Using a biphasic recombination strategy
(Kolb et al., 1999; Kolb, 2001), the hprt gene (exon 3) was first tagged by HR with a
neo expression cassette flanked by incompatible lox sites. In a subsequent step,
RMCE allowed the exchange of the neo gene with a BSD-Oct-4GW transgene
flanked by incompatible lox sites. An RMCE rate of 100 % was achieved by
coupling site-specific recombination to a promoter trap strategy.
Site-specific recombinants were recovered at the hprt gene using either
electroporation or lipofection protocols. Under the present experimental conditions,
absolute RMCE frequencies of 10"6 by electroporation, and up to 4 x 10"6 by
lipofection were observed at the hprt gene in the Hl.HPRT-1 cell line. Using a
positive and negative selection strategy in mouse ES cells, Kolb (2001) showed that
absolute RMCE frequencies between 2.4 x 10~6 and 1.6 x 1CT5 could be achieved at
the fi-casein gene tagged with a loxP and lox2272 sites. Thus the RMCE frequencies
observed in hES cells are in the range of those obtained in mouse ES cells.
EGFP expression was analysed following a site-specific recombination event
at the hprt gene. Because EGFP is under the transcriptional control of the human
oct-4 promoter, the hprt site-specific recombinants should express GFP in their
undifferentiated state and progressively down-regulate GFP upon differentiation.
Fluorescence microscopy analysis performed on three clones 9 days post-lipofection
(Hl.HPRT-l.RMCE-2 and Hl.HPRT-l.RMCE-3) or 14 days post-electroporation
(HI.FIPRT-l.RMCE-1) showed that these blasticidin-resistant hprt site-specific
Chapter VII 228
recombinants initially expressed GFP. However, progressive down-regulation of
GFP was observed in these site-specific recombinants, and by 13 days post-
lipofection or 20 days post-electroporation, no GFP-expressing cells could be
detected by fluorescent microscopy analysis (figure 7.8). GFP silencing was further
confirmed by flow cytometry analysis in the Hl.HPRT-l.RMCE-2 and
Hl.HPRT-l.RMCE-3 site-specific integrants. Although GFP expression was not
analysed by flow cytometry for the remaining hprt site-specific integrants,
progressive GFP down-regulation was also observed in these clones by fluorescence
microscopy analysis (data not shown).
Immunocytochemistry analysis of the ES-specific OCT-4 protein showed that
the Hl.HPRT-l.RMCE-2 site-specific integrant expressed the endogenous oct-4.
However, endogenous oct-4 expression was found to be down-regulated in the
Hl.HPRT-l.RMCE-3 cell line. Thus while spontaneous differentiation was likely
responsible for GFP down-regulation in the Hl.HPRT-l.RMCE-3 cell line, GFP
silencing was the result of a different mechanism in the Hl.HPRT-l.RMCE-2 cell
line.
These data may suggest that the hprt gene is not a suitable locus to obtain
reproducible transgene expression in hES cells. Several studies have however
demonstrated reproducible tissue-specific transgene expression at the hprt gene in
mouse ES cells (Bronson et al., 1996; Cvetkovic et al., 2000; Evans et al., 2000;
Guillot et al., 2000; Minami, et al., 2002; Heaney et al., 2004). Certain of these
reports also described reproducible transgene expression with transgenes introduced
in exon 3 in the opposite transcriptional orientation of the hprt gene (Shaw-White et
al, 1993; Le et al., 2003).
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Although the reason for progressive GFP silencing at the hprt locus in hES
cells is presently unclear, one possible explanation is that GFP down-regulation was
the result of transcriptional interference (TI) between the two transgenic promoters
(.EFl-a and oct-4) present at hprt locus in the site-specific integrants. TI often
occurs when two transcriptionally active units lie adjacent in head-to-tail tandem on
a chromosome (Kadesch and Berg, 1986; Proudfoot, 1986; Emerman and Termin,
1986; Shaw-White et al., 1993; Clark et al., 1997; Villemure et al., 2001; Hasegawa
and Nakatsuji, 2002; Eszterhas et al., 2002). Interference between two promoters
may affect the expression of two transgenes contained in a single construct, and is
probably caused by competitive binding of transcription factors and/or modification
of DNA structure (induced by transcription) at one site that affect the other site
(Emerman and Temin, 1984). Eszterhas et al. (2002) developed an elegant system to
study TI between two nearly identical transcriptional units (CMV-GFPpA and
CMV-YFPpA) juxtaposed in various arrangements (tandem, divergent, and
convergent) at a same locus. They used RMCE to insert the constructs into two
previously-tagged genomic sites in mouse erythroleukemia (MEL) cells. To study
TI, they compared by FACS analysis the mean expression of each gene in tandem
constructs in one site to expression of an identical single gene integrated at that site
in the same orientation. Their results showed that expression from each of two
active transcription units arranged in tandem was less than expression from a single
unit in the same integration site and orientation. The downstream gene was down
regulated to 10 % (when compared to the expression of the single unit) in one locus,
and to a basal transcription level in the other locus. The upstream gene was also
down-regulated but maintained from 50 % to 80 % of expression depending on the
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locus. Thus, the downstream (3') unit was more affected by TI than the upstream
(5') unit. Removal of the CMV promoter from the upstream transcription unit fully
restored expression of the down-stream transcription unit, showing that the
suppression of the downstream gene is dependent on transcription of the upstream
gene.
In our study, the two transcription units present in the hprt site-specific
recombinants were also arranged in head-to-tail tandem manner
(EFl-a-loxP-BSD-oct-4-GFF-Iox2272), as shown on figure 7.1. While the upstream
BSD gene was always expressed (as indicated by constant resistance to blasticidin
selection), the downstream GFP unit was progressively down-regulated. Thus based
on Eszterhas et al. 's data, it is possible that the expression of the upstream BSD gene
has affected the expression of the downstream GFP gene at the hprt locus in hES
cells.
TI from the BSD transcription unit could be tested by the elimination of the
EFl-a promoter and comparison of GFP expression and transcripts production with
or without expression of the BSD gene. A positive and negative selection system
such as hygromycin-thymidine kinase (hytk) fusion gene would be required in order
to recover hprt site-specific recombinants lacking the EFl-a promoter. In this
strategy, the hprt gene would first be tagged with a loxP-EFl-a-hytk-lox2272
transgene by HR, and targeted clones would be selected in hygromycin and 6-TG.
Following site-specific recombination with either loxP-EFl-a-BSD-Oct-4-GFP-
lox2272, or loxP-BSD-Oct-4-GFF-lox2272, site-specific recombinants would be
directly selected in gancyclovir. TI by BSD expression would be confirmed if GFP
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was expressed in the site-specific recombinants lacking the EFl-a promoter, but not
in those containing the EFl-a promoter.
If GFP silencing observed in the hprt site-specific recombinants was the
result of TI by BSD expression, this could possibly be avoided by introducing in the
RMCE construct the core HS4 insulator elements between the two transcriptional
units (Hasegawa and Nakatsuji, 2002; Villemure et al., 2001). Hasegawa and
Nakatsuji (2002) showed that two expression units in a single construct are expressed
in an independent manner and are controlled by their respective regulatory element
only if HS4 insulators are placed between the two transcription units. Similarly,
Villemure et al. (2001) showed that insertion of single copy of the HS4 insulator
between two strong ubiquitous transcriptional units in a double gene construct
prevents the interference of the upstream gene in the stable transfected cells.
Alternatively, a divergent arrangement of the two transcriptional units (EFl-a-loxP-
BSD-G¥V-Oct-4-lox2272) may be more suitable for the expression of both units, as
demonstrated by Eszterhas et al. (2002).
To conclude, we showed that Cre-mediated cassette exchange can be
achieved at the hprt gene in hES cells with a 100 % rate of site-specific recombinants
recovery. Further investigations (discussed above) will however be required to





The primary goal of this project was to generate a hES cell line with
reproducible transgene expression for future use in transgenic approaches. This issue
was addressed in hES cells, by combining gene targeting and site-specific
recombination at the /3-casein and hprt genes. At the start of this project, established
efficient transfection protocols adapted for hES cells were not available. Thus
transfection efficiencies were too low (Eiges et al., 2001) to be practical in the
context of a targeting experiment because of the predominance of illegitimate
recombination over homologous recombination. Therefore much of this work has
focused on the establishment of targeting and RMCE protocols in hES cells.
The establishment of electroporation protocols with high transfection
efficiencies (up to 4.9x10"4) has permitted the isolation of homologous-recombinants
with targeting frequencies of up to 0.4 % at the hprt gene in the male hES cell line
(HI). Although Southern blotting of the junctions at the 5' and 3' end (using a 5'
and 3' external probe) will be required to confirm a correct replacement event for the
three hprt-targeted hES cell lines generated, our data show that reasonable targeting
frequencies can be achieved at an expressed locus in hES cells. In contrast, gene
targeting at the unexpressed (3-casein gene in the female hES cell line (H9) was
unsuccessful, despite the high transfection efficiencies achieved (up to 3.5xl0"4).
These results may reflect a difference of targeting efficiency between cell lines (this
question could easily be answered by conducting a [3-casein targeting experiment in
HI cells), and/or that gene targeting efficiency in hES cells may be dependent on the
locus and/or transcriptional status of the gene. It has been shown that transcription
enhances HR in eukaryotes (Nickoloff and Reynolds, 1990). According to this
report, failure to target the untranscribed [3-casein gene would not be unexpected,
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since only one targeting event was obtained at the ubiquitously expressed hprt gene
in each targeting experiment (table 4.1).
Alternatively it is possible that a targeting event has occurred at the P-casein
locus but targeted clones could not be detected as a result of transgene silencing in
the P-casein gene, perhaps by heterochromatinisation of the locus. This scenario
would be consistent with a previous report in which a transgene was silenced when
targeted to a transcriptionally-inactive gene in bovine fetal fibroblast (Kuroiwa et al.,
2004). As discussed in chapter 3 (section 3.4), PCR screening may be sensitive
enough to detect a targeting event at the P-casein locus among small pools of early
G418-resistant colonies and therefore should be considered to confirm a targeting
event at the p-casein locus. If a targeting event was confirmed, then selection could
be relaxed as soon as colonies are formed in order to recover targeted clones. The
data presented in section 3.3.3 (chapter 3) suggests that insulators HS4 can protect
transgene expression from silencing. Insulators flanking the neo expression cassette
in the targeting vector may therefore provide another means to recover targeted
clones at the P-casein locus.
Given the low targeting frequencies achieved at the hprt locus in hES cells,
strategies that have been designed to enhance targeting frequencies in other
mammalian systems could be applied in hES cells. For instance, approaches aiming
to favour the HR pathway over the illegitimate recombination pathway by controlling
the expression of key enzymes involved in recombination and DNA repair, could be
explored in the context of this work. It was recently shown in our lab that over-
expression of the mammalian recombinase Rad51 (involved in double-strand break
DNA repair by HR) or down-regulation of poly(ADP-ribose) polymerase (PARP)
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(involved in double strand break DNA repair by illegitimate recombination)
increases targeting frequency by 4- and 3.3- fold, respectively, at the hprt locus in
mouse ES cells (Dominguez-Bendala et ai, 2006, Dominguez-Bendala et al., 2003).
It would therefore be interesting to determine whether similar enhancement of
targeting frequencies could be observed at both the fi-casein and hprt loci in hES
cells.
This work has also demonstrated the feasibility of correcting, by HR, the
previously modified hprt gene, thereby establishing the basic principle that
therapeutic cloning combined with gene repair in hES cells could be used as a novel
avenue for gene therapy strategies. As outlined in chapter 6 (section 6.4), future
work would require the confirmation of a correction event at the modified hprt gene
by Southern analysis.
We have also shown that the modified hprt gene tagged with heterospecific
lox sites could be further modified by Cre-mediated site-specific recombination, thus
exemplifying this alternative approach for the genetic manipulation of hES cells.
Furthermore, when using a promoter trap strategy, a 100-fold enrichment for site-
specific recombinants was achieved, demonstrating the efficiency of this method to
enrich for site-specific recombinants in hES cells. Southern blotting of the junctions
at the 5' and 3' end will however be required to confirm a correct site-specific
recombination event for all the hprt site-specific recombinants. Absolute RMCE
frequencies ranging from 10"6 (by electroporation) (table 7.2) to 4x10~6 (by
lipofection) (table 7.5) were similar to absolute targeting frequencies obtained in the
first modification (10"6) (table 4.1) and correction (3x10~6) (table 6.1) of the hprt
gene. It is strongly believed that RMCE frequency was hampered by the low cell
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survival and DNA uptake in the lipofection protocol and that RMCE frequencies
could be further enhanced with the improvement of lipofection protocols.
Karyotypic stability, pluripotency, and sternness of an /?/?rMargeted cell line
were also issues addressed in this work. Like the parental HI cell line, an /^re¬
targeted HI cell line predominantly maintains a normal diploid karyotype, and
expresses common hES cell markers (OCT-4, SSEA-4, TRA-1-60 and TRA-1-81).
These results showed that gene targeting did not affect the above properties.
However, in vitro differentiation experiments failed to establish pluripotency of the
parental HI cell line and the hprt targeted cell line. Nevertheless, there was no
evidence found that the gene targeting procedures affect the in vitro differentiation
potential of the hprt targeted cell line, since pluripotency was not established in the
parental HI cell line. It is possible that the inability to show pluripotency in these
cell lines was due to the lack of production of robust EBs, possibly related to the use
of the TEG (trypsin/EGTA)-based disaggregation regime. This is based on the
observation that collagenase-based disaggregation regime allows the production of
robust EBs from HI cells. Spontaneous in vitro differentiation of collagenase-treated
HI cells into the 3 germ layers has been demonstrated without aggregation into EBs
under prolonged suboptimal culture conditions (Reubinoff et al., 2000). This work
also demonstrated that by adding osteogenic factors to the medium, TEG-treated
cells can be induced to form mineralised nodules (consistent with bone formation) in
vitro without the EB stage. Thus, spontaneous differentiation without aggregation
into EBs may be an alternative approach to investigate pluripotency in the parental
HI cell line and the hprt targeted cell line passaged with TEG. An important
question that remains to be answered is whether the cell lines generated after double
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modification of the hprt gene either by HR in the case of the hprt correction
experiment, or by site-specific recombination, retain the properties of hES cells.
The primary goal of this work was to obtain a hES cell line tagged with
heterospecific lox sites at the hprt locus, such that reproducible transgene expression
could be achieved with any transgenes flanked with the same heterospecific lox sites
following a site-specific recombination event at this locus. The data presented in this
work, however, showed that a GFP transgene under the control of the human oct-4
promoter introduced at the hprt locus by site-specific recombination, was
progressively down-regulated. It is presently unclear whether this was the result of
transcriptional interference (TI) from the expression of the upstream BSD cassette, or
position effect due to the site of integration. As discussed in section 7.4 (chapter 7),
future work would require the removal of the promoter (i.e. EFl-a) driving the BSD
gene to confirm TI at the hprt gene. Furthermore, a divergent arrangement between
the two transcriptional units {oct-4-GFP and EFl-a-BSD) should also be examined.
Indeed, it has been shown that such an arrangement is more suitable for appropriate
expression of two transcription units (Eszterhas et al., 2002). Alternatively, GFP
silencing in the hprt site-specific integrants could possibly be overcome by flanking
each transcription unit in the RMCE vector with HS4 insulators, allowing each unit
to be expressed independently at the hprt locus.
In summary, it has been shown that the hprt gene can be modified in hES
cells using conventional gene targeting with similar frequencies to those achieved in
murine ES cells. Importantly, this work presents evidence that the modified hprt
locus tagged with heterospecific lox sites can be repeatedly modified either by
conventional gene targeting {hprt correction experiment) or site-specific
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recombination (RMCE experiment) in hES cells. Thus, the basic principle that a hES
cell line genetically modified at a specific locus can be re-used for further genetic
modification has been established. Although there is still a long way to bring
genetically modified hES-derived cells to the clinic, an immediate application would
be to introduce engineered lineage-specific reporter genes at the hprt locus
(dependent on whether reproducible transgene expression is eventually achieved at
this locus). This would allow the purification of a particular cell type (using for
instance FACS separation) and enable the study of gene expression and function in a
human developmental context as well as the screening of drug toxicity and provide a
source of a desired cell type for transplantation purposes. With respect to the latter,
our lab is specifically interested in the purification of bone progenitors cells for
transplantation therapy. Therefore, the generation of cell clones tagged with
heterospecific lox sites at loci that provide reliable transgene expression will be
particularly useful for the introduction of a reporter gene (e.g. GFP) under the
transcriptional control of a bone-specific promoter (e.g. osteocalcin and CBFA1) for
the enrichment of osteoblasts. Following induction towards the osteogenic lineage,
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A.T.F Absolute targeting frequency
ATG Translational initiation start
bFGF Basic fibroblast growth factor
Bp Base pair




CHO Chinese hamster ovary
dH20 Distilled water
DEAE Diethylaminoethylamine







EC cells Embryonic carcinoma cells
EDTA Ethylenediaminetetraacetic acid
EFl-a Elongation factor la
EG cells Embryonic germ cells
EGTA Ethyleneglycol-bis ((3-aminoethyl)-N,N,N',N'-tetraacetic acid
ES cells Embryonic stem cells
EtBr Ethidium bromide
E.T.F Effective targeting frequency
F Farad
FAC Fluorescence-activated cell sorting
F.C Final concentration
FCS Foetal calf serum
gDNA Genomic DNA
Abbreviations 273
GFP Green fluorescent protein
GMEM Glasgow modified Eagle's medium
HAT Hypoxanthine, Aminopterin, Thymidine
HEK Human embryonic kidney cells
HES Human embryonic stem cells
Hprt Hypoxanthine-guanine phosphoribosyl transferase
HR Homologous recombination
HSV-tk Herpes simplex virus-thymidine kinase
ICM Inner cell mass
Kb Kilobase pair
KO-DMEM Knock-out DMEM
LB Luria Bertani broth




MEF Mouse embryonic fibroblasts
MES Murine embryonic stem cells
MHC Major histocompatibility complex
mRNA Messenger RNA
NaAc Sodium acetate
NBCS New born calf serum
Neo Neomycine phosphotransferase
NGS Normal goat serum







PCR Polymerase chain reaction
Abbreviations 274
PEV Position effect variegation
PFA Paraformadehyde
PolyA Poly adenylation
PRPP 5' phosphoribosyl-1 -pyrophosphate
Rag2 Recombination-activating gene 2




SCID Severe combined immuno deficiency
SCNT Somatic cell nuclear transfer














Tris Tris (hydroxymethyl) aminoethane
UV Ultraviolet
V Volts
v/v Volume by volume
WT Wild-type





















































































































2.3. pEFGIN (6.7 kb)
Sail
2.4. pB-RMCE2272 (3 kb)
Earn 11051















2.5. pMMPoNeo (4.6 kb)
Xmnl 2706,
Seal 2598.
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